background
pneumococc
mening
pm
lifethreaten
diseas
recurr
pm
rel
rare
associ
predispos
condit
studi
analyz
outcom
patient
recurr
versu
nonrecurr
pm
method
conduct
retrospect
studi
analyz
record
patient
hospit
pm
institut
includ
patient
diagnost
pm
base
appear
gram
stain
posit
latex
agglutin
reaction
cerebr
spinal
fluid
csf
sampl
andor
posit
cultur
streptococcu
pneumonia
csf
cultur
blood
cultur
concomit
mening
defin
recurr
mening
least
two
episod
mening
separ
period
least
week
result
identifi
total
pm
episod
patient
thirti
eight
patient
diagnos
recurr
mening
prior
episod
record
major
patient
recurr
mening
experienc
two
mening
episod
found
patient
recurr
episod
nineteen
patient
recurr
mening
group
nonrecurr
group
men
median
age
patient
recurr
versu
nonrecurr
mening
versu
year
p
nine
patient
recurr
mening
versu
patient
nonrecurr
mening
underli
immunosuppress
condit
p
immunosuppress
diabet
mellitu
alcohol
endstag
liver
diseas
malign
malnutrit
pregnanc
splenectomi
immunosuppress
therapi
found
dissemin
infect
contigu
site
case
bone
defect
andor
csf
leakag
case
hematogen
spread
case
cranial
bone
discontinu
andor
csf
leakag
identifi
recurr
versu
nonrecurr
mening
versu
episod
p
hematogen
spread
observ
nonrecurr
mening
group
recurr
versu
nonrecurr
mening
impair
conscious
admiss
note
versu
note
one
death
among
patient
recurr
pm
group
vs
nonrecurr
group
p
death
associ
nonrecurr
mening
p
contigu
spread
p
immunodepress
p
impair
conscious
p
conclus
patient
recurr
mening
younger
less
immunosuppress
condit
better
surviv
versu
nonrecurr
mening
mortal
pm
associ
immunosuppress
impair
conscious
small
number
death
recurr
group
allow
us
analys
differ
two
group
background
bacteriophag
hypothes
contribut
biofilm
erad
multipl
action
amplif
host
cell
product
depolymer
enzym
degrad
matrix
extracellular
polymer
substanc
induct
depolymer
enzym
host
cell
infect
persist
bacteri
cell
lysi
upon
reactiv
method
perform
vitro
experi
nation
institut
infecti
diseas
prof
dr
matei
assess
influenc
biofilm
format
biofilm
erad
commerciallyavail
bacteriophag
cocktail
intesti
pyo
eliava
bioprepar
tbilisi
georgia
differ
binari
dilut
present
et
al
germ
use
two
bacteri
model
gramposit
model
strain
staphylococcu
spp
gramneg
model
strain
pseudomona
aeruginosa
result
intesti
pyo
bacteriophag
inhibit
biofilm
format
gramposit
p
p
gramneg
p
p
model
dilut
use
respect
median
optic
densiti
od
staphylococc
cultur
decreas
dilut
intesti
pyo
respect
median
od
decreas
dilut
intesti
pyo
respect
gramneg
model
od
decreas
intesti
pyo
dilut
od
decreas
intesti
pyo
dilut
respect
decreas
biofilm
densiti
measur
rate
chang
roc
higher
gramneg
model
compar
gramposit
model
statist
signific
ascertain
intesti
p
z
dilut
borderlin
signific
dilut
p
z
erad
preform
biofilm
achiev
model
addit
phage
intesti
pyo
staphylococcu
spp
p
p
intesti
pseudomona
aeruginosa
p
conclus
extrapol
find
hypothes
phage
may
eventu
repres
option
primari
prophylaxi
coat
orthoped
prosthes
secondari
prophylaxi
prevent
osteomyel
relaps
biofilm
reduct
administ
via
local
instil
refer
harper
parracho
h
walker
j
et
al
bacteriophag
biofilm
antibiot
ac
streinucercel
et
al
bacteriophagedriven
inhibit
biofilm
pseudomona
aeruginosa
paper
present
asm
microb
boston
usa
acknowledg
carol
davila
univers
medicin
pharmaci
young
research
grant
phd
thesi
acn
background
sepsi
sever
lifethreaten
syndrom
high
incid
mortal
rate
need
rapid
diagnosi
sever
evalu
order
avoid
fatal
complic
diagnosi
preset
criteria
sofa
score
prognosi
remain
import
problem
septic
patient
manag
year
sever
marker
inflamm
evalu
fibrinogen
c
reactiv
protein
procalcitonin
pct
object
appreci
efficaci
neutrophillymphocyt
ratio
nlr
mean
platelet
volum
mpv
red
cell
distribut
width
rdw
pct
sepsi
prognosi
correl
valu
sever
estim
mortal
rate
method
prospect
studi
realiz
matei
institut
octob
juli
includ
patient
diagnos
sepsi
evalu
number
sir
criteria
primari
site
infect
incrimin
germ
organ
failur
septic
metastas
calcul
two
score
sever
apach
acut
physiolog
chronic
health
evalu
ap
admiss
point
score
estim
mortal
rate
statist
analysi
realiz
use
spss
result
studi
includ
patient
mean
age
year
old
sex
ratio
f
primari
septic
focu
found
case
respiratori
digest
urinari
other
frequent
isol
germ
e
coli
streptococcu
pneumonia
clostridium
difficil
other
includ
klebsiella
legionella
neisseria
meningitidi
patient
septic
metastas
cerebr
cutan
present
least
one
organ
failur
hematolog
renal
respiratori
mean
valu
initi
nlr
statist
signific
correl
number
organ
failur
apach
p
ap
p
score
mortal
rate
p
last
correl
stronger
one
pct
mortal
vpm
mean
valu
fl
rdw
correl
two
score
pct
median
ngml
correl
apach
p
ap
p
mortal
rate
p
conclus
septic
patient
outcom
easili
appreci
use
nlr
prove
import
prognost
role
sepsi
statist
correl
sever
score
estim
mortal
rate
pct
also
remain
good
test
appreci
sever
although
studi
show
import
vpm
rdw
sepsi
marker
associ
prognosi
background
neonat
bacteri
mening
rare
diseas
character
particularli
high
sever
group
b
streptococcu
lead
caus
neonat
mening
respons
infect
follow
seriou
neurolog
sequela
although
neisseria
meningitidi
common
caus
agent
mening
age
group
clinic
case
diagnos
case
newborn
infant
month
object
studi
bacteri
mening
diagnos
newborn
infant
month
set
peculiar
determin
etiolog
agent
age
children
evolut
develop
sequela
method
retrospect
studi
case
bacteri
mening
children
age
month
admit
clinic
result
time
period
studi
clinic
case
bacteri
mening
diagnos
infant
younger
month
case
neonat
mening
produc
group
b
streptococcu
develop
seriou
neurolog
sequela
encephalomalacia
cortic
atrophi
ventriculomegali
neisseria
meningitidi
isol
newborn
infant
age
two
month
caus
purul
mening
evolv
favor
without
sequela
conclus
group
b
streptococcu
major
caus
neonat
sepsi
bacteri
mening
respect
respons
particularli
sever
neurolog
sequela
addit
measur
requir
surveil
pregnant
women
earli
detect
intrapartum
prophylact
treatment
reduc
morbid
newborn
infect
neisseria
meningitidi
although
consid
common
etiolog
agent
mening
infant
respons
four
case
detect
demonstr
presenc
n
meningitidi
popul
effect
expos
children
highli
pathogen
agent
first
day
life
although
case
treat
clinic
evolv
favor
presenc
alarm
signal
epidemiolog
measur
argument
complet
diagnost
guidelin
bacteri
mening
infant
background
rapid
diagnosi
sepsi
especi
case
without
evid
septic
focu
repres
import
challeng
clinic
practic
neutrophillymphocyt
count
ratio
nlcr
easili
measur
paramet
role
diagnosi
sepsi
also
assess
sever
septic
patient
nlcr
evalu
especi
patient
sever
sepsi
admit
icu
data
import
call
commun
acquir
sepsi
lacunar
object
analyz
diagnost
prognost
valu
nlcr
patient
commun
acquir
sepsi
method
perform
prospect
singl
center
studi
includ
consecut
case
sepsi
admit
matei
institut
patient
determin
nlcr
admiss
two
group
patient
creat
group
nlcr
group
nlcr
clinic
biolog
paramet
also
sever
calcul
apach
iv
ap
score
compar
analyz
two
group
result
fiftyf
consecut
patient
sepsi
analyz
mean
age
year
old
sex
ratio
f
group
includ
patient
nlrc
group
patient
nlrc
compar
analysi
two
group
show
patient
criteria
system
inflammatori
respons
syndrom
sir
second
group
vs
patient
identifi
etiolog
second
group
vs
without
statist
signific
p
patient
least
one
organ
dysfunct
vs
p
procalcitonin
baselin
ngml
medium
pct
first
group
ngml
vs
medium
pct
second
group
ngml
second
group
correl
initi
valu
nlrc
sever
score
apach
iv
ap
estim
mortal
rate
statist
signific
p
last
correl
stronger
one
procalcitonin
mortal
rate
p
conclus
nlrc
associ
sever
express
number
sir
criteria
presenc
organ
dysfunct
baselin
valu
nlrc
correl
sever
appreci
apach
iv
ap
score
estim
rate
mortal
nlrc
easi
obtain
biomark
help
order
assess
sever
sepsi
background
whoop
cough
highli
contagi
acut
infecti
diseas
caus
bacilli
genu
bordetella
pertussi
parapertussi
extrem
rare
human
b
bronchiseptica
paroxysm
cough
variabl
impair
gener
condit
hematolog
chang
high
risk
complic
case
report
present
year
patient
diagnos
hiv
stage
antiretrovir
treatment
abacavir
lamivudin
darunavir
ritonavir
scheme
initi
patient
came
clinic
infecti
diseas
fever
cough
initi
dri
thereaft
product
bout
fallow
episod
faint
sweat
exert
dyspnea
weight
loss
kg
last
week
moment
hospit
patient
show
influenc
gener
condit
orthopnea
oxygen
satur
without
mask
discreet
congest
pharynx
tongu
chalki
deposit
right
basal
crepit
rale
tachycardia
hr
bmin
liver
lower
edg
cm
right
costal
margin
without
mening
irrit
sign
biolog
leukocytosi
lymphocytosi
inflammatori
syndrom
lymphocyt
cellsl
viremia
copiesml
chestray
reveal
interstiti
draw
look
like
frost
glass
design
predominantli
perihilar
right
dilat
bronchi
alveolointerstiti
type
opac
suprahilar
infrahilar
right
side
suspect
pneumocystosi
pulmonari
tuberculosi
deni
whoop
cough
bordetella
pertussi
igm
posit
initi
treatment
oxygen
mask
rebalanc
electrolyt
solut
antibiot
antifung
expector
slowli
favor
evolut
conclus
diseas
contagi
consid
childhood
infect
identifi
also
adult
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
primoinfect
varicella
zoster
viru
caus
varicella
one
frequent
patholog
first
stage
childhood
complic
diseas
may
vari
pyogen
infect
pneumonia
neurolog
cerebellar
lesion
case
report
present
clinic
case
old
male
babi
signific
patholog
anteced
admit
clinic
victor
hospit
infecti
diseas
diagnosi
varicella
cronobact
sakazakii
sepsi
present
diseas
start
day
prior
admiss
clinic
polymorph
erupt
crust
stage
afterward
fever
associ
mention
fact
along
diseas
babi
follow
ibuprofen
treatment
due
fact
babi
condit
remain
strongli
influenc
nonsteroid
antiinflammatori
treatment
associ
cefuroxim
acyclovir
day
diseas
tumefact
right
inferior
limb
associ
admiss
babi
strongli
influenc
condit
tumefact
inferior
right
limb
dyspneic
sleepi
polymorph
erupt
crust
stage
therefor
babi
admit
directli
intens
care
unit
hemocultur
posit
cronobact
sakazakii
thrombocyt
vsh
mmh
crp
mgdl
serum
urea
mgdl
creatinin
mgdl
evolut
favor
symptomatolog
remiss
establish
treatment
conclus
within
last
year
medic
practic
complic
extrem
graviti
varicella
emerg
cellul
compart
syndrom
sepsi
variou
etiolog
streptococcu
staphylococcu
gram
neg
germ
etc
perform
modern
apparel
certainli
contribut
establish
bacteriolog
diagnosi
implicitli
antibiogram
led
optim
therapeut
behavior
experi
consid
varicella
zoster
viru
virul
abl
caus
sever
form
complic
certain
patient
categori
consent
written
inform
consent
obtain
parent
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
anaerob
bacteria
common
caus
prosthesi
joint
infect
pji
implic
may
greater
expect
mani
fals
neg
result
due
difficulti
isol
identifi
type
bacteria
sonic
import
tool
microbiolog
diagnosi
give
clinician
higher
chanc
find
microorgan
involv
pji
aim
studi
evalu
preval
anaerob
bacteria
pji
main
epidemiolog
characterist
infect
produc
anaerob
method
perform
prospect
studi
conduct
nation
institut
infecti
diseas
prof
dr
matei
bucharest
includ
orthoped
sonic
implant
sent
region
center
implant
sonic
khz
ultrason
bath
bandelin
germani
sonic
fluid
cultur
aerob
anaerob
media
period
incub
day
aerob
cultur
day
anaerob
cultur
respect
compact
autom
system
healthcar
usa
use
bacteria
identif
antibiot
suscept
interpret
result
made
accord
latest
eucast
breakpoint
result
among
sonic
orthoped
implant
isol
anaerob
bacteria
preval
propionibacterium
acn
isol
case
one
clavicl
plate
one
hip
one
shoulder
replac
parvimona
micra
finegoldia
magna
two
anaerob
isol
hip
knee
prosthesi
patient
anaerob
bacteria
isol
male
femal
median
age
year
anaerob
infect
monobacteri
median
time
surgeri
onset
symptom
month
isol
strain
sensit
antibiot
test
except
metronidazol
propionibacterium
acn
resist
conclus
studi
preval
anaerob
pji
preval
similar
one
cite
literatur
preval
may
higher
anaerob
bacteria
slow
grow
organ
requir
special
condit
grow
thu
number
fals
neg
result
signific
background
streptococcu
pneumonia
along
neisseria
meningitidi
repres
two
frequent
caus
bacteri
mening
adolesc
young
adult
delay
diagnosi
inadequ
treatment
condit
may
result
seriou
complic
brain
damag
hear
loss
even
death
case
report
present
case
year
old
femal
without
known
medic
condit
current
medic
admit
clinic
fever
chill
frontooccipit
headach
nausea
vomit
photophobia
symptom
present
last
hour
progress
enhanc
upon
physic
examin
febril
sweat
pulmonari
crackl
cardiac
murmur
blood
pressur
mmhg
puls
rate
bpm
without
hepatosplenomegali
orient
time
place
sign
mening
irrit
kernig
sign
brudzinski
sign
nuchal
rigid
laboratori
test
reveal
leukocytosi
neutrophilia
biolog
inflammatori
syndrom
electrolyt
imbal
posit
procalcitonin
neg
hiv
htlv
serolog
neg
marker
viral
hepat
b
c
normal
urinalysi
neg
hemocultur
sinu
xray
show
bilater
maxillari
sinus
lumbar
punctur
moment
show
cerebrospin
fluid
csf
modif
normal
pressur
clear
appear
neg
pandi
reaction
protein
mgdl
glucos
mgdl
chlorid
mgdl
neg
csf
cultur
pcr
use
mass
spectrometri
plex
id
perform
csf
identifi
streptococcu
pneumonia
cranial
magnet
reson
imag
mri
contrast
show
minim
mening
enhanc
modif
given
data
clinic
appear
identif
streptococcu
pneumonia
csf
use
plexid
consid
case
bacteri
mening
earli
stage
normal
csf
receiv
treatment
meropenem
g
vancomycin
g
dexamethason
day
good
clinic
respons
lumbar
punctur
repeat
day
show
chang
previou
examin
patient
fulli
recov
sequela
conclus
bacteri
mening
exhibit
appar
normal
csf
paramet
even
uncommon
wellrecogn
phenomenon
lumbar
punctur
show
abnorm
csf
exclud
bacteri
mening
earli
stage
diseas
empir
antibiot
use
diagnosi
bacteri
mening
strongli
suspect
even
case
normal
csf
result
pcr
techniqu
repres
great
tool
establish
caus
pathogen
mening
make
possibl
diagnosi
condit
even
earli
stage
chang
csf
notic
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
import
etiolog
agent
atyp
pneumonia
mycoplasma
pneumonia
caus
frequent
extrapulmonari
manifest
mep
neurolog
cardiac
skin
joint
gastrointestin
sometim
evolv
isol
thu
make
diagnosi
proper
treatment
difficult
method
studi
retrospect
includ
diagnos
case
infect
mycoplasma
pneumonia
hospit
depart
clinic
infecti
diseas
univers
medicin
pharmaci
grtpopa
period
result
annual
evolut
morbid
reveal
rel
constant
number
case
period
signific
increas
case
studi
includ
children
adult
sex
ratio
fm
predomin
urban
origin
case
rural
patient
show
sign
singl
respiratori
manifest
combin
skin
manifest
joint
liver
neurolog
manifest
respiratori
impair
common
adult
p
neurolog
impair
children
p
women
p
differ
gender
age
refer
extra
pulmonari
manifest
mep
patient
admit
hospit
earli
day
versu
day
averag
durat
occurr
respiratori
extrapulmonari
event
day
joint
day
neurolog
day
liver
manifest
day
skin
manifest
mep
appear
favor
patient
immun
suppress
statu
p
previous
administ
antibiot
therapi
hospit
p
pulmonari
manifest
frequent
receiv
macrolid
prior
hospit
p
differ
group
administr
betalactam
p
leukocytosi
detect
high
proport
mep
p
identifi
statist
signific
differ
two
group
term
valu
inflamm
test
liver
cytolysi
test
pulmonari
radiograph
chang
p
frequenc
complic
p
averag
length
hospit
higher
patient
mep
day
versu
nine
day
without
mep
conclus
mycoplasma
pneumonia
consid
case
fever
respiratori
symptom
evolv
unfavor
treat
betalactamin
associ
mep
background
children
bacteri
sepsi
common
condit
often
accompani
sever
complic
leav
sequela
sometim
lifethreaten
requir
complex
quickli
set
treatment
sepsi
common
immunosuppress
patient
method
conduct
year
studi
jan
dec
children
admit
pediatr
intens
care
unit
nation
institut
infecti
diseas
sever
form
sir
bacteri
sepsi
immunosuppress
watch
correl
data
obtain
hemocultur
csf
cultur
versu
pcr
clinic
evolut
patient
result
month
studi
children
met
clinic
biolog
criteria
sever
bacteri
sepsi
patient
came
hospit
reason
consid
etiolog
like
nosocomi
pathogen
sex
distribut
approxim
equal
consid
age
distribut
children
group
year
age
prevail
immunosuppress
patient
acquir
immunosuppress
congenit
mix
obtain
hemocultur
posit
result
obtain
molecular
method
data
correl
convent
method
diagnosi
conclus
bacteri
sepsi
children
seriou
condit
result
death
studi
requir
quick
etiolog
diagnosi
establish
appropri
emerg
treatment
pcr
effect
rapid
diagnosi
method
identifi
causal
agent
case
background
staphylococcu
aureu
common
colon
infect
agent
human
increas
mortal
case
bacteremia
case
report
year
old
man
histori
diabet
hypertens
refer
clinic
suspicion
infect
enceph
onset
symptom
day
prior
present
high
fever
malais
lower
limb
muscular
weak
progress
paresthesia
rigid
intens
headach
bradypsychia
bradylalia
patient
deni
use
recreat
drug
recent
head
trauma
open
skin
lesion
admiss
febril
bedridden
gener
muscular
atrophi
janeway
lesion
petechia
right
toe
necrosi
left
endophthalm
holosystol
murmur
apex
radiat
axilla
hepatomegali
sign
mening
irrit
lab
report
show
leukocytosi
neutrophilia
anemia
thrombocytopenia
acut
inflammatori
syndrom
posit
procalcitonin
hyperglycemia
high
glycat
hemoglobin
level
hyponatremia
hypokalemia
hypoalbuminemia
transthorac
echocardiographi
show
mobil
mitral
valv
veget
anterior
leaflet
mm
diamet
normal
eject
fraction
two
set
blood
cultur
grew
methicillinsuscept
staphylococcu
aureu
mssa
chest
xray
show
peripher
bilater
lower
lobe
infiltr
densiti
head
magnet
reson
imag
mri
show
suggest
imag
small
abscess
supratentori
region
given
data
diagnosi
infect
endocard
multipl
septic
emboli
pulmonari
ocular
cerebr
establish
antibiot
therapi
linezolid
rifampin
initi
due
good
multipl
organ
penetr
musculoskelet
secondari
determin
septic
arthriti
thigh
abscess
linezolid
hematolog
side
effect
anemia
occur
switch
therapi
oxacillin
amikacin
levofloxacin
patient
good
clinic
respons
total
cours
antibiot
therapi
week
refer
cardiovascular
surgeon
monitor
conclus
patient
suffer
uncontrol
diabet
higher
risk
infect
endogen
microb
sever
outcom
case
even
mssa
strain
isol
hemocultur
repres
therapeut
challeng
term
antibiot
option
develop
sever
life
threaten
ill
strain
mssa
possibl
use
energi
synthesi
multipl
virul
gene
adhes
penetr
invas
determin
numer
extracardiac
complic
endocard
refer
sulla
f
bussiu
dt
acquesta
f
et
al
vancomycin
minimum
inhibitori
concentr
lethal
staphylococcu
aureu
bacteremia
germ
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
streptococcu
sui
commens
pathogen
swine
neglect
pathogen
transmit
human
close
contact
sick
carrier
pig
mening
sepsi
frequent
clinic
manifest
human
recent
publish
systemat
review
identifi
studi
includ
patient
mening
due
streptococcu
sui
case
report
asia
object
draw
attent
potenti
underdiagnos
caus
mening
sepsi
countri
method
perform
retrospect
analysi
patient
diagnos
streptococcu
sui
infect
januari
one
tertiari
care
hospit
bucharest
romania
also
review
steptococcu
pneumonia
mening
accord
microbiolog
method
confirm
etiolog
result
identifi
five
patient
hospit
streptococcu
sui
infect
four
patient
mening
one
patient
endocard
two
patient
report
contact
pork
meat
patient
mening
median
age
year
iqr
male
femal
ratio
three
patient
present
alter
level
conscious
two
sever
hear
impair
cerebr
spinal
fluid
csf
examin
show
chang
characterist
bacteri
mening
latex
agglutin
test
streptococcu
pneumonia
posit
two
patient
nonetheless
streptococcu
sui
isol
csf
patient
treat
third
gener
cephalosporin
day
improv
two
patient
develop
sequela
consist
perman
sensorineur
deaf
ataxia
studi
period
identifi
total
case
pneumococc
mening
diagnosi
base
appear
gram
stain
andor
posit
latex
agglutin
reaction
csf
sampl
posit
cultur
patient
patient
endocard
year
old
male
admit
fever
malais
echocardiographi
show
aortic
valv
endocard
patient
underw
treatment
betalactambetalactamas
inhibitor
aminoglycosid
week
valv
replac
glycopeptid
week
conclus
streptococcu
sui
could
missidentifi
speci
streptococci
thu
set
lack
resourc
routin
speciat
streptococci
undercook
pork
basic
diet
underdiagnosi
streptococcu
sui
infect
like
hear
loss
although
complic
relat
streptococcu
sui
mening
frequent
report
refer
van
samkar
brouwer
mc
schultsz
c
van
der
end
van
de
beek
streptococcu
sui
mening
systemat
review
metaanalysi
plo
negl
trop
di
background
romania
report
increas
number
resist
klebsiella
pneumonia
kp
strain
isol
invas
infect
everi
year
recent
report
european
antimicrobi
resist
surveil
network
earsnet
place
us
among
first
countri
regard
kp
resist
fluoroquinolon
third
gener
cephalosporin
aminoglycosid
carbapenem
multidrug
resist
analyz
antimicrobi
resist
bloodstream
kp
isol
nation
institut
infecti
diseas
prof
dr
matei
bucharest
romania
method
antimicrobi
suscept
test
kp
strain
isol
blood
januari
decemb
januari
decemb
analyz
compar
resist
trend
two
period
statist
analysi
perform
use
fisher
exact
test
p
consid
signific
result
identifi
strain
kp
resist
aminopenicillinbetalactamas
inhibitor
associ
resist
piperacillintazobactam
resist
third
gener
cephalosporin
resist
fluoroquinolon
resist
aminoglycosid
find
strain
resist
carbapenem
strain
combin
resist
fluoroquinolon
third
gener
cephalosporin
aminoglycosid
extendedspectrum
betalactamas
esbl
produc
strain
strain
kp
isol
resist
rate
aminopenicillinbetalactamas
inhibitor
associ
piperacillintazobactam
third
gener
cephalosporin
fluoroquinolon
aminoglycosid
respect
one
strain
resist
carbapenem
strain
combin
resist
esbl
overal
resist
aminopenicillinbetalactamas
inhibitor
associ
piperacillintazobactam
third
gener
cephalosporin
fluoroquinolon
gentamycin
amikacin
trimethoprimsulfamethoxazol
combin
resist
decreas
statist
nonsignific
thing
notic
increas
rate
esbl
produc
strain
conclus
percentag
kp
strain
isol
blood
increas
find
statist
signific
chang
resist
rate
kp
class
test
antimicrobi
presenc
carbapenem
resist
among
isol
could
major
problem
public
health
hospitalacquir
infect
control
data
regard
proport
resist
bloodstream
kp
strain
differ
report
earsnet
found
lower
decreas
resist
rate
fluoroquinolon
aminoglycosid
third
gener
cephalosporin
carbapenem
combin
resist
still
romania
occupi
one
first
place
europ
regard
kp
isol
invas
infect
resist
antibiot
monitor
mandatori
effort
made
order
control
problem
background
staphylococcu
aureu
high
incid
human
infecti
patholog
regist
sever
infect
caus
antibioticresist
strain
romania
methicillinresist
aureu
mrsa
account
aureu
strain
isol
blood
cultur
earsnet
report
mani
european
countri
percentag
mrsa
invas
infect
caus
aureu
decreas
implement
program
design
limit
bacteri
resist
object
determin
antibiot
resist
aureu
strain
isol
blood
cultur
method
perform
retrospect
studi
analyz
blood
cultur
result
collect
patient
hospitalis
infect
diseas
pneumolog
clinic
victor
hospit
craiova
antibiot
resist
aureu
strain
isol
blood
cultur
analyz
base
result
disc
diffus
sensit
test
methicillinresist
strain
present
inhibit
zone
around
disk
cefoxitin
mcg
mm
result
evalu
carri
compar
percentag
differ
perform
test
result
studi
period
blood
cultur
perform
posit
blood
cultur
posit
aureu
case
klebsiella
pneumonia
case
escherichia
coli
case
distribut
age
blood
cultur
posit
aureu
year
old
case
year
old
year
old
blood
cultur
mrsa
percentag
test
strain
peak
strain
compar
strain
antibiot
resist
aureu
isol
strain
penicillin
oxacillin
clarithromycin
amoxicillinclavulan
acid
trimethoprimsulfamethoxazol
ceftriaxon
meropenem
levofloxacin
gentamicin
chloramphenicol
clindamycin
vancomycin
linezolid
mrsa
percentag
higher
infant
compar
adult
without
statist
signific
differ
conclus
aureu
common
etiolog
agent
isol
blood
cultur
high
preval
methicillinresist
strain
test
antibiot
lowest
resist
observ
linezolid
vancomycin
clindamycin
aminoglycosid
fluoroquinolon
activ
strain
mrsa
without
antibiot
multiresist
background
product
remain
import
mechan
resist
preval
extendedspectrum
esbl
hospit
commun
set
preferenti
hydrolyz
cefotaxim
belong
plasmidmedi
esbl
ctxm
object
studi
bacteri
resist
improv
diagnosi
treatment
infect
pathogen
method
fiftynin
strain
isol
urin
sever
blood
collect
june
septemb
two
hospit
quebec
citi
canada
strain
sent
research
center
infecti
diseas
laval
univers
quebec
citi
identif
antibiot
resist
determin
use
system
esbl
product
test
accord
clsi
recommend
crude
dna
extract
prepar
strain
rapid
dna
extract
method
dna
use
pcr
amplif
use
differ
primer
specif
bla
tem
bla
shv
bla
ctxm
gene
amplicon
produc
sequenc
identifi
gene
resist
result
strain
test
esbl
esbl
escherichia
coli
preval
speci
percentag
strain
test
esbl
producingstrain
posit
least
one
resist
gene
test
predomin
resist
gene
bla
ctxm
either
alon
combin
bla
tem
gene
present
e
coli
sequenc
analysi
bla
ctxm
gene
found
reveal
strain
member
ctxm
group
member
ctxm
group
two
differ
resist
gene
identifi
strain
bla
ctxm
bla
tem
bla
shv
bla
tem
howev
sequenc
data
reveal
bla
tem
gene
identifi
esbl
esbl
strain
encod
esbl
suggest
resist
phenotyp
esblproduc
strain
two
resist
gene
confer
bla
ctxm
bla
shv
gene
anoth
resist
gene
test
studi
like
respons
esbl
resist
phenotyp
strain
contain
bla
temnonesbl
gene
conclus
studi
show
bla
ctxm
preval
resist
gene
esblproduc
enterobacteriacea
quebec
citi
part
group
consist
global
data
show
predomin
ctxm
esbl
worldwid
recent
epidemiolog
data
region
canada
show
well
respect
part
group
commonli
found
background
acinetobact
baumannii
aerob
gram
neg
bacterium
depend
profil
resist
mdr
multidrug
resist
xdr
extens
drug
resist
pdr
pandrug
resist
may
except
sourc
sever
infect
less
therapeut
control
case
report
chosen
bring
forward
peculiar
case
year
old
man
transfer
depart
agit
confus
gc
fever
occur
day
postoperatori
period
left
otomastoidectomi
suspicion
bacteri
meningoenceph
patient
medic
record
emphas
histori
chronic
suppur
otomastoid
surgic
treat
twenti
year
moment
forward
patient
present
numer
relaps
left
ear
pain
purul
otorrhea
accompani
neurolog
involv
left
facial
nerv
peripher
palsi
local
treatment
outpati
antibiot
therapi
conduct
two
year
admiss
tympanicmastoid
caviti
purul
discharg
clinic
perceiv
mri
confirm
presenc
abscess
left
petrou
part
tempor
bone
success
evalu
conduct
multidisciplinari
approach
surgic
intervent
delay
current
admiss
blood
multipl
sampl
taken
lumbar
punctur
perform
csf
aspect
highli
suggest
bacteri
meningoenceph
patient
immedi
start
broadspectrum
antibiot
aim
cover
highli
resist
bacteria
csf
cultur
came
back
posit
acinetobact
baumannii
xdr
colistin
sensit
present
follow
complex
therapi
clinic
biolog
profil
improv
neurolog
statu
becam
stabl
gc
thu
permit
surgic
reintervent
conclus
minim
ear
infecti
involv
must
promptli
address
order
prevent
local
complic
may
lead
destruct
irrevers
lesion
lesion
appear
multidisciplinari
approach
becom
compulsori
high
financi
human
cost
impli
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
case
report
present
case
year
urban
femal
shortli
arthroscop
procedur
develop
fever
chill
partial
function
impot
local
swell
joint
punctur
isol
burkholderia
cepacia
suscept
meropenem
minocyclin
trimethoprim
week
meropenem
week
minocyclin
evolut
favor
soon
subfebril
swell
pain
function
impot
reappear
month
burkholderia
cepacia
similar
suscept
isol
took
meropenem
gday
combin
doxycyclin
day
follow
meropenem
trimethoprim
intraarticular
devic
remov
patient
becam
afebril
local
evolut
favor
cultur
neg
day
day
develop
agranulocytosi
discontinu
trimethoprim
decreas
dose
meropenem
supplement
granulocyt
growth
factor
evolut
favor
local
hematolog
bacteriolog
continu
therapi
anoth
week
meropenem
week
minocyclin
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
emerg
spread
antibiot
resist
becom
worldwid
top
prioriti
health
problem
besid
genet
resist
bacteria
develop
multitud
mechan
lead
toler
antimicrobi
estim
center
diseas
control
prevent
usa
peopl
die
everi
year
due
infect
multidrug
resist
bacteria
method
perform
pilot
experiment
studi
nation
institut
infecti
diseas
prof
dr
matei
treat
six
patient
combin
therapi
antibiot
bacteriophag
studi
receiv
ethic
committe
approv
matei
carol
davila
pathogen
agent
evalu
phage
suscept
commerci
georgian
phage
cocktail
name
pyo
intesti
eliava
bioprepar
tbilisi
georgia
includ
studi
patient
fail
antibiot
therapi
hardtotreat
infect
due
antibiot
resist
bacteria
biofilm
format
hard
steril
infect
site
phage
administ
oral
orand
topic
result
pilot
studi
includ
follow
type
infect
recurr
endocard
staphylococcu
aureu
chronic
osteomyel
aureu
p
aeruginosa
periprosthet
dorsolumbar
softtissu
infect
aureu
chronic
cutan
infect
simulan
e
coli
p
aeruginosa
axillari
hidraden
proteu
mirabili
epidermidi
chronic
osteomyel
aureu
six
case
combin
therapi
prove
safe
advers
reaction
advers
chang
laboratori
paramet
total
patient
neg
cultur
therapi
day
end
therapi
cultur
becam
posit
case
one
patient
recurr
endocard
aureu
conclud
timespan
relaps
longer
receiv
combin
therapi
compar
antimicrobi
treatment
alon
one
case
periprosthet
dorsolumbar
softtissu
infect
aureu
achiev
sustain
bacteriolog
respons
although
patient
consid
hardtotreat
due
histori
multipl
drug
allergi
syndrom
presenc
multipl
foreign
bodi
metal
rod
screw
biofilm
format
histori
unsuccess
long
term
antibiot
therapi
conclus
knowledg
first
experiment
trial
conduct
romania
combin
therapi
antibiot
bacteriophag
sinc
prove
safeti
bacteriophag
clinic
set
consid
studi
cornerston
futur
research
regard
vivo
phage
therapi
romania
acknowledg
carol
davila
univers
medicin
pharmaci
young
research
grant
phd
thesi
acn
background
healthcareassoci
infect
hai
surveil
program
may
focu
amongst
other
specif
microorgan
like
multidrug
resist
organ
mdro
methicillinresist
staphylococcu
aureu
mrsa
mdro
public
health
concern
may
pose
problem
acut
nonacut
healthcar
set
detect
monitor
import
hospitalbas
prevent
surveil
control
effort
program
hai
surveil
control
nation
institut
infecti
diseas
prof
dr
matei
includ
activ
screen
mdro
patient
admit
icu
regardless
ward
transfer
healthcar
set
hospit
method
studi
conduct
januari
juli
collect
swab
criteria
base
select
patient
pharyng
nasal
rectal
total
swab
process
month
interv
target
microorgan
mrsa
vancomycin
resist
enterococci
vre
multidrug
resist
gramneg
bacteria
swab
inocul
appropri
chromogen
cultur
media
oxoid
uk
brillianc
mrsa
agar
brillianc
vre
agar
brillianc
esbl
agar
interpret
hour
incub
aerob
atmospher
microorgan
identifi
test
suscept
antimicrobi
microscan
walk
away
plu
siemen
usa
eucast
guidelin
use
interpret
kpc
mbl
confirm
kit
rosco
diagnostica
denmark
use
determin
carbapenemaseproduc
strain
result
mrsa
detect
pharyng
nasal
swab
posit
rectal
swab
count
one
per
patient
percentag
rectal
swab
posit
one
microorgan
posit
microorgan
microorgan
total
number
microorgan
isol
rectal
swab
escherichia
coli
vre
klebsiella
pneumonia
pseudomona
aeruginosa
acinetobact
baumannii
mdro
less
vre
carriag
vari
proport
klebsiella
pneumonia
carbapenemaseproduc
strain
increas
year
first
month
one
microorgan
enterobact
cloaca
carbapenemas
produc
conclus
mrsa
colon
vari
pharyng
nasal
vre
carriag
increas
carbapenemaseproduc
klebsiella
pneumonia
doubl
first
month
compar
acknowledg
thank
emilia
mariana
import
help
isol
bacteri
strain
includ
studi
background
bacteri
infect
remain
one
import
caus
diseas
worldwid
option
treat
limit
due
emerg
antimicrobi
resist
amr
aim
studi
evalu
amr
gramposit
cocci
isol
nation
institut
infecti
diseas
prof
dr
matei
method
total
nondupl
strain
staphylococcu
aureu
coagulaseneg
staphylococci
streptococcu
pneumonia
enterococcu
faecali
enterococcu
faecium
streptococcu
pyogen
test
antimicrobi
resist
suscept
test
perform
autom
system
vitek
biomerieux
microscan
walkaway
siemen
also
sensititr
thermo
scientif
mic
plate
etest
biomerieux
streptococcu
pneumonia
disk
diffus
method
use
result
interpret
use
clsi
eucast
criteria
result
staphylococcu
aureu
resist
oxacillin
vari
decreas
erythromycin
clindamycin
resist
strain
staphylococcu
aureu
increas
respect
staphylococcu
aureu
strain
resist
quinolon
vari
annual
ciprofloxacin
moxifloxacin
without
clear
increas
decreas
tendenc
trimethoprimsulfamethoxazol
resist
remain
low
level
strain
resist
linezolid
vancomycin
incid
resist
higher
coagulaseneg
staphylococci
isol
blood
oxacillin
trimethoprimsulfamethoxazol
incid
penicillinresist
streptococcu
pneumonia
strain
isol
invas
infect
decreas
enterococcu
faecium
resist
compar
enterococcu
faecali
test
antimicrobi
gentamicin
compar
ciprofloxacin
compar
first
vancomycinresist
enterococcu
faecium
strain
isol
incid
reach
two
enterococcu
faecali
vancomycinresist
strain
isol
one
one
streptococcu
pyogen
resist
erythromycin
increas
significantli
time
conclus
oxacillin
resist
incid
staphylococcu
aureu
regist
slight
decreas
sinc
coagulaseneg
staphylococci
significantli
resist
staphylococcu
aureu
first
strain
enterococcu
faecium
resist
vancomycin
isol
proport
reach
continu
monitor
antimicrobi
resist
highli
need
particular
guid
effici
empir
therapi
background
carbapenem
probabl
import
lastlin
antibiot
treatment
infect
involv
multidrugresist
gramneg
bacteria
last
year
emerg
carbapenemresist
gramneg
bacilli
consid
one
worldwid
import
challeng
public
health
method
analysi
base
antimicrobi
resist
data
collect
niph
nation
antibiot
sale
provid
imshealth
romania
european
level
data
obtain
ear
net
esac
net
newest
report
result
percentag
carbapenemresist
escherichia
coli
low
past
four
year
past
four
year
sever
resist
isol
repres
alert
risk
commun
acquir
infect
due
xdr
strain
gramneg
bacteria
carbapenemresist
alreadi
high
rapidli
emerg
klebsiella
pneumonia
third
highest
resist
level
ear
net
pseudomona
aeruginosa
first
resist
percentag
ear
net
acinetobact
baumannii
fourth
resist
level
ear
net
similar
high
percentag
obtain
result
infecti
diseas
hospit
analyz
risk
factor
carbapenemresist
carbapenem
usag
carbapenemresist
bacteria
transmiss
carbapenem
usag
romania
increas
germ
transmiss
probabl
high
level
hospit
sever
recent
exampl
proven
conclus
high
percentag
carbapenemresist
romania
relat
misus
carbapenem
gener
pseudosci
myth
germ
transmiss
romanian
hospit
problem
need
address
infecti
diseas
specialist
could
play
pivot
role
control
public
health
sever
emerg
acknowledg
author
acknowledg
support
receiv
nation
institut
public
health
imshealth
romania
data
collect
background
healthcareassoci
mening
ventricul
seriou
lifethreaten
complic
invas
neurosurg
procedur
penetr
head
trauma
method
current
studi
review
case
health
careassoci
mening
ventricul
treat
sf
parascheva
infecti
diseas
hospit
januari
decemb
result
review
case
involv
adult
patient
age
patient
higher
frequenc
age
group
healthcareassoci
bacteri
mening
may
occur
neurosurg
procedur
head
trauma
placement
intern
extern
ventricular
cathet
ent
maxillofaci
surgeri
case
posit
cerebrospin
fluid
cultur
frequent
agent
gram
neg
bacilli
pseudomona
spp
acinetobact
spp
escherichia
coli
klebsiella
pneumonia
gram
posit
cocci
staphylococcu
aureu
particular
focu
mrsa
coagulaseneg
staphylococcu
streptococcu
pneumonia
admiss
clinic
sign
symptom
fever
headach
chang
mental
statu
glasgow
coma
scale
nauseavomit
focal
neurolog
deficit
neck
stiff
seizur
photophobia
diagnost
evalu
involv
neuroimag
investig
ctmri
cerebrospin
fluid
analysi
empir
antimicrobi
therapi
direct
toward
like
infect
pathogen
complic
involv
brain
abscess
ventricul
cranial
nerv
damag
deaf
blind
outcom
neg
case
posit
disabl
patient
without
disabl
patient
conclus
healthcareassoci
mening
ventricul
remain
challeng
term
diagnosi
treatment
prevent
background
medic
world
infect
caus
bacteria
increas
virul
nosocomi
infect
seriou
threat
medic
depart
epidemiolog
data
must
thoroughli
collect
interpret
set
clinic
fact
thu
guid
complex
process
therapeut
intervent
method
analyz
clinic
data
obtain
icu
depart
period
month
outlin
main
pattern
involv
occurr
evolut
nosocomi
infect
main
sourc
nosocomi
infect
venou
arteri
cathet
respons
bloodstream
infect
case
orotrach
intub
case
caus
sever
ventilatorassoci
pneumonia
bladder
catheter
respons
case
urinari
tract
infect
case
everi
nosocomi
infect
etholog
analyz
correl
clinic
impact
suggest
sign
develop
peripher
cathet
implant
fever
first
sign
catheterassoci
bloodstream
infect
purul
aspect
pulmonari
secret
intub
patient
first
omen
vap
turbid
aspect
urin
indic
potenti
hospitalacquir
infect
patient
bladder
catheter
result
institut
special
diagnosi
treatment
infecti
diseas
nosocomi
infect
differ
stage
evolut
part
current
patholog
base
argument
icu
januari
juli
case
consid
import
nosocomi
infect
failur
previou
treatment
case
declar
novel
nosocomi
infect
ventil
associ
pneumonia
vap
baumannii
immunocompromis
patient
end
stage
aidshiv
infect
unfortun
evolut
continu
unfavor
subsequ
death
ten
patient
import
nosocomi
infect
favor
evolut
discharg
good
condit
other
die
result
vap
mrsa
vap
p
aeruginosa
respect
conclus
patient
admit
clinic
period
month
infect
multiresist
bacteria
time
admiss
thu
emphas
spread
germ
high
antibiot
resist
commun
necess
thorough
bacteriolog
survey
time
interhospit
transfer
nosocomi
infect
remain
constant
threat
whose
dynam
must
close
monitor
futur
background
use
directli
act
antivir
agent
chronic
hcv
hepat
prove
effici
safe
clinic
trial
method
transaminas
bilirubin
blood
cell
count
initi
week
treatment
evalu
patient
hcv
associ
cirrhosi
undergo
treatment
dasabuvir
ombitasvir
paritaprevir
ritonavir
ribavirin
hvcrna
determin
initi
end
therapi
eot
result
includ
patient
male
mean
age
year
two
patient
liver
transplant
patient
hcv
genotyp
receiv
week
treatment
two
patient
receiv
ribavirin
one
minor
thalassemia
one
polyarthr
includ
patient
diabet
nephropathi
end
stage
renal
diseas
esrd
one
undergo
hemodialysi
patient
reach
end
treatment
one
patient
liver
transplant
undetect
viremia
one
viremia
iuml
patient
evalu
week
eot
undetect
viremia
eot
sustain
virolog
respons
ribavirin
discontinu
patient
due
sever
cutan
reaction
erythroderma
patient
esrd
discontinu
ribavirin
week
due
sever
anemia
one
patient
system
lupu
stop
ribavirin
week
due
hypotens
patient
thalassemia
present
duoden
hematoma
pancreat
reaction
first
week
improv
medic
therapi
discontinu
ribavirin
undetect
viremia
eot
ribavirin
dose
decreas
week
patient
varic
bleed
stop
week
due
sever
anemia
patient
also
virolog
respons
eot
anoth
patient
present
hepatocellular
carcinoma
week
underw
transarteri
chemoembol
week
decompens
ascit
ultim
good
evolut
undetect
viremia
eot
complet
respons
nodul
mean
initi
level
transaminas
doubl
normal
valu
decreas
dramat
first
two
week
treatment
low
level
maintain
throughout
therapi
mean
initi
bilirubin
level
normal
valu
increas
first
month
mgdl
week
mgdl
week
afterward
small
constant
decreas
normal
eot
conclus
therapi
well
toler
safe
effici
patient
chronic
hcv
hepat
cirrhosi
ribavirin
dose
reduct
mileston
therapi
background
clinic
hospit
infecti
diseas
studi
perform
evalu
antivir
hepatoprotect
effect
medicin
product
viusid
treatment
viral
hepat
b
c
method
studi
involv
patient
chronic
viral
hepat
b
patient
group
c
patient
group
ii
among
group
men
women
group
ii
respect
patient
examin
includ
physic
exam
biochemistri
test
alt
ast
ggt
complet
blood
count
molecular
biolog
assay
hbv
dna
hcv
rna
quantif
pcr
viusid
prescrib
follow
sachet
time
daili
everi
hour
month
patient
physic
examin
perform
monthli
laboratori
test
begin
end
treatment
result
clinic
manifest
scanti
group
right
hypochondriac
pain
case
group
group
ii
weak
fatigu
group
group
ii
end
treatment
clinic
manifest
present
complet
blood
count
leukocyt
count
remain
normal
rang
nonsignific
evolut
lymphocyt
count
trend
increas
within
normal
rang
platelet
count
chang
significantli
biochemistri
test
posit
evolut
total
direct
bilirubin
level
normal
group
observ
alt
ast
ggt
increas
patient
group
group
ii
averag
valu
paramet
tend
reduc
patient
group
reduct
signific
group
ii
molecular
biolog
assay
hcv
rna
level
decreas
iuml
iuml
becom
neg
hbv
dna
level
reduc
averag
begin
treatment
iuml
iuml
end
treatment
patient
hbv
dna
detect
conclus
treatment
patient
group
viusid
show
clinic
biochem
improv
appar
group
indic
protect
effect
medicin
product
viusid
reduct
hbv
dna
level
hcv
rna
level
denot
antivir
effect
drug
background
fda
warn
direct
act
antivir
daa
caus
sever
liver
injuri
patient
advanc
liver
diseas
howev
liver
decompens
report
patient
hcv
childpugh
cirrhosi
juli
case
hcv
childpugh
patient
treat
ombitasvirparitaprevirritionavirdasabuvir
oprd
sever
liver
decompens
report
jaundic
oprd
therapi
report
especi
hivhcv
coinfect
patient
guidelin
regard
manag
patient
publish
yet
object
analyz
predict
factor
hyperbilirubinemia
daa
therapi
hcv
childpugh
cirrhosi
also
establish
manag
patient
method
prospect
studi
patient
hcv
genotyp
childpugh
cirrhosi
treat
oprdribavirin
regimen
third
depart
matei
institut
analyz
patient
develop
hyperbilirubinemia
antivir
therapi
order
identifi
risk
factor
side
effect
manag
patient
also
analyz
statist
analysi
made
openepi
program
result
eightyseven
patient
hcv
compens
cirrhosi
treat
depart
oprdribavirin
regimen
three
patient
discontinu
antivir
therapi
two
liver
decompens
one
month
therapi
patient
total
bilirubin
mgdl
total
bilirubin
mgdl
maxim
valu
mgdl
time
patient
develop
anemia
perman
discontinu
ribavirin
five
patient
high
valu
bilirubin
mgdl
one
patient
predomin
unconjug
bilirubin
sever
anemia
hemolyt
mechan
recoveri
ribavirin
discontinu
patient
liver
decompens
discontinu
daa
regimen
three
patient
develop
liver
decompens
slow
recoveri
discontinu
ribavirin
observ
risk
factor
hyperbilirubinemia
analyz
two
highli
correl
side
effect
childpugh
score
baselin
rr
p
baselin
level
platelet
count
less
rr
p
conclus
hyperbilirubinemia
patient
compens
cirrhosi
treat
oprdribavirin
regimen
repres
sever
side
effect
ribavirin
must
discontinu
situat
sometim
daa
regimen
withdrawn
import
risk
factor
side
effect
childpugh
score
baselin
platelet
count
baselin
background
romanian
nation
health
system
approv
use
direct
act
antivir
daa
treatment
hcv
compens
cirrhosi
approv
regimen
contain
proteas
inhibitor
paritaprevir
boost
ritonavir
inhibitor
ombitasvir
nonnucleosid
inhibitor
dasabuvir
oprd
recommend
week
genotyp
week
genotyp
daa
regimen
associ
ribavirin
object
evalu
real
life
data
regard
efficaci
regimen
genotyp
hcv
infect
patient
compens
cirrhosi
method
perform
prospect
analysi
patient
hcv
compens
cirrhosi
treat
third
depart
matei
institut
sinc
novemb
juli
includ
patient
underw
least
four
week
antivir
therapi
analyz
evolut
clinic
biolog
paramet
also
trend
hcv
viral
load
result
patient
receiv
approv
oprd
therapi
compens
cirrhosi
one
fibrosi
sever
depress
patient
experienc
liver
decompens
third
month
therapi
cholangiocarcinoma
diagnos
die
week
later
patient
differ
stage
therapi
patient
end
followup
ef
patient
end
therapi
eot
patient
third
month
therapi
patient
second
month
therapi
patient
first
month
patient
whose
viral
load
analys
week
therapi
regist
undetect
patient
viral
load
low
limit
quantif
patient
finish
therapi
undetect
viral
load
patient
finish
week
monitor
period
regist
sustain
virolog
respons
two
patient
prematur
discontinu
antivir
therapi
due
liver
decompens
cardiac
disord
patient
abnorm
alt
baselin
normal
alt
week
therapi
patient
normal
alt
week
therapi
conclus
regimen
highli
effici
difficult
treat
patient
compens
cirrhosi
patient
complet
therapi
achiev
undetect
viral
load
furthermor
case
complet
week
period
followup
svr
achiev
background
regimen
approv
therapi
hcv
child
pugh
cirrhosi
contain
begin
differ
combin
direct
act
antivir
ribavirin
recent
studi
shown
associ
ribavirin
increas
efficaci
regimen
recent
countri
local
protocol
therapi
hcv
compens
cirrhosi
recommend
daa
without
ribavirin
avail
data
import
ribavirin
therapi
patient
compens
cirrhosi
came
clinic
studi
data
real
life
use
object
analyz
efficaci
ombitasvirparitaprevirritonavir
oprd
without
ribavirin
patient
hcv
child
pugh
cirrhosi
method
prospect
analysi
oprd
regimen
efficaci
without
ribavirin
patient
compens
hcv
cirrhosi
monitor
third
depart
matei
institut
result
novemb
juli
patient
receiv
approv
oprd
ribavirin
therapi
hcv
compens
cirrhosi
genotyp
one
patient
genotyp
undetermin
subtyp
patient
contraind
ribavirin
usag
chronic
anemia
patient
also
patient
prematur
discontinu
ribavirin
patient
start
ribavirin
one
month
antivir
therapi
ribavirin
discontinu
patient
patient
dose
reduc
import
reason
ribavirin
discontinu
dose
reduct
sever
anemia
also
patient
moder
mild
anemia
sever
jaundic
patient
total
bilirubin
mgdl
among
patient
bilirubin
mgdl
two
month
therapi
patient
discontinu
ribavirin
patient
receiv
least
month
therapi
patient
discontinu
ribavirin
patient
ribavirin
dose
reduc
patient
receiv
full
dosag
ribavirin
least
two
month
despit
ribavirin
dose
reduct
discontinu
patient
complet
week
therapi
achiev
undetect
viral
load
patient
complet
followup
period
achiev
sustain
virolog
respons
conclus
efficaci
oprd
regimen
patient
hcv
compens
cirrhosi
similar
without
ribavirin
sometim
ribavirin
side
effect
conduct
prematur
discontinu
antivir
regimen
thought
difficult
treat
patient
regimen
without
ribavirin
could
better
option
background
patient
hcv
cirrhosi
need
urgent
antivir
therapi
howev
patient
liver
cirrhosi
repres
difficult
treat
case
appropri
monitor
necessari
import
data
regard
safeti
ombitasvirparitaprevirritonavirdasabuvir
oprd
ribavirin
regimen
hcv
cirrhot
patient
came
turquois
ii
clinic
trial
real
life
data
lacunar
accord
romanian
guidelin
also
summari
product
characterist
regimen
recommend
child
cirrhosi
object
analyz
risk
liver
decompens
oprdribavirin
regimen
hcv
childpugh
cirrhot
patient
method
perform
prospect
studi
hcv
child
cirrhot
patient
monitor
third
depart
matei
institut
develop
liver
decompens
oprd
therapi
correl
liver
decompens
clinic
biolog
characterist
baselin
result
eighti
seven
child
cirrhot
patient
treat
depart
patient
point
child
score
patient
point
five
patient
develop
liver
decompens
antivir
therapi
two
patient
perman
discontinu
antivir
therapi
one
day
therapi
discontinu
ribavirin
support
therapi
outcom
good
second
one
diagnos
cholangiocarcinoma
week
therapi
two
patient
liver
decompens
good
outcom
cessat
ribavirin
support
therapi
complet
therapi
oprd
achiev
one
patient
still
hospit
strict
monitor
ribavirin
stop
oprd
regimen
yet
discontinu
mean
age
yearold
male
femal
naiv
patient
previous
treat
null
respons
patient
child
score
patient
baselin
abnorm
inr
less
limit
accept
child
pugh
score
platelet
count
mild
increas
total
bilirubin
mgdl
patient
mgdl
one
patient
albumin
gdl
one
patient
four
patient
esophag
varic
baselin
patient
increas
spleen
diamet
conclus
liver
decompens
patient
child
pugh
score
oprdribavirin
regimen
low
rate
probabl
situat
possibl
diagnosi
compens
cirrhosi
probabl
take
account
clinic
biolog
paramet
one
use
child
pugh
score
background
regimen
contain
inhibitor
ombitasvir
proteas
inhibitor
paritaprevir
boost
ritonavir
nonnucleosid
inhibitor
dasabuvir
oprd
associ
ribavirin
approv
romania
novemb
genotyp
hcv
infect
patient
compens
cirrhosi
safeti
data
regard
therapeut
regimen
came
clinic
studi
mani
patient
sever
comorbid
exclud
data
come
reallif
relev
context
object
aim
studi
analyz
report
side
effect
occur
oprdriba
regimen
also
manag
side
effect
method
perform
prospect
studi
use
databas
cirrhot
patient
treat
oprdriba
regimen
third
depart
matei
institut
advers
event
occur
patient
introduc
databas
establish
correl
regimen
side
effect
grade
side
effect
also
manag
result
total
patient
follow
median
age
year
iqr
year
male
patient
report
least
one
clinic
advers
event
common
fatigu
pruritu
dizzi
sleep
disord
nausea
andor
vomit
muscl
andor
bone
pain
headach
diarrhoea
skin
rash
main
laboratori
abnorm
anemia
hyperbilirubinemia
first
month
treatment
patient
develop
mild
anemia
hemoglobin
level
gdl
develop
moder
anemia
hemoglobin
level
gdl
total
bilirubin
level
mgdl
one
month
therapi
observ
patient
ribavirin
discontinu
three
patient
discontinu
treatment
two
liver
decompens
conclus
import
side
effect
anemia
correl
ribavirin
use
case
ribavirin
discontinu
necessari
jaundic
anoth
side
effect
difficult
control
complet
therapi
discontinu
due
advers
event
infrequ
background
romanian
patient
known
genotyp
hcv
compens
cirrhosi
access
direct
act
antivir
daa
therapi
sinc
novemb
free
nation
program
financ
romanian
health
insur
elig
criteria
daa
regimen
genotyp
hcv
detect
viral
load
cirrhosi
diagnos
fibromax
biopredict
franc
fibrotest
compens
cirrhosi
accord
child
pugh
score
child
pugh
score
point
object
analyz
caus
led
failur
access
daa
regimen
via
romanian
nation
program
method
perform
prospect
studi
enrol
patient
known
compens
cirrhosi
receiv
voucher
access
therapi
fibromax
viral
load
hcv
genotyp
test
current
statu
patient
analyz
result
patient
includ
daa
therapi
program
third
depart
matei
institut
among
receiv
approv
patient
await
approv
patient
inelig
despit
fibrosi
due
diagnosi
hepatocellular
carcinoma
fibrosi
less
inelig
accord
local
guidelin
patient
fibrosi
accord
fibromax
case
previou
fibrosi
investig
fibromax
fibroscan
patient
sever
comorbid
despit
data
evalu
fibromax
nation
program
show
fibrosi
inelig
daa
therapi
one
case
result
fibromax
patient
signific
clinic
sign
cirrhosi
therapi
approv
twentytwo
patient
fibromax
show
fibrosi
howev
known
compens
cirrhosi
previous
diagnos
fibromax
fibroscan
liver
biopsi
clinic
find
like
esophag
varic
among
patient
consid
elig
therapi
patient
alreadi
receiv
approv
patient
await
commiss
decis
eight
patient
without
clinic
sign
cirrhosi
declar
inelig
despit
previou
evalu
fibrosi
noninvas
method
conclus
fibrosi
alway
correctli
determin
fibromax
import
use
altern
test
accur
diagnosi
cirrhosi
moreov
even
test
manufactur
biopredict
recommend
fibrotest
score
valu
interpret
sever
fibrosi
must
treat
urgent
background
nucleo
ide
analogu
na
realiz
proper
suppress
viral
replic
chronic
hepat
b
hbv
neglig
immun
control
lifelong
therapi
necessari
highest
risk
therapi
discontinu
even
patient
achiev
undetect
viral
load
vl
viral
reactiv
reactiv
flare
appear
case
therapi
cessat
associ
jaundic
hepatocytolysi
high
vl
case
develop
fulmin
hepat
high
mortal
rate
method
present
seri
case
viral
reactiv
follow
discontinu
entecavir
etv
administ
chronic
hbv
result
three
patient
known
chronic
hbv
admit
depart
jaundic
alt
increas
first
case
young
woman
pregnant
week
etv
year
neg
hbeag
undetect
vl
decid
stop
therapi
discov
pregnanc
six
month
later
admit
clinic
import
hepatocytolysi
biolog
exam
reveal
alt
x
upper
limit
normal
uln
posit
hbeag
hbv
vl
log
iuml
normal
prothrombin
concentr
mild
hyperbilirubinemia
patient
receiv
label
lamivudin
slow
decreas
alt
vl
log
iuml
deliveri
etv
therapi
reintroduc
deliveri
favor
outcom
second
case
young
man
discontinu
etv
lost
medic
insur
antivir
therapi
normal
alt
undetect
vl
five
month
later
present
alt
jaundic
high
vl
patient
renew
insur
etv
reiniti
good
outcom
last
patient
yearold
man
still
hospit
etv
year
good
biolog
outcom
previou
therapi
peginterferon
januari
stop
etv
august
admit
clinic
jaundic
vomit
test
show
alt
hyperbilirubinemia
mgdl
posit
hbeag
decreas
prothrombin
concentr
fibrinogen
therapi
tenofovir
immedi
start
day
prothrombin
concentr
becam
normal
alt
bilirubin
remain
increas
conclus
na
therapi
must
continu
hb
seroconvers
even
patient
achiev
undetect
vl
risk
sever
liver
decompens
especi
young
peopl
extrem
high
women
childbear
potenti
etv
switch
tenofovir
therapi
must
continu
entir
pregnanc
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
regimen
approv
romania
patient
hcv
compens
cirrhosi
involv
ombitasvirparitaprevirritonavirdasabuvir
oprd
associ
ribavirin
import
side
effect
ribavirin
base
therapi
anemia
wellknown
era
peginterferonribavirin
regimen
object
analyz
hematolog
disord
occur
oprd
ribavirin
therapeut
regimen
hcv
compens
cirrhosi
method
prospect
studi
hcv
cirrhot
patient
treat
oprdribavirin
regimen
novemb
juli
third
depart
matei
institut
analyz
dynam
hemoglobin
level
platelet
count
week
daa
therapi
result
eightyseven
patient
hcv
compens
cirrhosi
treat
depart
mean
age
year
old
sex
ratio
f
one
month
therapi
patient
develop
moder
anemia
hemoglobin
gdl
gdl
gdl
medium
valu
gdl
sixteen
patient
perman
discontinu
ribavirin
first
month
antivir
therapi
two
patient
perman
discontinu
therapeut
regimen
one
patient
sever
cardiac
disturb
liver
decompens
import
jaundic
patient
dosag
ribavirin
reduc
patient
hemoglobin
level
first
month
therapi
gdl
mild
anemia
sever
fatigu
dosag
ribavirin
reduc
month
therapi
patient
reach
endpoint
patient
perman
discontinu
ribavirin
due
moder
anemia
gdl
patient
complet
therapi
anemia
despit
reduct
discontinu
ribavirin
patient
finish
monitor
therapi
patient
develop
anemia
normal
level
hemoglobin
regard
thrombocytopenia
improv
antivir
therapi
analysi
perform
patient
finish
therapi
baselin
patient
sever
thrombocytopenia
patient
platelet
count
end
treatment
patient
remain
sever
thrombocytopenia
patient
platelet
count
statist
analysi
show
signific
increas
platelet
count
conclus
frequent
hematolog
side
effect
oprdriba
therapi
hcv
hepat
anemia
recoveri
adjust
ribavirin
dosag
sometim
discontinu
ribavirin
necessari
without
impact
efficaci
regimen
term
platelet
count
signific
improv
shown
background
preval
risk
factor
behavior
knowledg
hbv
hcv
infect
vari
differ
area
world
perform
studi
determin
whether
classic
risk
factor
hbv
hcv
show
divers
due
differ
ethnic
geograph
origin
two
match
young
cohort
heterogen
studi
group
intern
medic
student
control
group
gener
romanian
popul
method
perform
cross
section
studi
base
standard
questionnair
serolog
test
assess
preval
risk
factor
transmiss
viral
hepat
two
studi
group
ztest
use
check
statist
signific
proport
specif
risk
factor
two
group
result
studi
includ
particip
studi
group
control
group
median
age
studi
group
year
interquartil
rang
iqr
year
year
iqr
year
control
group
maletofemal
ratio
studi
group
vs
control
group
follow
risk
factor
hbv
hcv
transmiss
significantli
preval
studi
group
blood
transfus
organ
transplant
p
histori
coagulopathi
p
inject
drug
use
p
live
someon
hepat
b
p
histori
travel
countri
high
hbv
risk
p
never
undergon
screen
hepat
p
hiv
p
histori
unprotect
oral
p
vagin
p
intercours
one
partner
last
year
occup
exposur
hivhepat
p
tattoo
pierc
p
howev
studi
group
also
present
posit
healthrel
behavior
histori
vaccin
hepat
p
hepat
b
p
previou
neg
result
upon
screen
hepat
p
hiv
p
conclus
worldwid
preval
certain
risk
factor
hbv
hcv
infect
seriou
issu
transcend
nation
gender
ethnic
origin
educ
level
result
suggest
global
strategi
prevent
control
hepat
infect
need
along
effect
vaccin
program
acknowledg
abstract
part
licens
thesi
hepat
risk
factor
distribut
young
cohort
perform
carol
davila
univers
medicin
pharmaci
bucharest
romania
coordin
dr
anca
streinucercel
md
phd
supervisor
dr
oana
md
phd
give
screen
chanc
hcv
gcshcv
project
janssen
background
data
hepat
c
viru
reactiv
hcvr
patient
hematolog
malign
hm
immunosuppress
therapi
limit
preval
hcv
infect
higher
romania
eu
countri
aim
evalu
clinic
characterist
outcom
patient
hm
undergo
immunosuppress
therapi
method
perform
prospect
studi
includ
patient
hm
treat
rituximab
contain
chemotherapi
anti
hcv
posit
patient
monitor
depart
prof
dr
matei
nation
institut
infecti
diseas
bucharest
romania
anti
hcv
hcvrna
pcr
biochem
test
measur
baselin
everi
three
month
viral
reactiv
defin
iuml
increas
hcvrna
follow
chemotherapi
result
enrol
hcvinfect
patient
male
femal
mean
age
year
case
nonhodgkin
lymphoma
nhl
chronic
lymphocyt
leukemia
cll
hodgkin
lymphoma
hl
macroglobulinemia
wm
base
histolog
featur
hm
indol
subtyp
predomin
versu
aggress
subtyp
advanc
fibrosi
stage
present
patient
moder
sever
necroinflammatori
activ
nine
patient
high
hcvrna
viral
load
iuml
baselin
hcvr
present
case
mean
month
rang
month
enrol
hepat
flare
associ
case
three
patient
die
one
due
hcv
associ
fulmin
hepat
two
due
hm
complicationsth
median
hcv
viral
load
baselin
iuml
iqr
iuml
hcvr
patient
versu
iuml
iqr
iuml
patient
without
hcvr
neither
sex
p
age
p
hcvrna
level
baselin
p
presenc
fibrosi
p
necroinflammatori
activ
hm
type
significantli
influenc
risk
hcvr
conclus
one
third
patient
hcvr
hcv
caus
fulmin
hepat
failur
patient
hm
close
monitor
hcvrna
everi
month
perform
acknowledg
studi
support
sop
hrd
financ
esf
rg
contract
number
background
interferon
gamma
ifn
play
key
role
elimin
hepat
c
viru
first
week
follow
infect
infect
becom
chronic
role
ifn
becom
unclear
increas
level
cytokin
associ
favor
evolut
current
studi
aim
analyz
level
ifn
sustain
respond
standard
therapi
method
studi
employ
assess
serum
ifn
level
patient
year
hospit
nation
institut
infecti
diseas
bucharest
romania
chronic
hcv
infect
genotyp
hepat
fibrosi
receiv
treatment
mcg
weekli
ribavirin
mgday
patient
show
undetect
hcv
rna
viral
load
first
month
treatment
remain
undetect
next
year
followup
studi
perform
compar
analysi
beforeaft
treatment
serum
level
ifn
elisa
bio
scientif
first
month
interferon
treatment
result
patient
show
constant
evolut
ifn
level
moder
increas
ifn
pgml
first
month
treatment
interestingli
patient
recent
infect
year
show
much
higher
pretherapi
serum
level
ifn
pgml
distant
infect
ifn
serum
level
pgml
conclus
hcv
patient
sustain
respons
peg
therapi
display
constant
level
ifn
first
month
treatment
level
ifn
recent
hcv
infect
much
higher
compar
distant
infect
pretherapi
level
serum
ifn
influenc
virolog
outcom
standard
interferon
therapi
background
riskreduct
campaign
essenti
part
nation
health
program
better
select
popul
group
target
undergon
assess
specif
risk
factor
transmiss
hbv
hcv
hiv
infect
romania
method
implement
nationwid
screen
program
chronic
viral
infect
also
includ
standard
questionnair
assess
preval
risk
factor
hbv
hcv
hiv
transmiss
gener
popul
romania
statist
analysi
perform
ibm
spss
statist
version
armonk
usa
result
analyz
signific
sampl
gener
popul
romania
median
interquartil
rang
age
year
male
femal
ratio
identifi
higher
preval
risk
factor
male
popul
name
histori
sexuallytransmit
infect
sti
ci
piercingtattoo
unprotect
anal
vagin
oral
intercours
homosexu
intercours
p
multipl
sex
partner
p
inject
drug
use
idu
p
needl
share
p
preval
idu
significantli
higher
patient
also
histori
sti
true
needl
share
similarli
piercingstattoo
significantli
associ
idu
needl
share
type
unprotect
intercours
homosexu
oral
vagin
anal
multipl
sex
partner
past
month
conclus
although
overal
preval
risk
factor
gener
popul
romania
appear
low
underdeclar
identifi
certain
highrisk
group
cumul
larg
number
risk
factor
high
likelihood
acquir
hbv
hcv
hiv
infect
propos
prioriti
target
special
popul
group
though
inform
campaign
risk
reduct
intervent
acknowledg
studi
part
ro
project
strengthen
prevent
control
hivaid
hbv
hcv
romania
financ
norway
financi
mechan
public
health
initi
case
report
yo
patient
recent
hospit
hospit
jaundic
immunoglobulin
antibodi
hepat
detect
blood
hospit
institut
supervis
continu
treatment
recent
medic
histori
show
onset
symptom
day
fever
jaundic
patient
recogn
contact
person
confirm
infect
hepat
develop
diseas
patient
becam
comatos
gc
sever
respiratori
acidosi
depend
advanc
respiratori
support
hour
becom
consciou
show
limp
quadriplegia
facial
asymmetri
thenar
hypothenar
emin
atrophi
abolish
tendin
reflex
preserv
sensit
mri
reveal
alter
could
explain
neurolog
deficit
lumbar
punctur
within
normal
limit
patient
favor
biolog
trend
correct
coagul
disord
improv
sepsi
marker
second
lumbar
punctur
show
albuminocytolog
dissoci
find
motor
nerv
conduct
studi
show
markedli
reduc
amplitud
compound
muscl
action
potenti
suggest
demyelin
polyneuropathi
base
syndrom
diagnosi
conduct
five
session
plasma
exchang
notic
progress
improv
motor
deficit
includ
respiratori
muscl
therefor
respiratori
support
ceas
day
conclus
acut
hepat
hav
also
trigger
immun
respons
therefor
clinician
consid
rare
seriou
possibl
syndrom
follow
acut
hepat
infect
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
liver
fibrosi
histor
consid
irrevers
progress
process
howev
recent
data
shown
obtain
sustain
virolog
respons
svr
antiinfecti
treatment
liver
stiff
start
decreas
potenti
return
back
normal
postinfect
valu
method
analyz
evolut
liver
fibrosi
assess
shearwav
elastographi
aixplor
superson
imagin
franc
patient
chronic
hcv
infect
cirrhosi
treat
regimen
ombitasvirparitaprevirritonavir
plu
dasabuvir
abbvi
usa
liver
stiff
determin
baselin
end
week
treatment
followup
visit
week
posttreat
data
analyz
use
wilcoxon
sign
rank
test
spearman
rankord
correl
spss
statist
window
ibm
corp
usa
result
present
result
patient
maletofemal
ratio
median
interquartil
rang
iqr
age
year
mean
standard
deviat
durat
hcv
evolut
year
followup
data
current
avail
patient
achiev
sustain
virolog
respons
median
iqr
liver
stiff
baselin
kpa
decreas
significantli
kpa
week
posttreat
p
z
median
decreas
liver
stiff
kpa
interv
week
correl
shorter
evolut
hcv
infect
prior
start
treatment
rs
p
conclus
base
result
would
recommend
earlier
therapi
chronic
hcv
infect
ensur
faster
decreas
liver
stiff
treatment
longterm
studi
need
determin
exact
pace
liver
fibrosi
decreas
past
point
svr
acknowledg
romanian
center
appli
biomolecular
research
infecti
diseas
project
financ
sector
oper
programm
increas
econom
competit
po
cce
ro
project
strengthen
prevent
control
hivaid
hbv
hcv
romania
financ
norway
financi
mechan
public
health
initi
background
estim
million
peopl
around
world
infect
hepat
c
viru
hcv
due
popul
screen
hcv
initi
antivir
treatment
hcv
preval
decreas
countri
purpos
antivir
treatment
erad
hcv
complet
obtain
sustain
virolog
respons
svr
bibliograph
data
confirm
patient
svr
remain
hcv
rna
neg
year
stop
treatment
method
assess
patient
diagnos
chronic
hcv
genotyp
receiv
combin
therapi
sofosbuvir
plu
daclatasvir
sofdcv
week
patient
cirrhosi
includ
studi
degre
fibrosi
establish
fibroscan
fibromax
result
patient
chronic
hcv
naiv
pretreat
pegifn
ribavirin
men
women
age
year
patient
poor
clinic
pictur
like
fatigu
right
upper
quadrant
pain
patient
moder
level
hepat
cytolysi
alt
averag
ul
bilirubin
within
normal
limit
hcv
rna
detect
prior
treatment
rang
million
copiesml
averag
million
copiesml
degre
fibrosi
establish
patient
patient
advers
event
occur
patient
treatment
sofdcv
week
antivir
therapi
show
undetect
viremia
hcvrna
one
patient
decreas
million
copiesml
patient
achiev
alt
normal
limit
week
treatment
patient
experienc
virolog
respons
hcv
rna
undetect
week
start
treatment
patient
svr
hcv
rna
undetect
patient
point
complet
treatment
dynam
supervis
week
conclus
studi
show
high
rate
svr
treatment
sofosbuvir
daclatasvir
naiv
well
pretreat
patient
chronic
hcv
signific
side
effect
take
drug
refer
cornberg
zu
siederdissen
c
maasoumi
b
mann
mp
wedemey
h
standard
therapi
chronic
hepat
c
viru
infect
mauss
berg
rockstroh
j
sarrazin
c
wedemey
w
editor
hepatolog
clinic
textbook
edit
hamburg
medizin
foku
verlag
background
hiv
syphili
found
similar
patient
group
associ
two
infect
becom
frequent
two
diseas
influenc
evolut
presenc
one
facilit
infect
addit
present
diagnosi
manag
syphili
differ
subtl
way
hivinfect
hivuninfect
patient
object
determin
preval
syphili
newli
diagnos
hiv
patient
identifi
epidemiolog
clinic
laboratori
aspect
coinfect
method
perform
retrospect
studi
patient
newli
diagnos
hiv
infect
nation
institut
infecti
diseas
prof
dr
matei
januari
june
patient
test
syphili
collect
data
regard
demograph
epidemiolog
clinic
laboratori
aspect
patient
baselin
dynam
result
includ
studi
adult
newli
diagnos
hiv
infect
nation
institut
infecti
diseas
prof
dr
matei
januari
june
diagnos
hiv
men
women
syphili
diagnost
test
perform
patient
hivsyphili
coinfect
concomit
hivsyphili
diagnosi
establish
patient
patient
treponem
test
perform
csf
neg
result
patient
diagnos
neurosyphili
patient
hiv
syphili
coinfect
reproduct
age
patient
age
year
old
men
women
second
age
group
year
old
men
women
patient
diagnos
hiv
syphili
diagnos
also
least
one
type
hepat
viru
infect
hepat
c
viru
hepat
b
viru
patient
coinfect
aid
time
diagnosi
medium
viral
load
baselin
copiescmm
patient
viral
load
copiescmm
patient
diagnos
hiv
receiv
antiretrovir
therapi
conclus
test
sexual
transmit
diseas
especi
syphili
remain
import
object
hiv
infect
patient
order
prevent
transmiss
improv
outcom
background
thrombophilia
group
hereditari
acquir
hematolog
condit
predispos
thrombot
phenomena
trigger
molecular
dysfunct
hemostasi
protein
thrombophilia
comorbid
hivposit
pregnant
women
littl
studi
method
studi
carri
clinic
hospit
obstetr
gynecolog
prof
dr
panait
bucharest
refer
number
hiv
posit
patient
diagnos
thrombophilia
result
studi
carri
number
hiv
posit
patient
pregnant
women
eventu
gave
birth
second
trimest
spontan
abort
patient
deliber
pregnanc
patient
deliv
caesarian
section
vagin
birth
case
diagnos
thrombophilia
case
antiphospholipid
syndrom
case
congenit
thrombophilia
thrombophilia
diagnosi
establish
case
spontan
abort
repetit
second
pregnanc
trimest
case
treatment
low
molecular
weight
heparin
initi
conclus
correl
incid
thrombophilia
hiv
infect
stage
durat
arv
therapi
found
background
relaps
difficult
treat
oropharyng
candidiasi
case
reveal
hiv
infect
common
fungal
infect
patient
object
studi
determin
preval
oropharyng
candidiasi
hiv
infect
patient
method
present
retrospect
studi
patient
born
includ
patient
diagnos
aid
stage
c
aid
monitor
infecti
diseas
hospit
admit
januari
decemb
result
group
patient
evalu
studi
percentag
femal
patient
men
preval
urban
area
versu
rural
environ
aid
stage
diseas
repres
follow
stage
stage
therapi
establish
local
antifung
treatment
case
receiv
system
treatment
diflucan
institut
hospit
conclus
degre
immunosuppress
correl
oropharyng
manifest
infect
oropharyng
candidiasi
high
preval
stage
patient
earli
detect
treatment
lesion
provid
perman
collabor
infecti
diseas
specialist
dentist
background
tuberculosi
common
opportunist
infect
major
caus
death
hiv
infect
patient
annual
risk
activ
tuberculosi
patient
per
year
compar
lifetim
uninfect
individu
object
determin
preval
tb
infect
hiv
infect
patient
method
studi
retrospect
observ
chart
patient
gener
tuberculosi
lung
lymph
node
hiv
infect
hospit
region
hivaid
center
januari
decemb
result
year
infecti
diseas
hospit
case
tb
regist
among
total
hiv
infect
patient
mean
preval
patient
number
nonadher
noncompli
arv
therapi
case
tb
belong
pediatr
cohort
known
treat
hiv
infect
sinc
childhood
case
tb
infect
revelatori
aid
regist
death
patient
hospit
tb
note
case
patient
arv
nonadher
noncompli
moment
detect
tb
infect
level
vari
cellscmm
valu
viremia
oscil
copiesml
averag
durat
hospit
day
requir
therapeut
approach
infecti
diseas
specialist
teamintens
care
specialistpsychologist
conclus
although
low
preval
mycobacterium
tuberculosi
infect
condit
challeng
infecti
diseas
specialist
psychologist
ati
specialist
regard
therapeut
adher
complianc
longterm
care
followup
hiv
posit
patient
also
tuberculosi
background
record
data
obtain
analysi
hivaid
death
necropsi
last
year
hospit
propos
updat
hivaid
databas
belong
clinic
hospit
infecti
diseas
focus
paramet
express
epidemiolog
tendenc
evolut
hivaid
region
object
analysi
data
refer
hivaid
death
record
clinic
infecti
diseas
hospit
period
formul
gener
epidemiolog
consider
method
conduct
retrospect
epidemiolog
studi
data
regist
death
regist
patholog
examin
necropsi
clinic
infecti
diseas
hospit
constanta
period
result
total
death
f
appear
record
patholog
depart
death
hiv
aid
f
autopsi
f
distribut
hivaid
death
accord
resid
background
urban
rural
resid
town
mention
medgidia
mangalia
rural
proven
resid
local
de
su
poarta
cobadin
pecineaga
lumina
dobromir
oituz
valu
traian
mihail
canlia
ostrov
techirghiol
hivaid
patient
die
birth
year
f
male
predomin
belong
cohort
death
death
death
number
regist
hivaid
death
fell
year
year
death
death
first
month
design
period
age
group
year
highest
mortal
death
follow
age
group
year
death
common
patholog
diagnos
type
liver
damag
liver
b
cirrhosi
chronic
hepat
c
lymphoma
burkitt
grow
trend
lung
diseas
pulmonari
tb
decreas
trend
pneumocystosi
sepsi
conclus
hiv
aid
patient
continu
experi
difficulti
specif
assess
monitor
role
epidemiolog
specialist
clinician
commun
specialist
palli
care
death
hivaid
patient
requir
palli
care
pathologist
diagnost
certainti
revis
background
patient
hivaid
repres
risk
group
viral
hepat
may
progress
sever
liver
failur
complic
present
case
patient
acut
liver
failur
chronic
b
hepat
known
hiv
infect
late
present
case
report
patient
diagnos
chronic
b
hepat
hiv
infect
august
admit
clinic
infecti
diseas
scleral
skin
jaundic
hyperchrom
urin
hepatalgia
nausea
anorexia
asthenia
etc
physic
examin
admiss
reveal
influenc
gener
state
afebril
scleral
skin
jaundic
gener
lymphadenopathi
inferior
edg
liver
palpabl
cm
costal
margin
lower
pole
spleen
palpabl
sign
mening
irrit
biolog
sampl
collect
cell
blood
count
biochemistri
coagul
electrophoresi
hiv
viral
load
vl
hbv
vl
acvhd
achcv
bilirubin
alkalin
phosphatas
cholinesteras
urinalysi
etc
patient
unemploy
low
intellectu
level
elementari
grade
low
adher
arv
therapi
combivir
tabletday
mg
prezista
tabletday
mg
norvir
tabletday
result
blood
test
rbc
hb
gdl
ht
plt
prothrombin
time
sec
total
bilirubin
mgdl
direct
bilirubin
mgdl
tgp
ul
tgo
ul
total
protein
gdl
cholinesteras
ul
gt
ul
alkalin
phosphatas
ul
iuml
electrophoresi
albumin
globulin
globulin
hiv
vl
copiesml
hbv
dna
iuml
neg
hdv
ab
neg
hcv
ab
treatment
complex
ampicillin
cefort
argininesorbitol
aspatofort
hepamerz
ursofalk
bilichol
phenobarbit
hydrocortison
hemisuccin
omeprazol
kcl
vitamin
calcium
glucon
plasma
glucos
sodium
chlorid
etc
day
hospit
clinic
biolog
evolut
favor
tb
mgdl
tgp
ul
pt
sec
total
protein
gdl
k
mmoll
patient
cooper
fed
oral
without
nausea
vomit
without
bleed
jaundic
remiss
note
made
switch
antiretrovir
therapi
use
emtricitabin
mgday
tenofovir
mgday
raltegravir
mg
tabletsday
conclus
earli
diagnosi
associ
specif
therapi
rigor
monitor
clinic
biolog
data
contribut
favor
evolut
patient
hivhbv
coinfect
acut
liver
failur
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
introduct
highli
activ
antiretrovir
therapi
move
step
forward
hiv
infect
reduc
mortal
caus
opportunist
infect
make
diseas
manag
chronic
condit
method
perform
crosssect
studi
consent
hivinfect
patient
nation
institut
infecti
diseas
prof
dr
matei
bucharest
time
span
assess
medic
histori
lipid
profil
cell
count
viral
load
lifestyl
habit
result
studi
group
male
femal
ratio
almost
median
interquartil
rang
age
year
mean
standard
deviat
bodi
mass
index
bmi
kgsqm
total
patient
overweightobes
almost
patient
antiretrovir
therapi
patient
comorbid
median
recent
cell
count
cellsml
regard
risk
factor
patient
consum
alcohol
almost
half
patient
smoker
patient
perform
moder
intens
physic
activ
bmi
influenc
lipid
profil
higher
proport
overweightobes
patient
identifi
group
patient
high
triglycerid
level
high
ldl
level
compar
group
normal
valu
p
p
also
observ
triglycerid
cholesterol
influenc
alcohol
consumpt
p
p
smoke
p
p
heavi
drink
may
neg
impact
glycemia
level
becom
risk
factor
diabet
studi
higher
percentag
alcohol
user
group
patient
high
glycemia
p
smoke
associ
hydroxyvitamin
concentr
p
parathyroid
hormon
valu
p
smoke
identifi
risk
factor
femor
osteopenia
p
physic
activ
associ
hiv
statu
proport
patient
perform
intens
physic
activ
similar
group
patient
recent
cell
count
less
cellscmm
compar
group
patient
recent
cell
count
higher
cellscmm
p
conclus
consid
durat
hiv
infect
risk
factor
complic
due
chronic
inflamm
modifi
risk
factor
smoke
alcohol
consumpt
sedentari
avoid
better
qualiti
life
acknowledg
licens
thesi
lifestyl
impact
hiv
manag
perform
carol
davila
univers
medicin
pharmaci
bucharest
supervisor
anca
streinucercel
coordin
alina
cardiometabol
project
merck
sharp
dohm
background
women
childbear
age
hiv
infect
want
procreat
manag
repres
challeng
infecti
diseas
doctor
method
studi
retrospect
observ
chart
hiv
posit
patient
observ
region
hivaid
center
period
januari
result
region
center
follow
patient
hiv
infect
women
repres
percentag
total
number
repres
women
childbear
age
year
repres
hiv
posit
women
mention
period
women
gave
birth
repres
women
hiv
infect
childbear
age
counti
distribut
show
higher
incid
name
newborn
year
birth
occur
newborn
patient
receiv
treatment
klt
cvb
women
detect
hiv
infect
birth
children
born
caesarian
section
year
two
death
children
one
die
day
birth
anoth
stillborn
newborn
receiv
prophylaxi
week
one
case
prophylaxi
interrupt
month
three
children
declar
hiv
posit
month
conclus
correct
track
teamwork
infect
diseas
doctor
social
worker
psychologist
made
number
hiv
posit
patient
gave
birth
hiv
neg
children
significantli
high
due
good
adher
complianc
arv
therapi
background
two
foremost
neurolog
impair
develop
hiv
late
present
consist
progress
multifoc
leukoencephalopathi
pml
hiv
encephalopathi
hive
pml
viral
opportunist
patholog
associ
almost
exclus
hiv
infect
hive
notopportunist
diseas
directli
mediat
hiv
diagnos
pml
hive
repres
challeng
physician
take
consider
myriad
variabl
associ
condit
could
brought
hiv
infect
advent
new
tool
could
success
use
order
provid
diagnosi
method
observ
crosssect
studi
consist
hivinfect
patient
treat
nation
institut
infecti
diseas
prof
matei
exitu
due
hivassoci
complic
subject
brain
necropsi
brain
tissu
sampl
analyz
pathologist
colentina
clinic
hospit
bucharest
compar
patholog
diagnos
correspond
clinic
one
enforc
clinic
present
laboratori
medic
imag
data
collect
archiv
medic
record
endpoint
identifi
superposit
clinic
patholog
diagnos
result
four
pml
patholog
diagnos
issu
three
confirm
respect
three
clinic
supposit
one
without
correspond
clinic
diagnosi
pml
also
suspect
patient
lack
relev
patholog
evid
confirm
howev
patient
prove
suffer
cerebr
cryptococcosi
case
two
patient
pml
sole
patholog
diagnosi
wherea
rest
exhibit
pml
accompani
hiv
encephalopathi
also
three
clinic
diagnos
specul
alongsid
pml
refut
postmortem
examin
cerebr
hemorrhag
cerebr
toxoplasmosi
lymphoma
four
hive
patholog
diagnos
issu
correl
clinic
supposit
infer
regard
concern
patient
patholog
diagnos
associ
ischem
stroke
pml
cerebr
hemorrhag
lymphoma
toxoplasmosi
hive
clinic
suspect
six
patient
prove
affect
disord
meningoencephalithi
hyperemia
cerebr
edema
pml
ponscerebellar
decrepitud
confirm
case
hiv
encephalopathi
conclus
superposit
pml
clinic
patholog
diagnos
patholog
confirm
case
hive
elev
level
diagnosi
thu
observ
lack
correl
call
better
understand
ill
extend
present
provid
date
diagnosi
algorithm
background
releas
unaid
fast
trackend
aid
epidem
set
certain
target
romania
achiev
close
monitor
perinat
hiv
henc
nation
antenat
hiv
screen
process
reveal
increas
number
hiv
infect
women
intraven
drug
user
idu
sinc
due
consumpt
synthet
cannabinoid
cathinon
call
legal
high
moreov
percentag
new
iduhiv
case
increas
highest
number
consum
live
around
bucharest
method
januari
june
pediatr
immunosuppress
unit
nation
institut
infecti
diseas
prof
dr
matei
survey
hivexpos
newborn
perinat
expos
new
drug
consum
mother
howev
end
rate
hiv
mothertochild
transmiss
romania
remain
stablebelow
follow
paramet
evalu
mother
time
hiv
screen
time
hiv
diagnosi
age
prenat
care
time
taken
activ
surveil
program
treatmentprophylaxi
type
birth
drug
taken
screen
coinfect
hbv
hcv
sti
paramet
interest
children
sex
age
time
diagnosi
art
prophylaxi
type
birth
type
feed
neurolog
assess
count
hivrna
ultrasound
evalu
result
year
monitor
period
follow
result
hiv
time
detect
iduhiv
mother
obtain
mother
test
found
hiv
pregnanc
pregnanc
deliveri
first
hour
birth
although
newborn
perinat
expos
hividu
benefit
postpartum
prophylaxi
receiv
artifici
nutrit
expos
drug
use
hiv
infect
children
poor
neonat
adapt
mainli
sever
withdraw
syndrom
newborn
monitor
neurolog
lesion
conclus
major
pregnant
women
hivconsum
drug
especi
new
drug
littl
access
antenat
care
lead
late
discoveri
hiv
use
synthet
cannabinoid
cathinon
hiv
pregnant
women
import
effect
newborn
subsequ
develop
pose
challeng
postpartum
surveil
system
women
come
poor
famili
ensur
proper
support
furthermor
due
issu
associ
riski
behavior
difficult
includ
hiv
screen
prevent
programm
need
adapt
need
background
countri
preval
hiv
hepat
b
viru
hbv
coinfect
young
hiv
posit
patient
high
measur
liver
fibrosi
use
noninvas
method
transient
elastographi
te
hiv
patient
use
tool
determin
monitor
hepat
diseas
evalu
abil
apri
score
differenti
differ
stage
fibrosi
fibrosisminim
fibrosi
moderatesever
fibrosiscirrhosi
take
refer
absenc
liver
biopsi
hepat
fibrosi
stratif
fibroscan
method
studi
group
patient
infect
hiv
coinfect
hivhbv
determin
cutoff
valu
apri
identifi
signific
fibrosi
maximum
specif
auroc
group
kappa
score
calcul
concord
method
result
hivhbv
coinfect
patient
identifi
signific
fibrosi
compar
apri
versu
fibroscan
kappa
score
ci
identif
fibrosi
f
versu
fibroscan
kappa
score
ci
moder
concord
regard
comparison
two
method
apri
kappa
score
ci
concord
signific
patient
hiv
identifi
signific
fibrosi
apri
versu
fibroscan
kappa
ci
identif
fibrosi
f
kappa
ci
correl
reduc
regard
comparison
two
method
apri
kappa
ci
confirm
low
correl
conclus
evid
test
use
apri
abil
distinguish
group
patient
hiv
hivhbv
two
class
fibrosi
f
patient
without
advanc
liver
diseas
although
patient
hiv
infect
low
concord
seen
noninvas
method
diagnosi
fibrosi
coinfect
patient
moder
test
could
use
evalu
method
monitor
liver
injuri
especi
result
test
concord
background
highli
activ
antiretrovir
therapi
haart
repres
cornerston
manag
hivinfect
patient
main
goal
immun
restor
rapidli
achiev
maintain
undetect
hivrna
viral
load
method
perform
retrospect
descript
studi
includ
hivinfect
patient
care
counti
select
patient
achiev
rapid
longlast
undetect
hivrna
plasma
viral
load
month
collect
data
regard
demograph
featur
rout
transmiss
durat
hiv
infect
nadir
tcell
count
maximum
hivrna
plasma
viral
load
result
hivinfect
patient
counti
care
clinic
infecti
diseas
counti
clinic
hospit
haart
present
time
undetect
viral
load
past
month
male
patient
femal
part
romanian
cohort
acquir
infect
via
sexual
rout
averag
length
hivinfect
histori
year
maximum
year
nadir
tlymphocyt
count
regist
averag
highest
hivrna
plasma
viral
load
averag
level
copiesml
recent
tcell
count
averag
patient
good
adher
haart
regimen
conclus
combin
antiretrovir
therapi
lead
good
result
immunolog
virolog
success
provid
good
complianc
correct
administr
background
lipopolysaccharid
lp
heteropolym
synthes
gram
neg
bacilli
consid
marker
microbi
transloc
immun
activ
hiv
infect
patient
nevertheless
low
lp
serum
level
alway
correl
favor
clinic
outcom
studi
explor
serum
lp
level
correl
virolog
immunolog
marker
treatment
adher
clinic
evolut
hivinfect
patient
method
perform
prospect
studi
patient
admit
matei
nation
institut
infecti
diseas
hiv
infect
patient
women
male
age
year
control
thirtytwo
hivinfect
patient
follow
antiretrovir
treatment
least
month
consid
adher
treatment
two
patient
refus
treatment
serum
lp
level
endoblock
elisa
test
kit
lymphocyt
count
flowcytometri
patient
hiv
rna
real
time
pcr
viral
load
assess
patient
classifi
depend
hiv
rna
viral
load
respondernondetect
rna
hiv
versu
nonresponderdetect
rna
hiv
cell
count
cell
cellcmm
clinic
outcom
favor
unfavor
due
opportunist
infect
malign
next
year
length
previou
antiretrovir
treatment
year
year
compar
serum
level
lp
differ
group
hiv
infect
patient
hivinfect
patient
healthi
control
statist
analysi
perform
use
student
test
analysi
pearson
correl
result
level
lp
correl
lymphocyt
count
p
virolog
respons
p
clinic
outcom
p
therapeut
adher
p
nevertheless
serum
level
lp
significantli
higher
hivinfect
patient
pgml
compar
pgml
p
valu
conclus
hiv
infect
patient
display
significantli
higher
valu
lp
irrespect
length
treatment
clinic
outcom
although
lp
level
correl
immunolog
virolog
paramet
possibl
dynam
measur
could
help
ascertain
role
lp
clinic
evolut
patient
background
cathelicidin
human
immunomodulatori
peptid
synthes
monocytesmacrophag
tcell
secret
ifn
induct
follow
activ
vitamin
receptor
also
detect
biliari
liver
endothelium
recent
studi
indic
direct
antivir
effect
hcv
cell
cultur
role
liver
inflamm
remain
unknown
method
perform
prospect
studi
patient
women
men
age
year
hcv
infect
control
hospit
nation
institut
infecti
diseas
prof
dr
matei
bucharest
romania
patient
recent
receiv
treatment
peginterferon
ribarivin
show
neg
rna
hcv
viral
load
patient
cure
follow
acut
hcv
infect
untreat
posit
rna
hcv
viral
load
studi
record
serum
level
elisa
hycult
biotech
ifn
elisa
bioo
scientif
along
liver
injuri
marker
alanin
aminotransferas
alt
aspart
aminotransferas
ast
alkalin
phosphatas
alp
gammaglutamyl
transferas
ggt
bilirubin
bil
cell
lymphocyt
count
flowcytometri
result
mean
level
serum
hcv
patient
lower
control
ngml
versu
ngml
differ
statist
signific
p
mean
valu
also
numer
higher
hcv
infect
patient
pgml
control
pgml
p
level
exhibit
moder
posit
correl
ifn
r
well
mild
posit
correl
alt
r
statist
signific
correl
serum
concentr
found
compar
biolog
paramet
virolog
respons
conclus
posit
correl
serum
level
ifn
alt
suggest
possibl
implic
peptid
liver
injuri
hcv
patient
studi
need
translat
result
vitro
studi
clinic
practic
background
pulmonari
tuberculosi
one
import
opportunist
infect
patient
hivaid
frequent
associ
difficulti
regard
clinic
therapeut
supervis
patient
purpos
paper
present
clinic
case
patient
stage
hivaid
infect
noncomplaint
antiretrovir
therapi
precoci
diagnos
pulmonari
tuberculosi
pneumonia
pseudomona
spp
candidiasi
digest
system
toxoplasmosi
case
report
author
present
case
year
old
patient
diagnos
hiv
infect
year
ago
refus
antiretrovir
medic
patient
admit
clinic
present
fever
chill
dysphagia
dysphonia
cough
mucopurul
sputum
vomit
epigastralgia
cephalalgia
cachexia
onset
durat
symptomatolog
approxim
two
week
physic
examin
upon
admiss
reveal
pale
skin
mucou
membran
dri
lip
white
coat
tongu
stomat
asthen
thorax
bilater
harsh
vesicular
murmur
bp
mmhg
puls
oxygen
satur
room
air
awak
alert
fulli
orient
clinic
sign
mening
irrit
biolog
sampl
collect
confirm
diagnosi
rbc
wbc
count
got
gpt
alkalin
phosphatas
serum
urea
creatinin
creactiv
protein
blood
cultur
viral
load
toxoplasma
igm
antibodi
geneexpert
specimen
bk
coprocultur
sputum
cultur
etc
pulmonari
xray
ct
scan
thorax
also
perform
result
lab
test
includ
wbc
rbc
hemoglobin
gdl
hct
esr
h
got
ul
gpt
ul
ggt
ul
alp
ul
crp
mgl
vl
copiesml
posit
igm
ab
toxoplasma
sputum
cultur
pseudomona
spp
candida
yeast
coprocultur
candida
cfusml
urin
cultur
candida
cfusml
geneexpert
posit
bk
neg
bk
cultur
thorax
ct
scan
condens
process
right
inferior
lobe
follow
therapeut
regimen
establish
sumetrolim
tabletsday
levofloxacin
mgday
gentamicin
mgday
accord
antibiogram
fluconazol
mgday
dexamethason
mgday
tuberculostat
isoniazid
mgday
rifampicin
mgday
pyrazinamid
gday
ethambutol
gday
arv
combivir
inviras
norvir
antipyret
mucolyt
hydroelectrolyt
rebalanc
fluid
slow
favor
evolut
period
one
year
patient
discontinu
arv
medic
die
conclus
modern
molecular
biolog
techniqu
geneexpert
offer
possibl
earli
pulmonari
tuberculosi
diagnosi
subsequ
treatment
patient
hivaid
howev
advanc
immunosuppress
togeth
noncompli
treatment
may
associ
unfavor
evolut
consent
written
inform
consent
obtain
next
kin
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
introduct
new
antiretrovir
drug
therapeut
practic
led
chang
antiretrovir
regimen
recommend
patient
hiv
infect
aim
identifi
main
therapeut
chang
patient
diagnos
hiv
infect
nation
institut
infecti
diseas
prof
dr
matei
method
retrospect
analysi
demograph
therapeut
characterist
patient
diagnos
hiv
infect
period
januari
june
data
obtain
compar
data
patient
diagnos
hiv
infect
aim
identifi
statist
signific
chang
p
use
epi
info
version
result
analyz
period
adult
confirm
hiv
infect
compar
patient
antiretrovir
treatment
administ
patient
vs
control
group
p
ci
mean
age
patient
year
vs
year
control
group
male
account
patient
vs
patient
control
group
treatment
initi
follow
nrti
nnrti
patient
vs
p
ci
nrti
pisr
patient
vs
nrti
integras
inhibitor
patient
vs
p
ci
scheme
patient
vs
initi
treatment
mean
valu
similar
cellscmm
proport
patient
count
cellscmm
vs
mean
viral
load
much
smaller
cml
vs
cml
group
analyz
conclus
main
chang
identifi
patient
newli
diagnos
hiv
infect
first
month
significantli
higher
percentag
receiv
antiretrovir
treatment
vs
p
ci
signific
decreas
weight
scheme
nnrti
vs
significantli
increas
weight
scheme
integras
inhibitor
vs
percentag
scheme
pisr
remain
constant
scheme
prefer
institut
detect
new
case
earli
stage
hiv
infect
still
delay
patient
count
cellscmm
background
system
infect
commonli
encount
disord
hivinfect
patient
influenc
risk
death
aim
analyz
risk
factor
associ
unfavor
evolut
patient
method
retrospect
analysi
demograph
clinic
cours
treatment
characterist
patient
hiv
infect
hospit
prof
dr
matei
institut
period
januari
decemb
posit
blood
cultur
hospit
watch
accur
risk
factor
associ
death
identifi
statist
signific
differ
p
use
epi
info
version
result
analyz
period
patient
identifi
hiv
infect
hospit
posit
blood
cultur
hospit
die
evolv
favor
averag
age
deceas
patient
year
vs
year
p
percentag
male
higher
group
vs
acut
episod
appear
averag
year
detect
hiv
infect
die
vs
year
p
patient
receiv
antiretrovir
arv
treatment
histori
vs
follow
entri
gate
identifi
respiratori
vs
skin
vs
digest
vs
urinari
vs
cathet
iv
vs
unspecifi
vs
respiratori
entri
gate
significantli
associ
risk
death
p
ci
signific
differ
identifi
term
weight
isol
microorgan
afb
vs
gpc
vs
gpb
vs
gnb
vs
fungi
vs
microorgan
resist
mechan
classic
antibiot
antifung
vs
averag
level
count
significantli
lower
group
hiv
deceas
cellscmm
vs
cellscmm
p
mean
hivrna
significantli
lower
cml
vs
cml
p
averag
valu
procalcitonin
higher
pgml
vs
pgml
averag
length
hospit
significantli
lower
die
vs
day
conclus
risk
factor
associ
death
hivinfect
patient
posit
blood
cultur
older
age
patient
longer
durat
evolut
hiv
uncontrol
infect
respiratori
entri
gate
system
infect
sever
immunosuppress
count
cellscmm
short
durat
hospit
object
analysi
epidemiolog
aspect
hiv
infect
method
retrospect
studi
craiova
region
center
crc
romania
two
lot
hiv
infect
person
hip
group
hip
new
case
diagnos
period
group
hip
new
case
diagnos
period
result
demograph
group
afm
vs
group
bfm
p
chronolog
distribut
new
case
show
top
incid
main
mode
transmiss
sexualgroup
vs
group
b
vs
p
children
born
hiv
infect
mother
group
vs
group
vs
viralimmun
statu
time
hiv
diagnosi
group
vs
group
baverag
lymphocyt
cellscmm
vs
p
averag
viremia
hiv
log
copiesml
vs
log
copiesml
p
frequent
opportunist
infect
hip
group
vs
hip
group
b
case
hip
late
present
group
vs
group
hip
vs
hip
p
first
month
hiv
diagnosi
hip
group
vs
hip
group
b
die
p
conclus
oltenia
region
new
case
hiv
infect
frequent
men
predomin
mode
transmiss
heterosexu
hip
late
present
present
two
group
patient
tuberculosi
major
caus
morbimort
background
hiv
epidem
romania
increasingli
driven
last
year
intraven
drug
user
idu
men
sex
men
msm
studi
compar
sex
inject
risk
behavior
among
male
femal
idu
admit
mmt
center
method
juli
june
new
patient
admit
mmt
ask
complet
questionnair
regard
hiv
risk
behavior
test
hiv
hcv
hbv
result
sampl
femal
like
stabl
relationship
men
signific
differ
age
femal
vs
male
averag
age
year
old
male
report
daili
median
inject
femal
day
prior
enter
treatment
vs
also
report
std
vs
femal
higher
hivposit
serolog
result
male
vs
hiv
risk
femal
report
use
common
contain
vs
frequent
although
male
particip
report
sex
multipl
partner
vs
femal
report
significantli
sex
without
condom
vs
sex
idu
partner
vs
conclus
high
risk
behavior
hiv
preval
among
idu
thu
need
rapid
introduct
intervent
address
problem
background
psoriasi
repres
chronic
immunemedi
skin
condit
genet
background
character
sharpli
defin
erythemat
scali
plaqu
limit
extens
involv
howev
challeng
patient
present
diseas
treatment
must
adapt
care
especi
deal
patient
hiv
infect
hepat
c
viru
case
report
herein
describ
case
caucasian
male
person
histori
psoriasi
vulgari
onset
age
patient
receiv
treatment
fumar
acid
ester
week
germani
favor
clinic
respons
due
financi
issu
treatment
discontinu
admit
dermatolog
depart
assess
gener
skin
erupt
involv
trunk
buttock
arm
feet
scalp
character
prurit
sharpli
demarc
erythemat
plaqu
cover
silveri
scale
tendenc
develop
erythoderma
invers
psoriasi
fingernail
affect
also
distal
interphalang
joint
patient
also
test
hiv
viral
hepat
syphili
result
show
presenc
hiv
infect
hepat
c
far
treatment
concern
hospit
topic
therapi
appli
includ
emolli
keratolyt
potent
corticoid
good
clinic
outcom
due
laboratori
find
patient
refer
infecti
diseas
specialist
order
continu
investig
start
treat
hiv
infect
viral
hepat
c
moder
sever
case
treat
topic
therapi
phototherapi
first
line
second
line
oral
retinoid
option
care
monitor
potenti
advers
event
refractori
sever
diseas
treat
tnfalpha
inhibitor
posit
role
highli
activ
antiretrovir
therapi
observ
led
improv
psoriasi
patient
conclus
hiv
associ
psoriasi
often
refractori
tradit
therapi
patient
also
hepat
c
viru
treatment
even
challeng
requir
care
consider
particular
case
repres
fact
patient
test
hiv
infect
treat
fumar
acid
ester
gener
psoriasi
erupt
young
patient
lead
investig
includ
hiv
test
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
author
focus
character
humor
immun
profil
develop
gangliosid
asymptomat
hivinfect
patient
host
immun
respons
viral
infect
might
influenc
antibodi
method
investig
asymptomat
hivinfect
patient
treatment
without
neurolog
manifest
nonhivinfect
volunt
determin
antigangliosid
antibodi
igm
type
direct
perform
immunoblot
techniqu
use
eurolin
kit
evalu
result
realiz
use
eurolin
scan
softwar
read
signal
intens
strip
mark
gangliosid
antigen
interpret
result
made
cutoff
valu
equal
establish
accord
manufactur
instruct
result
consid
posit
valu
signal
intens
greater
neg
valu
lower
result
antigangliosid
autoantibodi
identifi
asymptomat
hivinfect
patient
control
group
exhibit
differ
serolog
profil
hiv
infect
patient
preval
autoantibodi
igm
type
gangliosid
follow
control
group
antigangliosid
antibodi
igm
type
absent
conclus
author
consid
gangliosid
express
membran
hivinfect
cell
might
induc
synthesi
antigangliosid
antibodi
presenc
antigangliosid
antibodi
seem
primari
immunolog
event
hiv
infect
might
play
physiopatholog
role
studi
viral
infect
abil
host
produc
earli
antigangliosid
respons
might
seen
defens
mechan
direct
elimin
danger
signal
background
sinc
discoveri
becom
extens
studi
pathogen
histori
antiretrovir
therapi
markedli
improv
qualiti
lifespan
peopl
live
hiv
despit
achiev
viral
suppress
mani
hiv
infect
patient
may
still
harbor
persist
low
level
inflamm
may
contribut
prematur
age
cardiovascular
comorbid
object
evalu
subclin
chronic
inflamm
cohort
person
live
hiv
undergo
art
base
persist
viral
replic
method
perform
crosssect
studi
cohort
caucasian
patient
attend
nation
institut
infecti
diseas
prof
dr
matei
bucharest
romania
includ
patient
art
least
month
blood
sampl
test
hiv
viral
load
cell
count
creactiv
protein
crp
tumor
necrosi
factor
alpha
tnfalpha
level
patient
evalu
inflammatori
marker
compar
two
group
undetect
patient
hiv
viral
load
level
detect
group
hiv
patient
persist
replic
group
independ
sampl
ttest
test
use
assess
statist
differ
group
result
sixti
patient
mean
age
year
includ
studi
male
mean
time
art
month
patient
serum
hiv
load
limit
detect
group
mean
count
cellscmm
entir
cohort
cellscmm
group
cellscmm
group
median
crp
valu
iqr
mgl
group
compar
iqr
mgl
patient
detect
viremia
without
statist
signific
p
mean
valu
pgml
group
vs
pgml
group
level
statist
signific
close
cutoff
valu
p
tnfalpha
mean
valu
pgml
detect
patient
group
compar
pgml
group
p
conclus
cohort
undergo
art
note
similar
level
crp
tnfalpha
patient
persist
viral
replic
undetect
viremia
level
seem
higher
group
detect
viremia
background
syndrom
acut
inflammatori
demyelin
polyneuropathi
trigger
acut
infecti
process
etiopathogenet
condit
usual
follow
viral
infect
cytomegaloviru
epsteinbarr
viru
varicellazost
herp
present
case
acut
polyradiculoneur
manifest
patholog
pictur
instal
evolut
acut
varicella
syndrom
immunocompet
patient
case
report
author
present
case
patient
age
year
chickenpox
hospit
clinic
infecti
diseas
victor
hospit
develop
acut
tetraparesi
polyradiculoneur
symptom
start
two
day
admiss
featur
high
fever
malais
appear
trunk
limb
face
itchi
small
blister
drop
dew
cardiopulmonari
balanc
consciou
sign
mening
irrit
week
hospit
patient
present
tetraparet
motor
deficit
type
accompani
tingl
limb
progress
transfer
neurolog
clinic
emerg
counti
hospit
day
admiss
neurolog
patient
condit
worsen
becom
dyspneic
decid
transfer
intens
care
unit
underw
orotrach
intub
mechan
ventil
intens
care
unit
patient
receiv
treatment
immunoglobulin
octagam
flday
day
signific
improv
done
seven
session
plasmapheresi
treatment
establish
antibiot
gastric
antisecretori
anticoagul
analges
opioid
antipyret
corticosteroid
vitamin
blood
product
solut
calori
electrolyt
rebalanc
admiss
neurolog
biolog
investig
carri
show
anyth
patholog
lumbar
punctur
perform
wbc
rbc
protein
gl
skull
cervic
spine
mri
show
anyth
patholog
chest
radiographi
highlight
discret
decreas
transpar
basal
right
lung
result
cathet
tip
cultur
show
proteu
mirabili
bronchial
aspir
cultur
posit
klebsiella
pneumonia
antibiot
sensit
determin
patient
favor
evolut
conclus
biolog
rigor
clinic
monitor
along
effect
interdisciplinari
collabor
chickenpox
case
neurolog
complic
may
favor
influenc
evolut
patient
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
almost
individu
present
asymptomat
enteroviru
infect
one
known
serotyp
small
percentag
patient
may
experi
selflimit
nonspecif
rash
along
flulik
symptom
clinic
indistinguish
viral
infect
rare
enterovirus
held
respons
sever
manifest
acut
asept
mening
enceph
hepat
pulmonari
cardiac
complic
case
report
yearold
man
smoker
relev
medic
histori
present
hospit
fever
chill
dri
cough
intens
myalgia
persist
amoxicillin
selfmed
clinic
exam
reveal
high
fever
dyspnea
mild
exert
tachycardia
lab
test
show
intens
acut
inflammatori
syndrom
leukocytosi
lymphocytosi
normochromicnormocyt
anemia
moder
cytolysi
high
valu
ntermin
probrain
natriuret
peptid
ntprobnp
pgml
high
antibodi
titer
echoviru
chest
xray
show
lesion
suggest
right
medial
lobe
pneumonia
cardiolog
consult
echocardiographi
diagnos
myocard
pericard
eject
fraction
given
critic
state
patient
bronchoscopi
could
perform
time
point
receiv
posit
serolog
echoviru
clinic
state
continu
deterior
despit
adequ
cardiolog
antibiot
therapi
levofloxacin
ertapenem
highdos
corticotherapi
milligram
dexamethason
per
day
week
ad
slow
improv
clinic
biolog
paramet
two
month
appar
good
health
present
hospit
clinic
biolog
find
stabl
cardiac
function
ctscan
reveal
alveolar
condens
right
medial
lobe
bronchoalveolar
lavag
fluid
suggest
lymphocyt
alveol
repeat
high
dose
corticotherapi
lead
slow
steadi
improv
autoimmun
marker
neg
cultur
sputum
bronchoalveolar
fluid
neg
bacteria
fungi
conclus
rule
bacteri
immunolog
etiolog
two
time
row
echoviru
remain
incrimin
infecti
agent
lymphocyt
alveol
cardiac
complic
literatur
data
show
sever
enteroviru
infect
mostli
illustr
asept
mening
case
reveal
echoviru
infect
respons
sever
cardiac
complic
myocard
pericard
also
recurr
lymphocyt
alveol
patient
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
backgound
although
remark
progress
made
brain
imagist
investig
along
diversif
antivir
therapi
herpet
enceph
remain
brain
diseas
poor
prognosi
high
mortal
risk
purpos
present
clinic
case
herpet
enceph
occur
adult
immunocompet
femal
patient
favor
evolut
case
report
author
present
case
adult
patient
present
six
day
prior
admiss
headach
confusion
syndrom
nausea
diarrhea
sever
fatigu
patient
present
counti
hospit
admit
neurolog
clinic
order
put
correct
diagnosi
biolog
investig
blood
cell
identif
esr
fibrinogen
blood
glucos
creactiv
protein
urin
analysi
blood
cultur
serum
urea
creatinin
urin
cultur
exud
lingual
yeast
etc
paraclin
investig
cerebr
comput
tomographi
ct
cerebr
mri
lumbar
punctur
made
base
clinic
data
conjunct
result
biolog
sampl
laboratori
investig
diagnosi
herpet
enceph
establish
patient
transfer
clinic
infecti
diseas
therapeut
clinic
monitor
physic
examin
admiss
clinic
reveal
afebril
patient
moder
influenc
gener
state
temporospati
disorient
without
mening
sign
tongu
whitish
deposit
cardiopulmonari
digest
system
patholog
sing
lumbar
punctur
perform
antivir
symptomat
treatment
set
wbc
rbc
plt
normal
valu
neutrophil
lymphocyt
lumbar
punctur
clear
normotens
liquid
glucos
mgdl
protein
gl
erythrocyt
leukocyt
cerebr
mri
corticosubcort
lesion
uncu
partial
tempor
lobe
anterior
intern
left
island
captur
aspect
suggest
herpet
enceph
result
blood
cultur
csf
cultur
bacteri
flora
bk
neg
bacteri
etiolog
exclud
lingual
exud
yeast
candida
albican
posit
treatment
consist
acyclovir
mg
flday
ceftriaxon
g
fluconazol
mg
dexamethason
mannitol
vitamin
symptomat
agent
solut
hydroelectrolyt
rebalanc
patient
state
favor
headach
remit
three
day
confusion
syndrom
disappear
six
day
hospit
conclus
earli
diagnosi
herpet
enceph
along
specif
antivir
therapi
favor
influenc
evolut
diseas
immunocompet
adult
brain
disord
known
high
potenti
sever
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
measl
repres
problem
current
infecti
patholog
possibl
appear
sever
form
measl
andor
type
patient
absenc
vaccin
due
variou
reason
lead
spread
diseas
recept
popul
evolut
infect
center
small
epidem
outbreak
object
analysi
incid
measl
last
year
counti
comparison
situat
countri
countri
complex
analysi
regard
condit
develop
sever
form
complic
concret
measur
regard
evalu
incid
diseas
method
perform
mani
studi
regard
case
measl
last
year
hospit
clinic
ii
infecti
diseas
v
hospit
result
measl
highli
contagi
occur
anytim
prevent
vaccin
emphas
three
month
mayjuli
case
measl
count
hospit
affect
age
group
year
repres
case
latest
year
much
atyp
form
measl
record
sever
predominantli
pulmonari
complic
even
children
interstiti
lung
diseas
countri
europ
measl
case
occur
likewis
romania
counti
measl
present
conclus
diseas
prevent
follow
vaccin
program
background
pathogenesi
influenza
includ
impair
pulmonari
defens
said
open
gate
bacteri
superinfect
streptococcu
pneumonia
one
lead
pathogen
superinfect
particularli
children
without
histori
antipneumococc
vaccin
method
perform
retrospect
studi
influenza
season
one
pediatr
ward
tertiarycar
hospit
bucharest
romania
collect
demograph
clinic
microbiolog
data
regard
influenza
diseas
characterist
outcom
regard
incid
outcom
pneumococc
colonizationinfect
herebi
report
preliminari
result
studi
result
studi
includ
case
influenza
occur
children
median
interquartil
rang
age
year
influenza
season
start
late
decemb
last
late
may
virus
predomin
complic
influenza
diagnos
case
also
main
present
complaint
complic
includ
myositi
enceph
central
nervou
system
complic
viral
pneumonia
bacteri
superinfect
pneumonia
acut
otiti
media
eight
patient
influenza
present
posit
nasal
cultur
one
case
present
acut
pneumococc
otiti
media
identifi
median
iqr
durat
influenza
ill
day
patient
influenza
plu
pneumococc
colon
number
complic
significantli
higher
median
vs
p
u
erythrocyt
sediment
rate
good
indic
pneumococc
presenc
median
vs
mmh
p
u
oppos
fibrinogen
median
vs
mgdl
p
u
creactiv
protein
median
vs
mgl
p
u
importantli
durat
hospit
admiss
significantli
longer
median
vs
day
p
u
case
concomit
pneumococc
colon
conclus
identifi
low
preval
pneumococc
colon
pediatr
patient
influenza
howev
colon
present
associ
significantli
longer
hospit
stay
significantli
higher
number
complic
highlight
need
close
monitor
screen
pneumococc
colon
children
acknowledg
abstract
part
licens
thesi
epidemiolog
etiopathogenesi
influenza
pneumococc
colon
children
clinic
paraclin
microbiolog
characterist
perform
carol
davila
univers
medicin
pharmaci
bucharest
romania
coordin
prof
dr
adrian
streinucercel
supervisor
dr
oana
romanian
center
appli
biomolecular
research
infecti
diseas
project
financ
sector
oper
programm
increas
econom
competit
po
cce
background
varicella
highli
contagi
infecti
diseas
frequent
encount
childhood
gener
recept
often
selflimit
evolut
case
varicella
present
sever
complic
acut
enceph
cerebel
rare
myeliti
often
host
previou
immunosuppress
complic
rare
patient
normal
immunolog
statu
case
report
present
case
year
old
girl
diagnos
day
prior
varicella
without
signific
medic
histori
admit
pediatr
intens
care
unit
nation
institut
infecti
diseas
prof
dr
matei
lower
back
pain
myalgia
muscl
weak
difficulti
walk
onset
symptom
day
prior
evolut
toward
exacerb
clinic
exam
upon
admiss
confirm
varicella
furthermor
urinari
retent
enlarg
bladder
diminish
patellar
right
plantar
clonu
decreas
muscl
strength
myalgia
paresthesia
coordin
impair
lower
limb
asymmetr
paraparesi
predominantli
right
side
workup
within
normal
rang
myeliti
suspect
therefor
mri
head
spine
perform
show
medullar
inflammatori
lesion
cervicothorac
segment
lumbar
punctur
normal
except
posit
varicellazost
viru
pcr
csf
posit
diagnosi
consist
cervicothorac
varicellazost
viru
myeliti
treatment
acyclovir
mgkgday
ceftriaxon
gday
corticotherapi
methylprednisolon
human
immunoglobulin
iv
fluid
promptli
institut
day
slow
favor
evolut
paresthesia
motor
deficit
urinari
retent
sensit
impair
resolv
treatment
conclus
although
patient
normal
immunolog
statu
present
sever
complic
varicella
requir
antivir
cortison
treatment
high
dose
extend
period
time
eventu
led
complet
recoveri
consent
written
inform
consent
obtain
parent
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
enterovirus
group
singlestrand
rna
virus
commonli
encount
infecti
agent
especi
infant
children
respons
broad
array
clinic
manifest
herpangina
handfootandmouth
diseas
hfmd
myocard
asept
mening
method
face
increas
number
enterovirus
associ
infect
summer
season
present
paper
analyz
manag
case
pediatr
depart
nation
institut
infecti
diseas
prof
dr
matei
bucharest
refer
special
sever
challeng
case
particularli
toward
one
associ
meningoenceph
result
simplest
form
enteroviru
infect
regist
case
handfootandmouth
diseas
requir
hospit
manag
secondari
dehydr
associ
gastroenter
regist
number
hfmd
exceed
case
repres
enterovirus
induc
infect
record
secondari
myocard
overwhelm
number
acut
viral
meningoenceph
case
report
undergo
sever
form
meningoenceph
syndrom
complic
convuls
statu
plegia
andor
import
motor
deficit
epidem
peak
reach
midsumm
season
junejuli
integr
pediatr
intens
care
pic
depart
manag
regist
case
season
import
central
nervou
system
involv
magnet
reson
imag
document
lesion
present
patient
fatal
case
regist
conclus
tradit
enteroviru
infect
present
benign
symptom
take
form
uncompl
summer
ill
summer
regist
high
number
sever
life
threaten
form
manifest
requir
initi
pic
manag
long
hospit
manag
particular
case
meningoenceph
associ
motor
sequela
kinesiotherapi
physic
therapi
fact
highlight
associ
burden
summer
infect
background
combin
antiretrovir
therapi
significantli
improv
prognosi
life
expect
hiv
patient
along
profil
hiv
associ
malign
patholog
chang
among
lymphoma
higher
incid
poorer
prognosi
gener
popul
import
caus
mortal
morbid
hiv
infect
peopl
case
report
present
two
case
hivassoci
lymphoma
differ
outcom
first
case
newli
hiv
diagnos
patient
good
immunolog
statu
lymphocyt
count
hivrna
copiesml
develop
nonhodgkin
burkitttyp
lymphoma
fulmin
evolut
toward
death
second
case
patient
known
twenti
year
hiv
infect
discord
immunolog
virolog
respons
antiretrovir
therapi
lymphocyt
count
undetect
hivrna
diagnos
hodgkin
lymphoma
favor
evolut
chemotherapi
patient
present
system
extranod
involv
b
symptom
classifi
stage
iv
lymphoma
extranod
involv
includ
central
nervou
system
liver
case
patient
nonhodgkin
burkitttyp
lymphoma
liver
spleen
involv
case
patient
hodgkin
lymphoma
patient
requir
exhaust
medic
investig
close
interdisciplinari
cooper
entir
time
diagnost
therapeut
procedur
conclus
hivassoci
lymphoma
manifest
variou
form
clinic
set
unlik
gener
popul
hivassoci
lymphoma
usual
aggress
poor
prognost
therefor
must
includ
differenti
diagnosi
panel
patient
present
sudden
increas
lymph
node
neurolog
manifest
abrupt
decreas
lymphocyt
count
hivassoci
lymphoma
differenti
diagnosi
involv
wide
panel
infecti
oncolog
patholog
therefor
extens
investig
implic
specialist
variou
medic
field
requir
fast
accur
diagnosi
may
warrant
futur
evolut
patient
consent
written
inform
consent
obtain
patientfrom
next
kin
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
among
immunocompet
host
enterovir
infect
frequent
benign
autolimit
ill
except
summer
viral
patholog
evolv
dramat
present
sever
form
diseas
import
associ
complic
sometim
lead
death
present
paper
present
clinic
evolut
acut
coxsacki
viru
infect
immunocompet
child
complic
pancytopenia
case
report
young
babi
girl
month
age
without
particular
patholog
medic
histori
submit
pediatr
depart
nation
institut
infecti
diseas
prof
dr
matei
fever
poor
feed
sleepi
diarrhea
clinic
onset
regist
hour
hospit
submiss
character
fever
poor
feed
initi
clinic
evolut
found
moder
ill
appear
child
pallor
identifi
without
associ
petechia
bruis
without
particular
exanthemat
element
stabl
cardiocirculatori
statu
clinic
sign
renal
function
impair
diarrheal
stool
emit
nuchal
rigid
neurolog
focal
sign
present
laboratori
investig
isol
franc
pancytopenia
nl
hb
gdl
plt
patholog
find
serolog
screen
hiv
htlv
adenoviru
ebv
cmv
parvoviru
influenza
came
back
neg
normal
peripher
smear
bone
marrow
aspir
clinic
relev
result
commun
microbiolog
laboratori
neg
hemocultur
nasal
pharyng
swab
urocultur
stool
cultur
posit
igm
serolog
coxsacki
viru
obtain
cortison
iv
immunoglobulin
endoven
hydrat
support
therapi
initi
subsequ
favor
evolut
rapid
normal
hemogram
paramet
discret
hypochrom
anemia
persist
level
previous
identifi
infant
clinic
restor
conclus
acut
coxsacki
viru
infect
immunocompet
pediatr
popul
sometim
evolv
sever
complic
acut
diarrheal
manifest
subsequ
dehydr
possibl
hematolog
involv
evolut
present
case
maintain
residu
anemia
hb
gdl
paraclin
imbal
consent
written
inform
consent
obtain
patient
next
kin
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
viral
respiratori
infect
lead
caus
morbid
children
improv
manag
prioriti
clinic
etiolog
diagnosi
respiratori
viral
infect
provid
necessari
condit
proper
manag
improv
clinic
outcom
object
identif
viral
etiolog
respiratori
infect
establish
correl
pathogen
clinic
manifest
infect
produc
children
method
test
patient
age
year
diagnos
viral
respiratori
infect
clinic
decemb
may
identif
respiratori
virus
achiev
rapid
test
maripoc
molecular
method
pcr
perform
nasal
secret
record
chang
biolog
constant
clinic
manifest
caus
respiratori
virus
result
identif
etiolog
agent
allow
appropri
epidemiolog
measur
necessari
isol
patient
studi
incid
season
virus
season
domin
influenza
viru
much
smaller
proport
diagnos
infect
respiratori
syncyti
viru
influenza
b
viru
adenoviru
human
metapneumoviru
influenza
infect
evolv
season
high
sever
index
sever
complic
influenza
children
sever
neurolog
diseas
repres
febril
seizur
enceph
enceph
reaction
two
case
enceph
progress
death
conclus
etiolog
diagnosi
respiratori
viral
infect
epidemiolog
therapeut
implic
infect
influenza
virus
caus
sever
complic
death
need
prophylact
measur
earli
diagnosi
time
treatment
administ
background
hepatocellular
carcinoma
hcc
common
malign
tumor
liver
overal
incid
approxim
case
annual
predomin
male
hcc
consid
third
lead
caus
death
malign
second
lead
caus
death
respect
field
digest
cancer
patient
previous
diagnos
hepat
b
c
incid
hcc
patient
diagnos
cirrhosi
viral
b
c
etiolog
increas
overal
surviv
year
continu
remain
due
one
hand
discoveri
tumor
advanc
stage
ineffect
screen
patient
risk
factor
hcc
hand
lack
cur
therapi
applic
categori
patient
cur
palli
treatment
hcc
depend
mainli
local
tumor
extens
preexist
liver
diseas
angiogen
agent
type
sorafenib
may
caus
increas
overal
surviv
compar
placebo
patient
advanc
hcc
case
report
present
case
year
old
male
known
cirrhosi
viral
etiolog
b
consum
ethanol
refus
antivir
therapi
entecavir
diagnos
februari
hcc
extrahepat
extens
patient
admit
januari
suceava
emerg
hospit
jaundic
fever
right
upper
quadrant
pain
loss
appetit
weight
loss
clinic
exam
patient
intens
jaundic
emaci
superfici
lymph
impalp
ascit
fluid
quantiti
averag
slightli
sensit
right
upper
quadrant
laboratori
find
signific
hepat
cytolysi
cholestasi
elev
amylas
alphafetoprotein
slightli
elev
thrombocytopenia
moder
inflammatori
syndrom
ct
mri
exam
reveal
nodular
lesion
segment
vivii
extra
capsular
extens
diaphragm
chest
wall
invas
histopatholog
immunohistochemistri
outlin
trabecular
hepatocellular
carcinoma
develop
background
chronic
activ
hepat
advanc
fibrosi
patient
indic
liver
transplant
liver
resect
could
benefit
treatment
sorafenib
patient
devlop
import
ascit
right
massiv
pleurisi
hepat
encephalopathi
phenomena
die
month
diagnosi
hcc
one
month
start
treatment
sorafenib
conclus
current
medic
treatment
less
effect
advanc
hcc
role
liver
transplant
liver
resect
explor
current
hope
turn
new
molecular
target
therapi
explor
biolog
pathway
involv
carcinogenesi
signal
liver
consent
written
inform
consent
obtain
next
kin
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
influenza
season
repres
major
strain
health
care
system
vari
sever
time
durat
one
season
anoth
patient
infect
influenza
viru
exhibit
symptom
mild
respiratori
symptom
high
fever
case
regardless
age
comorbid
sever
diseas
complic
due
infect
includ
death
may
occur
case
seri
studi
meant
analyz
epidemiolog
clinic
paraclin
characterist
patient
infect
type
influenza
viru
admit
intens
care
depart
inbi
prof
dr
matei
influenza
season
method
retrospect
observ
case
seri
studi
conduct
period
adult
patient
admit
intens
care
depart
confirm
sever
influenza
infect
nasopharyng
swab
tracheal
secret
pcr
analysi
time
collect
data
demograph
comorbid
clinic
data
microbiolog
sampl
imagist
extract
patient
medic
chart
thorough
analysi
eventu
therapeut
measur
statist
correl
outcom
result
subject
enrol
median
age
year
old
male
caucasian
highrisk
condit
present
major
influenza
virus
patient
case
studi
match
strain
present
season
vaccin
none
patient
vaccin
demograph
spectrum
impress
divers
mortal
rate
take
account
influenza
might
trigger
latent
disord
exacerb
chronic
afflict
put
patient
risk
acquir
bacteri
superinfect
data
strongli
implic
influenza
viru
infect
combin
bacteri
superinfect
primari
caus
mortal
influenza
outbreak
conclus
incid
sever
influenza
case
intens
care
depart
rel
low
sever
high
case
might
prevent
follow
recommend
vaccin
risk
group
romania
background
measl
acut
infecti
diseas
highli
contagi
death
among
infant
still
remain
high
proport
due
bronchopneumonia
respiratori
diseas
result
measl
viru
associ
bacteri
infect
may
includ
respiratori
area
secondari
lesion
viral
immun
cellular
depress
case
report
present
case
child
month
old
femal
unvaccin
multipl
hospit
bronchiol
last
month
suppur
otiti
febril
convuls
syndrom
last
hospit
loui
turcanu
emerg
hospit
children
day
present
clinic
emphysemat
acut
bronchiol
otiti
media
effus
affirm
day
discharg
patient
fever
nasal
obstruct
rhinorrhea
cough
erupt
element
child
guid
hospit
gener
physician
admiss
child
present
influenc
gener
condit
adynamia
nasal
obstruct
cough
expiratori
secus
saburr
tongu
throat
congest
erythematomacular
element
erupt
tendenc
confluenc
face
chest
liver
cm
lower
edg
costal
margin
biolog
test
admiss
anemia
inflammatori
syndrom
present
diagnosi
measl
bronchial
hyperreact
suspect
subsequ
anti
measl
igm
posit
treatment
begun
water
electrolyt
rebalanc
treatment
bronchodil
corticosteroid
antibiot
administr
day
due
persist
fever
isol
febril
hook
posit
procalcitonin
day
gener
condit
alter
polypnea
intercost
draft
oxygen
satur
without
oxygen
mask
requir
transfer
intens
care
endotrach
intub
necessari
desatur
episod
highlight
radiolog
imag
diffus
fog
lung
field
attempt
extub
patient
present
pulmonari
edema
sever
bronchospasm
requir
reintub
day
week
child
respiratori
statu
degrad
evolv
acut
respiratori
distress
syndrom
metabol
acidosi
sever
episod
bradycardia
mechan
ventil
becom
oligoanur
bradycardia
respond
atropin
cardiopulmonari
arrest
occur
conclus
overal
measl
prognosi
favor
children
satisfi
nutrit
statu
good
live
condit
prognosi
remain
poor
children
year
dystroph
syndrom
anemia
ricket
multipl
comorbid
consent
written
inform
consent
obtain
next
kin
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
rightsid
infecti
endocard
ie
common
condit
iv
drug
user
ivdu
staphylococcu
spp
involv
pathogen
mani
ivdu
hiv
posit
condit
make
extrem
suscept
infect
aim
present
challeng
rais
manag
ie
hiv
posit
ivdu
case
report
former
ivdu
current
methadon
substitut
hcv
chronic
infect
hiv
infect
naiv
treatment
admit
hospit
fever
dyspnea
minim
exert
spontan
cough
gener
arthromyalgia
temporalspati
disorient
take
account
hiv
statu
correl
sever
gener
present
import
lymphopenia
patient
insert
left
jugular
central
venou
line
cvl
easier
administr
medic
blood
cultur
taken
start
maxim
antimicrobi
therapi
associ
dexamethason
mannitol
treat
potenti
mening
later
rule
lumbar
punctur
drug
abus
histori
continu
deterior
state
urg
transthorac
echocardiographi
tte
reveal
veget
locat
tricuspid
valv
evoc
ie
therapi
adapt
possibl
staphylococc
endocard
vancomycin
iv
g
day
gentamycin
iv
mg
singl
dose
day
diuret
betablock
drug
day
later
one
blood
cultur
came
posit
methicillinsensit
aureu
mssa
diagnosi
ie
mssa
tricuspid
valv
revis
duke
criteria
major
criterion
veget
seen
tte
minor
criteria
predispos
factor
one
posit
blood
cultur
fever
antibiotherapi
chang
oxacillin
iv
g
per
day
day
despit
correct
treatment
patient
evolut
worsen
low
fever
intens
dyspnea
increas
biolog
inflammatori
syndrom
pulmonari
rale
chest
radiographi
consist
pneumonia
bronchoscopi
bronchoalveolar
lavag
perform
tuberculosi
exclud
mssa
confirm
probabl
septic
emboli
blood
cultur
taken
cvl
one
posit
vancomycinresist
enterococcu
faecium
new
find
interpret
nosocomi
infect
due
patient
poor
adher
hygien
procedur
involv
cvl
linezolid
use
week
oxacillin
resum
complet
week
success
antibiotherapi
conclus
hiv
posit
patient
especi
ivdu
character
great
suscept
infect
make
challeng
physician
diagnos
treat
even
adequ
therapi
patient
prone
develop
lifethreaten
complic
mainli
poor
adher
treatment
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
infect
influenza
viru
mani
type
subtyp
also
airborn
spread
remain
public
health
problem
lack
specif
therapi
safe
decreas
immun
host
aggress
germ
extern
environ
possibl
sourc
super
infect
lead
great
sever
condit
reflect
mortal
rate
patient
flu
confirm
pcr
patient
die
death
rate
season
method
retrospect
analysi
case
hospit
period
decemb
april
confirm
influenza
viru
sever
respiratori
failur
arf
highlight
clinic
data
biolog
viral
biolog
imag
specif
patient
result
bacteri
reinfect
uniqu
mix
germ
type
mdr
pdr
cocci
mrsa
pneumonia
e
faecium
gram
neg
bacilli
baumannii
k
pneumonia
e
coli
fungi
c
albican
c
non
albican
glabrata
kefir
detect
carriag
patholog
product
surfac
cathet
probe
target
antimicrobi
therapi
ab
latest
dose
multipl
associ
support
therapi
antifung
therapi
appropri
stage
sepsi
antivir
therapi
oseltamivir
initi
earli
individu
casework
advanc
support
vital
function
physiopathogen
support
therapi
intens
nurs
form
basi
therapeut
complex
behavior
death
patient
care
analyz
bacteriolog
standpoint
case
die
sever
sepsi
septic
complic
caus
pneumococcu
k
pneumonia
p
c
baumannii
fumigatu
mrsa
case
admit
extrem
statu
seriou
critic
condit
unstabl
condit
septic
shock
msof
unidentifi
etiolog
death
day
admiss
conclus
data
present
show
us
great
serious
respiratori
infect
influenza
quick
develop
respiratori
failur
requir
advanc
support
iot
vm
method
immin
help
increas
risk
superinfect
extrem
sever
bacteri
infect
multipl
resist
creat
great
difficulti
ensur
success
bacteriolog
control
optim
success
particular
materi
resourc
need
cover
acquisit
highest
technolog
latest
equip
well
human
resourc
highli
qualifi
experienc
practic
abl
make
quick
decis
accur
respons
multidisciplinari
work
group
background
influenza
acut
infecti
diseas
increas
epidem
potenti
flu
sever
acut
respiratori
infect
sari
import
public
health
problem
object
evalu
typessubtyp
influenza
season
patient
clinic
hospit
infecti
diseas
scbi
epidemiolog
character
sari
hospit
scbi
accord
criteria
surveil
methodolog
influenza
acut
respiratori
infect
ari
sever
acut
respiratori
infect
sari
season
method
retrospect
analysi
laboratoryconfirm
flu
case
season
scbi
retrospect
analysi
sari
case
accord
epidemiolog
criteria
distribut
gender
age
area
origin
prior
vaccin
statu
season
travel
histori
contact
confirm
case
influenza
associ
chronic
diseas
sign
sever
clinic
sign
pneumonia
complic
acut
respiratori
failur
secondari
bacteri
infect
oxygen
therapi
mechan
ventil
antibiot
therapi
result
total
number
laboratori
confirm
influenza
case
type
subtyp
type
neg
subtyp
type
type
subtyp
type
b
hospit
necessari
patient
sari
femal
male
belong
differ
age
group
year
year
background
differ
origin
urban
rural
comorbid
cardiovascular
bronchopulmonari
diabet
case
pregnanc
obes
histori
travel
abroad
bulgaria
libya
case
previou
contact
person
confirm
influenza
person
person
histori
influenza
vaccin
sixtysix
patient
clinic
sign
pneumonia
medic
complic
like
acut
respiratori
failur
case
secondari
bacteri
infect
pneumonia
case
patient
receiv
antibiot
therapi
patient
receiv
oxygen
surviv
patient
mechan
ventil
conclus
clinic
hospit
infecti
diseas
romania
sari
mortal
zero
recept
popul
unprotect
vaccin
mostli
consist
adult
comorbid
preval
subtyp
flu
season
background
interleukin
involv
pathogenesi
inflamm
infect
neoplasm
autoimmun
diseas
biolog
activ
exert
two
mechan
involv
bind
specif
membran
receptor
abbrevi
classic
signal
pathway
bind
solubl
form
receptor
abbrevi
tran
signal
pathway
step
follow
interact
previous
form
complex
transduc
subunit
gp
investig
intracellular
signal
pathway
mediat
pro
antiinflammatori
effect
viral
infect
repres
aim
prospect
studi
method
studi
includ
subject
divid
group
group
patient
viral
infect
hiv
hcv
hbv
group
b
patient
cutan
malign
melanoma
group
c
patient
malign
melanoma
associ
viral
infect
group
healthi
subject
determin
serum
level
solubl
glycoprotein
sgp
perform
elisa
techniqu
result
serum
level
significantli
higher
patient
viral
infect
pgml
p
malign
melanoma
pgml
p
malign
melanoma
associ
viral
infect
pgml
p
control
group
pgml
compar
control
ngml
serum
level
moder
elev
patient
viral
infect
ngml
p
malign
melanoma
ngml
p
malign
melanoma
associ
viral
infect
ngml
p
signific
variat
also
obtain
sgp
follow
ngml
control
group
ngml
p
patient
viral
infect
ngml
p
patient
malign
melanoma
ngml
p
patient
malign
melanoma
associ
viral
infect
conclus
secret
respons
viral
infect
malign
transform
subunit
overexpress
viral
infect
solubl
glycoprotein
synthes
small
amount
studi
viral
infect
therefor
may
involv
regul
inflammatori
respons
human
bodi
mani
mechan
viral
infect
tran
signal
pathway
overexpress
knowledg
intracellular
signal
mechan
import
consequ
therapeut
strategi
aim
block
activ
cytokin
background
studi
evolut
clinic
humor
patholog
paramet
patient
persist
hbsag
month
acut
phase
method
follow
studi
patient
hospit
clinic
within
year
patient
studi
diagnos
acut
b
type
hepat
patient
posit
hbsag
observ
patient
persist
hbsag
month
patient
present
frequent
unfavor
evolut
toward
heal
result
subject
patient
describ
sign
weak
fatigu
effort
pain
object
detect
presenc
hepatomegali
splenomegali
year
persist
hbsag
patient
vascular
star
present
later
shown
sign
chronic
activ
hepat
follow
dynam
viral
marker
evolv
pursu
hepatodepress
syndrom
syndrom
retent
cytolysi
inflammatori
dysproteinemia
humor
chang
present
hbsag
persist
hepat
gener
encount
acut
phase
differ
intens
plu
develop
intensifi
inflammatori
syndrom
case
persist
hbsag
dynam
develop
humor
syndrom
categor
differ
compar
evolut
hepat
syndrom
case
acut
infect
evolv
hbsag
neg
conclus
persist
hbsag
acut
phase
detect
case
observ
evolut
toward
chronic
evolut
toward
heal
seroconvers
seen
case
month
acut
phase
background
bacteri
infect
colon
pregnanc
may
innocu
may
lead
signific
consequ
mother
fetu
earli
diagnosi
appropri
antimicrobi
treatment
essenti
step
toward
best
possibl
pregnanc
outcom
method
perform
retrospect
studi
assess
preval
potenti
pathogen
bacteria
fungi
identifi
smear
cultur
vagin
cervic
discharg
collect
pregnant
patient
attend
one
gynecologyobstetr
ward
tertiari
care
hospit
bucharest
romania
juli
juli
statist
analysi
includ
chisquar
test
categor
variabl
nonparametr
test
continu
variabl
perform
ibm
spss
statist
armonk
usa
result
assess
pregnant
femal
patient
median
interquartil
rang
age
year
median
interquartil
rang
durat
pregnanc
week
time
smear
cultur
test
perform
roughli
half
patient
present
normal
gramposit
tinctori
predomin
vagin
smear
present
appar
pathogen
gramneg
flora
although
vagin
discharg
cultur
grew
gramneg
bacilli
name
e
coli
anoth
vagin
cultur
posit
yeast
neg
aureu
klebsiella
spp
trichomona
vaginali
among
cervic
cultur
grew
e
coli
includ
two
case
also
posit
vagin
cultur
e
coli
grew
klebsiella
pneumonia
grew
yeast
grew
enterococcu
spp
none
posit
aureu
trichomona
vaginali
identifi
e
coli
strain
almost
half
n
resist
ampicillin
resist
ciprofloxacin
suscept
cephalosporin
carbapenem
cotrimoxazol
klebsiella
strain
posit
extendedspectrum
betalactamas
significantli
frequent
lower
gestat
age
p
z
fungal
growth
cervic
cultur
significantli
associ
younger
matern
age
p
z
conclus
identifi
fairli
low
preval
cervic
pathogen
popul
pregnant
femal
patient
close
monitor
tertiari
care
hospit
bucharest
romania
result
suggest
screen
klebsiella
perform
earlier
pregnanc
younger
women
higher
incid
fungal
infect
background
group
b
streptococci
gb
major
caus
morbid
longterm
disabl
babi
borntomoth
colon
infect
germ
neonat
gb
infect
prevent
intrapartum
antibiot
asymptomat
pregnant
women
screen
gb
vagin
intrarect
cultur
week
pregnanc
method
perform
retrospect
studi
ascertain
preval
gb
colonizationinfect
juli
pregnant
patient
monitor
tertiari
care
hospit
bucharest
romania
result
studi
pregnant
women
median
iqr
gestat
age
week
patient
sampl
repres
southern
romania
urban
area
bucharestilfov
area
southern
southeastern
southwestern
area
romania
two
patient
ukrain
moldova
onefourth
patient
previou
obstetr
medic
histori
uterin
scar
n
uterin
fibroid
n
histori
preeclampsia
n
cervic
scar
septat
uteru
histori
placenta
praevia
histori
intrauterin
death
n
none
vagin
cultur
yield
gb
cervic
cultur
grew
gb
patient
consent
intrarect
cultur
therefor
real
preval
gb
colon
may
somewhat
underestim
mean
age
sd
patient
posit
gb
cultur
year
cultur
collect
median
gestat
age
week
urin
cultur
perform
one
case
gb
colon
one
yield
asymptomat
gb
bacteriuria
requir
treatment
pregnanc
along
standard
intrapartum
antimicrobi
prophylaxi
gb
colon
preval
gb
colon
slightli
higher
patient
urban
area
vs
differ
fail
reach
statist
signific
probabl
due
small
number
overal
posit
cultur
p
preval
gb
influenc
obstetr
histori
p
patient
age
p
z
gestat
age
p
z
gb
colon
increas
odd
csection
p
conclus
identifi
fairli
low
preval
gb
colon
one
case
urinari
gb
infect
pregnanc
studi
reveal
major
risk
factor
gb
colon
infect
cohort
pregnant
women
southern
romania
refer
chukwu
mo
mavenyengwa
rt
monyama
cm
et
al
antigen
distribut
streptococcu
agalactia
isol
pregnant
women
garankuwa
hospit
south
africa
germ
puopolo
k
madoff
l
baker
c
group
b
streptococc
infect
pregnant
women
post
ed
uptod
waltham
uptod
background
absenc
clinic
evid
trauma
difficult
diagnos
muscl
hematoma
easili
mistaken
profound
thrombophleb
case
report
year
old
patient
come
rural
area
histori
penil
tumor
lymph
node
expans
oper
diabet
coronari
patient
treatment
trombex
one
year
hospit
accus
fever
dysuria
cloudi
urin
object
without
modif
admiss
paraclin
prostat
hypertrophi
retain
ultrasound
initi
interpret
urinari
infect
therapi
ciprofloxacin
start
urin
cultur
collect
day
admiss
patient
fall
height
go
bathroom
without
appar
trauma
without
loss
conscious
second
day
admiss
patient
accus
right
lower
back
right
lower
leg
pain
without
object
cutan
modif
third
day
pain
central
right
lower
leg
gradual
evolut
toward
posterior
edema
posit
hoffman
sign
situat
interpret
deep
vein
thrombosi
therefor
anticoagul
therapi
initi
three
day
treatment
patient
afebril
still
present
edema
pain
calf
neutrophil
leukocytosi
appear
inflammatori
evid
increas
metabol
imbal
present
urin
cultur
steril
treatment
chang
ceftriaxon
ultrasound
right
lower
leg
section
show
fluid
collect
cm
punctur
perform
area
collect
noth
extern
vascular
surgeri
consult
refut
diagnosi
thrombophleb
thu
maintain
suspicion
possibl
infecti
hematoma
patient
transfer
surgeri
ward
suspicion
confirm
surgic
collect
evacu
conclus
calf
muscl
hematoma
easili
mistaken
clinic
profound
thrombophleb
absenc
cutan
modif
correct
diagnosi
extend
investig
need
sinc
therapi
complet
differ
two
situat
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
million
individu
infect
tlymphotrop
viru
htlv
world
first
describ
human
oncoviru
etiolog
link
adult
leukemialymphoma
atll
spread
viru
endem
japan
africa
central
south
america
littl
known
infect
rate
romania
test
blooddonor
structur
epidemiolog
ongo
program
regard
htlv
infect
start
direct
mutagen
effect
viru
present
paper
want
rais
awar
toward
endem
problem
face
method
high
clinic
suspicion
atll
diagnosi
establish
hematolog
depart
clinic
hospit
colentina
bucharest
januari
march
analyz
lymphocyt
morpholog
immunophenotyp
histolog
tissu
affect
pure
lymphoma
form
antibodi
detect
use
enzymelink
immunosorb
assay
elisa
confirm
realtim
pcr
assay
confirm
case
prospect
record
age
sex
immun
statu
form
sever
diseas
respons
first
appli
second
line
chemotherapi
instanc
associ
antiretrovir
therapi
epidemiolog
link
possibl
htlv
infect
sourc
explor
use
standard
questionnair
result
survey
period
depart
work
case
atll
mean
surviv
period
month
postdiagnosi
hypercvad
chop
regimen
base
chemotherapi
implement
associ
antiretrovir
therapi
manag
case
patient
known
htlv
posit
patient
oncolog
diagnost
follow
monitor
infecti
diseas
center
one
case
vertic
transmiss
identifi
mother
diagnosi
atll
patient
present
hbv
hcv
coinfect
patient
declar
travel
practic
atrisk
activ
htlv
endem
area
conclus
despit
major
advanc
understand
pathogenesi
diseas
manag
patient
remain
challeng
clinician
respond
achiev
transient
respons
easi
constant
access
antiretrovir
therapi
essenti
transplant
consid
prevent
program
standard
nation
integr
intern
need
becom
public
health
prioriti
background
clinic
practic
sometim
meet
case
prove
real
profession
challeng
case
report
present
male
patient
year
old
retir
hospit
adult
infecti
diseas
clinic
victor
hospit
craiova
transfer
intens
care
unit
clinic
region
hospit
craiova
diseas
acut
onset
week
present
infecti
diseas
clinic
psychomotor
agit
languag
disord
confus
admit
neurolog
clinic
suspicion
stroke
infirm
subsequ
imagist
explor
presenc
fever
confus
patient
without
stroke
determin
solicit
infecti
diseas
specialist
consult
perform
lumbar
punctur
follow
lumbar
punctur
diagnosi
meningoenceph
clear
cerebrospin
fluid
csf
formul
patient
transfer
intens
care
unit
sustain
vital
function
receiv
also
etiolog
target
treatment
ceftriaxon
acyclovir
dot
three
day
later
due
favor
evolut
patient
transfer
infecti
diseas
clinic
anamnest
data
relev
contact
tuberculosi
infect
parent
daili
alcohol
consumpt
grday
former
smoker
physic
examin
admiss
reveal
averag
gener
state
fever
awar
cooper
balanc
cardiorespiratori
stiff
neck
stage
diagnosi
meningoenceph
clear
csf
biolog
examin
reveal
complet
blood
count
normal
leukocyt
number
balanc
leukocyt
formula
moder
biolog
inflammatori
syndrom
esr
mm
slight
hepatocytolysi
syndrom
tgp
ul
tgo
ul
neg
hiv
serolog
lumbar
punctur
perform
dynam
highlight
csf
persist
albumin
cytolog
dissoci
element
count
pandi
decreas
chlorid
mg
pneumophtiziolog
consult
recommend
continu
dot
ent
consult
diagnos
oropharyng
candidosi
rest
explor
normal
limit
posit
diagnosi
meningoenceph
probabl
bacillari
etiolog
druginduc
toxic
hepat
receiv
treatment
acyclovir
ceftriaxon
day
dot
initi
shift
hepatocytolysi
syndrom
nistatin
corticosteroid
dexamethason
mannitol
hepatoprotect
symptomat
drug
evolut
slowli
favor
rais
manag
issu
hepatocytolysi
syndrom
conclus
bacillari
meningoenceph
rais
diagnosi
issu
atyp
onset
acut
presenc
rough
mening
syndrom
therapi
problem
link
appear
hepatocytolysi
syndrom
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
ocular
impair
hivposit
patient
appear
mostli
sever
immunodefici
involv
especi
opportunist
germ
also
case
hiv
viru
caus
ocular
manifest
case
report
present
case
year
old
woman
known
hiv
infect
admit
nation
institut
infecti
diseas
prof
dr
matei
sudden
visual
acuiti
decreas
associ
blur
vision
eye
pain
exacerb
motion
time
admiss
hiv
rna
copiesml
patient
droppedoff
antiretrovir
therapi
sever
year
ago
investig
rule
infect
viral
bacteri
fungal
tbc
neoplasia
autoimmun
diseas
ophthalm
examin
reveal
normal
ocular
fundu
right
visual
field
defect
cerebrospin
fluid
examin
obtain
lumbar
punctur
cell
free
protein
glucos
chlorid
normal
rang
neg
china
ink
test
neg
cryptococcu
antigen
test
neg
vdrl
undetect
pcrbk
undetect
polyomaviru
jc
dna
hiv
rna
copiesml
neg
cultur
bacteria
fungi
bk
brain
mri
recommend
neurologist
reveal
swollen
optic
nerv
without
brain
demyelin
lesion
favor
cours
notic
ful
recoveri
visual
acuiti
iv
treatment
dexamethason
resumpt
antiretrovir
therapi
conclus
hiv
induc
optic
nerv
damag
may
occur
hivposit
patient
sever
immunodefici
hiv
relat
retrobulbar
optic
neuriti
demonstr
imag
studi
mri
exclus
infecti
noninfecti
caus
highlight
favor
outcom
cortison
antiretrovir
therapi
effect
antiretrovir
treatment
result
increas
undetect
hiv
rna
significantli
decreas
extinct
incid
ocular
manifest
hiv
viru
infect
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
q
fever
zoonosi
caus
coxiella
burnetii
clinic
present
polymorph
nonspecif
often
character
selflimit
influenzalik
ill
pneumonia
hepat
hand
clinic
form
less
frequent
like
cardiovascular
neurolog
obstetr
manifest
dermatolog
form
erythema
nodosum
nonspecif
exanthema
maculopapular
rash
diffus
punctiform
prurit
rash
case
report
report
case
year
old
caucasian
femal
consum
raw
milk
present
clinic
diagnost
reevalu
persist
fever
initi
case
diagnos
acut
acalcul
cholecyst
cholestat
syndrom
associ
hepat
cytolysi
thick
gallbladd
wall
ct
treat
ertapenem
ciprofloxacin
patient
becam
afebril
fever
reappear
soon
left
hospit
time
admiss
clinic
case
consid
angiochol
treat
initi
ampicillinsulbactam
h
escal
piperacillintazobactam
doxycyclin
meropenem
doxycyclin
day
meropenem
day
doxycyclin
patient
present
relaps
fever
treatment
maximum
day
hospit
patient
develop
erythemat
indur
nodul
sharpli
margin
cm
diamet
locat
anterior
lower
leg
investig
extend
find
etiolog
new
manifest
diagnos
histopatholog
examin
erythema
nodosum
exclud
pulmonari
tuberculosi
sarcoidosi
streptococc
yersinia
salmonella
mycoplasma
infect
cholangiocarcinoma
genit
cancer
posit
find
posit
igm
antibodi
coxiella
burnetii
reintroduc
doxycyclin
despit
lack
respons
begin
hospit
soon
fever
remit
repeat
coxiella
serolog
still
found
high
antibodi
titer
favor
evolut
erythema
nodosum
doxycyclin
plead
diagnosi
q
fever
moreov
import
mention
patient
forgot
take
treatment
day
determin
apparit
new
nodul
evolut
new
lesion
favor
compat
aspect
therapeut
confirm
diagnosi
confirm
efficaci
manag
conclus
case
highlight
rare
clinic
form
q
fever
particular
evolut
slow
respons
usual
therapi
time
case
illustr
differenti
diagnosi
persist
fever
associ
erythema
nodosum
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
tinea
incognita
atyp
manifest
dermatophytos
often
due
inappropri
treatment
corticosteroid
steroidmodifi
tinea
system
topic
prescrib
preexist
patholog
given
mistakenli
treatment
misdiagnos
tinea
inflamm
scali
typic
clinic
sign
dermatophytos
suppress
make
diagnosi
difficult
usual
site
problem
occur
face
groin
lower
leg
hand
longstand
steroid
modifi
case
may
requir
prolong
oral
antifung
therapi
case
report
present
case
yearold
femal
patient
sever
month
erythematosquam
erupt
locat
face
distribut
especi
malar
region
dorsum
hand
distribut
erupt
photoexpos
area
establish
clinic
diagnosi
lupu
erythematosu
began
treatment
topic
corticosteroid
initi
improv
clinic
manifest
rash
reappear
continu
expand
gradual
patient
refer
clinic
diagnosi
therapeut
manag
addit
clinic
manifest
describ
dermatolog
examin
reveal
nail
chang
includ
finger
usual
laboratori
investig
within
normal
limit
hiv
serolog
neg
immunolog
investig
lupu
erythematosu
inconclus
direct
mycolog
examin
lesion
week
period
treatment
cessat
neg
biopsi
carri
one
face
lesion
histopatholog
examin
reveal
fungal
element
initi
topic
system
antifung
treatment
rash
disappear
three
month
treatment
nail
chang
remit
also
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
infect
pregnanc
may
significantli
impact
fetal
develop
caus
minim
matern
morbid
particularli
true
subset
pathogen
toxoplasmaothersrubellacytomegaloviru
cmv
herpesvirus
torch
among
highest
risk
congenit
malform
associ
earli
pregnanc
acut
rubella
infect
cmv
toxoplasma
also
account
signific
fetal
development
issu
herpesvirus
pose
highest
threat
newborn
infect
transmit
vertic
method
studi
incid
acut
toxoplasma
rubella
cmv
infect
serum
igm
screen
seropreval
serum
igg
antibodi
pregnant
femal
attend
refer
center
obstetricsgynecolog
romania
studi
implement
norwegian
financi
mechan
access
screen
program
avail
pregnant
femal
romania
trimest
pregnanc
date
patient
screen
torch
project
statist
analysi
perform
spss
statist
window
ibm
corp
usa
use
pearson
chisquar
test
multigroup
comparison
independentsampl
ttest
normallydistribut
continu
variabl
result
present
preliminari
result
first
patient
screen
mean
standard
deviat
age
year
urban
area
wide
nation
coverag
bucharestilfov
south
southwest
southeast
northeast
romania
screen
perform
median
interquartil
rangeiqr
gestat
age
week
highest
seropreval
record
cmv
median
iqr
valu
auml
follow
rubella
median
iqr
iuml
toxoplasma
median
iqr
iuml
antitoxoplasma
igm
igm
igg
posit
patient
rubella
cmv
igm
igg
patient
posit
anticmv
igm
higher
gestat
age
screen
vs
week
p
high
effects
patient
posit
antitoxoplasma
igm
significantli
like
cumul
pregnancyassoci
adversebehavior
eg
smoke
p
antirubella
igm
frequent
exsmok
p
rural
dwell
risk
factor
acut
infect
conclus
report
high
seropreval
major
pregnanc
pathogen
suggest
protect
immun
also
pose
risk
reactiv
pregnanc
incid
acut
infect
pregnanc
fairli
low
patient
acut
infect
pregnanc
also
cumul
pregnancyassoci
adversebehavior
requir
close
monitor
special
counsel
acknowledg
project
initi
public
financi
mechan
background
acut
respiratori
infect
common
caus
hospit
icu
inbi
matei
patient
sever
sepsi
admit
patient
experienc
respiratori
dysfunct
ard
patient
experienc
cardiac
dysfunct
patient
show
dysfunct
nsc
ard
defin
acut
inflammatori
syndrom
character
bilater
parenchym
lung
infiltr
chest
x
ray
ratio
result
caus
acut
left
ventricular
dysfunct
inflammatori
lung
lesion
may
induc
differ
caus
like
virus
pathogen
germ
parasit
fungi
etc
outcom
patient
depend
comorbid
age
statu
immunocompromis
pattern
stage
infect
moment
admiss
icu
method
monitor
analysi
clinic
data
biolog
imag
microbiolog
evolut
gase
blood
guid
us
effect
therapi
manag
follow
result
monitor
data
present
demonstr
patient
acut
respiratori
failur
arf
patient
develop
sever
sepsi
bacteri
etiolog
ard
respiratori
start
point
nosocomi
pneumonia
pathogen
involv
put
patholog
product
sputum
case
tracheal
aspir
case
hemocultur
case
invas
devic
cathet
eg
iot
case
cvc
case
urinari
cathet
case
cocci
pathogen
account
case
pneumococcu
mrsa
staphylococcu
aureu
enterococcu
spp
gramneg
bacilli
case
baumanii
pseudomona
klebsiela
pneumonia
fungi
case
c
krusei
c
albican
c
glabrata
develop
nosocomi
pneumonia
unfavor
evolut
death
rate
median
age
affect
patient
year
antimicrobi
therapi
accord
microbiolog
evid
includ
associ
last
gener
antibiot
individu
dose
antifung
antivir
oseltamivir
case
flu
arf
requir
specif
protect
measur
use
noninvas
ventil
mechan
ventil
ard
influenza
analyz
separ
conclus
great
progress
made
manag
ard
nowaday
novel
agent
techniqu
avail
includ
antimicrobi
drug
extracorpor
membran
oxygen
well
support
treatment
advanc
mechan
ventil
seem
subgroup
patient
rel
mild
earli
ard
like
benefit
noninvas
ventil
background
granulicatella
speci
nutrit
variant
streptococci
normal
compon
oral
flora
associ
varieti
invas
infect
human
especi
bacteri
endocard
abdomin
abscess
recent
granulicatella
elegan
isol
central
nervou
system
cn
well
cn
involv
earli
recogn
sinc
granulicatella
infect
increas
morbid
mortal
well
great
bacteriolog
failur
relaps
rate
case
report
present
case
yearsold
woman
mening
first
consid
tuberculosi
tb
receiv
antitb
treatment
includ
streptomycin
seven
day
treatment
initi
gener
condit
improv
patient
experienc
bilater
deaf
well
sever
disequilibrium
document
pure
tone
audiometri
vestibular
investig
posturographi
videonystagmographi
video
head
impuls
test
hit
perman
sensori
deficit
huge
neg
impact
qualiti
life
patient
commun
anymor
walk
alon
perform
daili
activ
togeth
appropri
new
antibiot
treatment
granulicatella
infect
hear
aid
vestibular
rehabilit
program
recommend
case
granulicatella
mening
report
none
hear
equilibrium
deficit
secondari
infect
consid
case
cochleovestibular
bilater
deficit
secondari
mening
ototox
treatment
sinc
major
adult
case
ototox
lesion
aminoglycosid
affect
one
sensori
structur
inner
ear
hear
sensori
epithelium
vestibular
one
conclus
granulicatella
induc
invas
infect
rapid
initi
adequ
antibiot
therapi
minim
sever
diseas
well
longterm
sequel
case
sudden
sever
bilater
onset
hear
loss
limit
commun
perman
hear
loss
partial
compens
hear
aid
regard
bilater
vestibular
deficit
rehabilit
difficult
longlast
dramat
limit
daili
activ
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
season
influenza
public
health
problem
associ
everi
year
import
number
hospit
especi
elderli
popul
method
aim
studi
describ
clinic
epidemiolog
virolog
characterist
influenza
case
peopl
age
year
older
admit
three
infecti
diseas
hospit
romania
two
bucharest
one
season
studi
fund
imov
project
screen
patient
admit
sign
symptom
compat
influenza
infect
three
infecti
diseas
hospit
week
till
week
collect
inform
demograph
vaccin
underli
condit
use
standard
questionnair
person
data
transmit
questionnair
patient
gave
written
inform
consent
swab
case
patient
rtpcr
posit
influenza
control
neg
influenza
viru
result
influenza
activ
start
romania
week
reach
peak
week
last
week
character
domin
influenza
virus
enrol
studi
subject
met
influenza
clinic
case
definit
inclus
criteria
analys
sixtysix
patient
influenza
laboratori
confirm
six
vaccin
season
influenza
vaccin
median
age
year
femal
frequent
sign
symptom
present
admiss
cough
fever
malais
short
breath
myalgia
least
one
medic
chronic
condit
heart
diseas
diabet
lung
diseas
frequent
seven
patient
die
one
vaccin
major
case
receiv
antivir
treatment
case
posit
influenza
b
strain
isol
antigen
relat
vaccin
strain
influenza
virus
detect
belong
genet
group
subgroup
type
b
detect
belong
bvictoria
lineag
conclus
peopl
year
old
greater
risk
complic
influenza
might
result
hospit
death
effect
way
prevent
influenza
remain
vaccin
also
antivir
treatment
may
reduc
sever
complic
death
acknowledg
acknowledg
hospit
team
patient
laboratori
staff
epiconcept
team
project
receiv
fund
european
union
horizon
research
innov
programm
grant
agreement
background
chickenpox
common
childhood
infecti
diseas
contagi
usual
benign
selflimit
complic
believ
rare
method
purpos
studi
describ
epidemiolog
varicella
complic
immunolog
healthi
children
admit
infecti
diseas
hospit
within
period
januari
juli
analyz
clinic
evolut
aspect
studi
case
result
case
hospit
period
chickenpox
diagnosi
present
variou
complic
major
complic
occur
preschool
age
children
impress
number
case
one
year
age
found
gender
predomin
male
femal
primarili
within
urban
popul
frequent
complic
varicella
bacteri
superinfect
skin
lesion
pneumonia
cellul
occur
case
case
present
abscess
variou
locat
facial
extrem
trunk
requir
multidisciplinari
treatment
streptococcu
pyogen
lead
caus
bacteri
infect
also
staphylococcu
aureu
found
case
cutan
complic
includ
hemorrhag
varicella
case
purpura
fulminan
case
associ
thrombocytopenia
dissemin
intravascular
coagul
invas
group
streptococc
diseas
ga
appear
four
case
present
posit
blood
cultur
multiorgan
involv
two
case
favor
evolut
treatment
complic
neurolog
report
children
mening
lead
diagnosi
follow
enceph
cerebel
one
case
deceas
occur
child
purpura
fulminan
conclus
bacteri
infect
complic
chickenpox
caus
signific
morbid
mortal
mainli
patient
younger
year
age
varicella
increas
risk
acquir
ga
diseas
cellul
common
infect
deepseat
septic
infect
occur
immunolog
healthi
children
varicella
chickenpox
continu
caus
signific
morbid
pediatr
popul
background
clostridium
difficil
coliti
current
public
health
issu
rise
number
case
report
children
adult
condit
aris
excess
antibiot
use
also
immunodepress
caus
chemotherapi
oncolog
treatment
propos
apprais
clinic
form
clostridium
difficil
coliti
children
well
evolut
treatment
method
carri
retrospect
studi
case
acut
c
difficil
infect
children
admit
pediatr
depart
nation
institut
infecti
diseas
prof
dr
matei
patient
monitor
age
sex
immunolog
statu
clinic
form
diseas
evolut
treatment
diagnosi
coliti
establish
base
clinic
criteria
confirm
laboratori
method
detect
c
difficil
ab
toxin
stool
case
receiv
treatment
accord
standard
protocol
except
one
case
allergi
antibiot
therapeut
scheme
prompt
us
perform
fecal
microbiota
transplant
result
aforement
period
regist
case
clostridium
difficil
coliti
children
affect
categori
year
age
group
femal
patient
patient
immunosuppress
death
regist
case
relaps
case
relaps
case
relaps
case
relaps
case
relaps
case
relaps
perform
fecal
microbiota
transplant
one
case
multipl
antibiot
allergi
perform
fecal
microbiota
transplant
first
choic
treatment
without
previou
antibiot
treatment
fecal
transplant
procedur
success
without
incid
none
case
regist
relaps
conclus
clostridium
difficil
coliti
repres
import
caus
morbid
children
high
number
relaps
sometim
sever
life
threaten
evolut
fecal
microbiota
transplant
repres
effici
altern
therapi
clostridium
difficil
coliti
unrespons
standard
treatment
background
communityacquir
pneumonia
cap
common
diseas
caus
wide
varieti
pathogen
may
profession
challeng
sir
william
osler
note
fourth
edit
book
principl
practic
medicin
pneumonia
import
caus
morbid
mortal
acut
diseas
centuri
later
promin
pneumonia
chang
pneumonia
one
import
caus
morbid
mortal
worldwid
object
establish
demograph
clinic
aspect
evolut
etiolog
cap
method
retrospect
studi
juli
hospit
patient
cap
adult
infecti
diseas
clinic
victor
hospit
craiova
analyz
demograph
clinic
laboratori
data
evolut
case
result
identifi
patient
cap
constitut
studi
lot
gener
data
studi
lot
gender
distribut
male
femal
patient
urban
area
patient
rural
area
predomin
elderli
patient
case
age
year
durat
hospit
studi
group
significantli
higher
durat
hospit
patient
infecti
diseas
day
vs
day
p
case
cap
typic
pneumonia
laennec
classif
unfavor
outcom
record
case
evalu
criteria
sever
ie
score
sepsi
criteria
studi
group
show
subject
met
sever
criteria
follow
point
case
sepsi
defin
consensu
criteria
case
case
patient
studi
group
associ
comorbid
common
comorbid
chronic
lung
diseas
case
cap
etiolog
identifi
case
etiolog
frequent
involv
cap
studi
group
repres
streptococcu
pneumonia
conclus
cap
patient
often
elderli
patient
urban
area
durat
hospit
subject
cap
significantli
higher
vs
subject
infecti
diseas
common
clinic
present
typic
pneumonia
meet
criteria
sever
ie
score
point
andor
presenc
sepsi
criteria
patient
associ
comorbid
sometim
fatal
outcom
common
identifi
etiolog
pneumonia
background
varicella
erupt
diseas
mild
clinic
evolut
adult
patient
develop
sever
form
due
complic
might
occur
cardiac
complic
caus
varicella
zoster
viru
rare
potenti
high
mortal
rate
myocard
frequent
case
report
present
case
year
old
femal
patient
diagnos
prior
admiss
clinic
gener
skin
blister
rash
fever
chill
dyspnea
rest
precordi
chest
pain
irradi
shoulder
patient
person
patholog
anteced
famili
histori
cardiovascular
diseas
clinic
examin
patient
present
mild
fever
maculopapular
gener
rash
dyspnea
rest
normal
breath
sound
tachycardia
bpm
ventricular
gallop
mitral
systol
murmur
istiind
degre
laboratori
test
troponin
ngml
posit
igm
vzv
serolog
echo
coxsacki
cmv
epstein
barr
toxoplasma
igm
neg
vdrl
hiv
serolog
neg
normal
lung
chest
xray
ecg
admiss
show
sinu
rhythm
bpm
neg
wave
precordi
lead
dii
diii
avf
echocardiographi
show
global
hypokinesia
systol
dysfunct
lvef
mitral
valv
prolaps
moder
mitral
regurgit
iind
degre
diagnosi
intrainfecti
myocard
establish
accord
minimum
element
objectiv
clinic
heart
exam
tachycardia
gallop
rhythm
mitral
systol
murmur
istiind
degre
etiolog
context
maculopapular
gener
rash
ig
vzv
posit
abnorm
enzym
valu
troponin
ngml
ecg
abnorm
neg
wave
dii
diii
avf
chang
exist
previou
ecg
element
myocardi
dysfunct
echocardiographi
day
treatment
acyclovir
gramsday
betablock
bed
rest
evolut
favor
precordi
chest
pain
dyspnea
remiss
normal
troponin
valu
echocardiographi
perform
day
show
improv
lvef
persist
moder
mitral
regurgit
ecg
normal
achiev
week
conclus
although
varicella
pneumonia
common
caus
dyspnea
myocard
complic
chickenpox
determin
short
breath
earli
diagnosi
appropri
treatment
rare
form
myocard
lead
complet
recoveri
patient
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
diphtheria
mostli
elimin
result
routin
childhood
introduct
antidiphtheria
vaccin
worldwid
romania
last
case
identifi
case
report
yearold
femal
medic
histori
present
otorhinolaryngolog
ent
depart
bucharest
sore
throat
odynophagia
mild
fever
malais
bilater
refer
otalgia
date
back
day
recent
instal
short
breath
clinic
ent
exam
laryngoscopi
reveal
swollen
palatin
lingual
tonsil
cover
purul
exud
edema
posterior
pharyng
wall
uvula
epiglotti
interarytenoid
mucosa
well
narrow
glotti
cleft
throat
swab
perform
moment
diagnos
probabl
epiglott
abscess
receiv
treatment
ceftriaxon
gentamicin
metronidazol
corticotherapi
given
absenc
clinic
improv
result
laryngoscopi
coalesc
adher
pseudomembran
spread
tonsil
pharyng
area
patient
refer
clinic
suspicion
diphtheria
admiss
clinic
detail
anamnesi
reveal
develop
short
breath
minut
appli
propoli
tinctur
left
tonsil
epidemiolog
investig
identifi
patient
complet
immun
childhood
travel
endem
area
clinic
exam
show
afebril
patient
satisfactori
gener
state
without
palpabl
lymph
node
balanc
cardiovascular
respiratori
function
lab
report
show
leukocytosi
neutrophilia
acut
inflammatori
syndrom
throat
cultur
neg
corynebacterium
diphtheria
posit
group
f
streptococcu
level
antidiphtheria
toxin
igg
antibodi
protect
valu
order
monitor
evolut
lesion
daili
ent
consult
flexibl
fiberopt
laryngoscopi
perform
consid
data
interpret
case
viral
acut
tonsil
follow
caustic
wound
gener
applic
propoli
tinctur
superinfect
group
f
streptococcu
patient
receiv
treatment
penicillin
g
dexamethason
full
recoveri
day
conclus
although
except
rare
diphtheria
exclud
differenti
diagnosi
especi
given
latest
romanian
epidemiolog
report
show
decreas
childhood
vaccin
rate
immun
booster
adulthood
natur
therapi
may
time
harm
effect
one
describ
aforement
case
produc
drugdrug
interact
increasedecreas
efficaci
medic
therapi
acknowledg
carol
davila
univers
medicin
pharmaci
young
research
grant
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
diarrhea
commonli
occur
among
hivinfect
patient
mani
possibl
caus
includ
infecti
agent
especi
opportunist
germ
immun
loss
cancer
antiretrovir
therapi
multipl
prior
hospit
admiss
antibiot
use
treatment
prophylaxi
increas
risk
clostridium
difficil
infect
cdi
case
method
retrospect
analyz
hivinfect
patient
diarrhea
defin
least
loos
stool
hour
admit
nation
institut
infecti
diseas
prof
dr
matei
januari
decemb
incid
case
defin
first
posit
c
difficil
toxin
andor
b
use
enzym
immunoassay
techniqu
pcr
toxin
ab
gene
stool
sampl
use
genexpert
method
relaps
cdi
exclud
studi
result
patient
complet
inclus
criteria
repres
total
hivposit
patient
diarrhea
hivposit
patient
infecti
etiolog
diarrhea
cdi
frequent
agent
male
gender
prevail
mean
age
group
year
rang
year
averag
hospit
period
day
rang
day
case
diagnosi
establish
pcr
case
previou
hospit
within
last
month
recent
antibiot
treatment
regimen
use
opportunist
infect
prophylaxi
biolog
abnorm
mean
wbc
count
rang
averag
valu
cell
count
cellscmm
rang
cellscmm
patient
cell
count
cellscmm
sustain
undertreat
viral
suppress
notic
case
total
case
antiretrovir
therapi
remiss
symptom
obtain
use
oral
treatment
vancomycin
patient
metronidazol
intraven
treatment
tigecyclin
case
fulmin
cdi
report
death
case
directli
attribut
cd
infect
patient
encount
relaps
conclus
studi
conform
intern
medic
data
clostridium
difficil
prove
frequent
caus
infecti
diarrhea
hivposit
patient
background
candida
superfici
mycosi
common
fungal
infect
one
frequent
candida
stomat
usual
associ
immunocompromis
statu
certain
nutrit
habit
seriou
epidemiolog
evalu
romania
publish
yet
method
raw
data
obtain
medic
statist
direct
romanian
ministri
health
data
entir
countri
statist
analysi
base
usual
method
mean
standard
deviat
annova
fisher
test
student
test
perform
order
valid
result
result
identifi
case
annual
averag
case
regist
urban
area
case
compar
rural
area
case
affect
mainli
men
casesyear
compar
candida
infect
stomat
repres
averag
incid
case
higher
year
old
group
mainli
male
children
year
old
age
percentag
tend
revers
test
show
signific
correl
age
patient
conclus
candida
stomat
frequent
urban
area
casesyear
half
men
littl
children
studi
need
order
evalu
involv
differ
candida
speci
infect
laboratori
confirm
data
need
good
collabor
laboratori
doctor
clinician
epidemiologist
strictli
necessari
acknowledg
studi
made
sectori
programm
human
resourc
develop
sophrd
financ
european
social
fund
romanian
govern
contract
number
posdru
background
anthrax
consid
rare
diseas
european
countri
twentyon
case
report
confirm
europ
last
updat
ecdceuropaeu
romania
nation
institut
public
health
confirm
one
case
probabl
case
among
suspicion
confirm
case
among
suspicion
cutan
form
one
meningoenceph
relat
anim
andor
anim
product
exposur
aim
studi
describ
anthrax
case
recent
diagnos
southeastern
romania
method
review
data
patient
admit
anthrax
suspicion
infecti
diseas
id
hospit
southeastern
romania
nation
institut
idbucharest
pitesticounti
hospit
hospit
januari
august
along
ecdc
definit
confirm
probabl
use
categori
suspect
case
cdc
definit
http
result
among
suspicion
confirm
probabl
remain
suspect
cutan
lesion
one
main
form
meningoenceph
median
age
yearold
male
femal
ratio
live
rural
area
contact
cowsgoatssheep
case
confirm
yearold
man
butcher
black
eschar
malign
edema
left
upper
limb
subsequ
develop
necrot
fasciiti
superinfect
mdr
gramneg
bacilli
requir
adapt
salvag
antibiot
therapi
surgic
decompress
case
suspect
case
femal
yearold
painless
redvesicular
lesion
black
eschar
finger
surround
edema
contact
similar
lesion
anim
posit
b
anthraci
inhous
serolog
case
yearold
shepherd
meningoenceph
fever
psychomotor
agit
hemiparesi
aphasia
neckstiff
csf
compat
acut
bacteri
mening
black
eschar
hand
csf
cutan
lesion
dnabacillu
anthraci
posit
pcrtechniqu
perform
victor
clinic
hospit
bucharest
patient
transfer
icu
case
confirm
probabl
shepherd
deceas
anim
cutan
form
cluster
men
woman
yearold
yearold
man
patient
favor
evolut
conclus
import
increas
anthrax
case
southeastern
romania
animalbreed
connect
inappropri
veterinari
surveil
cutan
form
rapid
good
evolut
one
develop
potenti
fatal
complic
anthrax
meningoenceph
describ
unexpect
favor
outcom
probabl
due
young
age
good
previou
health
earli
suspicion
prompt
treatment
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
outbreak
ebola
viru
diseas
evd
exert
great
pressur
healthcar
system
insid
also
outsid
african
contin
attempt
identifi
manag
import
case
order
prevent
transmiss
romania
nation
institut
infecti
diseas
prof
dr
matei
design
medic
facil
manag
possibl
case
evd
studi
aim
evalu
knowledg
attitud
risk
percept
institut
healthcar
worker
hcw
regard
ebola
viru
diseas
recent
epidem
method
design
crosssect
survey
base
selfadminist
print
questionnair
compris
question
june
medic
doctor
nurs
invit
take
part
voluntarili
anonym
studi
data
analyz
use
microsoft
excel
ibm
spss
statist
v
result
questionnair
fill
hcw
physician
repres
respond
particip
familiar
ebola
viru
diseas
nurs
learn
epidem
oppos
medic
doctor
frequent
symptom
main
rout
ebola
viru
transmiss
correctli
identifi
major
respond
wherea
possibl
airborn
transmiss
common
mispercept
epidem
particip
slightli
worri
health
famili
mean
score
rather
person
risk
contract
ebola
p
hcw
involv
medic
care
ebola
suspect
case
two
time
like
volunt
care
patient
futur
rr
ci
p
particip
obtain
inform
ebola
workplac
hcw
attend
least
one
specif
train
believ
adequ
person
protect
method
avail
institut
donningremov
person
protect
equip
frequent
cours
mani
particip
think
provid
suffici
inform
evd
want
know
prevent
method
treatment
prepared
plan
romania
conclus
hcw
possess
signific
knowledg
ebola
viru
diseas
african
epidem
experienc
moder
degre
worri
reli
mostli
inform
provid
institut
studi
reveal
import
profession
educ
offer
employe
medic
institut
could
help
improv
train
session
held
public
health
emerg
situat
background
extens
mass
due
abdominopelv
actinomycosi
rais
challeng
diagnost
therapeut
problem
due
frequent
confus
malign
tumor
firstlin
therapi
includ
high
dose
penicillin
prolong
period
month
data
concern
antibiot
shorter
cours
therapi
actinomycosi
limit
present
case
abdominopelv
actinomycosi
complet
remiss
day
penicillin
combin
day
tigecyclin
yearold
woman
hospit
matei
nation
institut
infecti
diseas
later
follow
week
treatment
case
report
yearold
woman
solitari
right
kidney
histori
intrauterin
devic
present
urolog
depart
sf
ioan
clinic
emerg
hospit
histori
nausea
abdomin
pain
kg
weight
loss
dysuria
imag
laboratori
investig
reveal
sever
anemia
obstruct
renal
failur
right
ureterohydronephrosi
larg
retroperiton
mass
cm
cm
cm
involv
right
ovari
uteru
invad
sigmoid
rectum
urinari
bladder
compress
right
uret
doubl
j
stent
urinari
cathet
place
patient
consult
surgeri
ward
believ
metastat
ovarian
carcinoma
exploratori
laparoscopi
reveal
dens
friabl
adhes
allow
left
anexectomi
partial
omentectomi
imped
complet
resect
histolog
sampl
show
inflammatori
granulomat
tissu
multipl
abscess
contain
coloni
actinomyc
spp
patient
refer
matei
nation
institut
infecti
diseas
patient
start
penicillin
million
unitsday
total
day
first
day
penicillin
tigecyclin
mgday
ad
day
treatment
concurr
urinari
infect
mdr
klebsiella
pneumonia
resist
colistin
sensit
tigecyclin
fosfomycin
patient
favor
clinic
biolog
outcom
ct
assess
week
reveal
complet
remiss
abdominopelv
mass
right
ureterohydronephrosi
small
abdomin
adenopathi
mm
conclus
case
highlight
favor
effect
tigecyclin
day
associ
standard
therapi
penicillin
case
abdominopelv
actinomycosi
remiss
week
therapi
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
raoultella
planticola
gramneg
bacillu
primarili
consid
environment
bacteria
belong
famili
enterobacteriacea
relat
klebsiella
spp
r
planticola
sensit
cephalosporin
aminoglycosid
fluoroquinolon
strain
r
planticola
resist
almost
clinic
avail
antibiot
except
tigecyclin
colistin
report
report
r
planticola
infect
limit
bacterium
report
cholecyst
urinari
tract
infect
skin
soft
tissu
infect
pancreat
pneumonia
case
report
present
case
year
old
male
rural
area
hospit
adult
infecti
diseas
clinic
victor
hospit
craiova
onset
ill
day
admiss
fever
chill
product
cough
purul
sputum
medic
histori
hypertens
congest
heart
failur
class
iii
nyha
admiss
exam
afebril
right
basal
crackl
chest
exam
biolog
examin
reveal
complet
blood
count
leukocyt
number
cellsml
granulocyt
percentag
rest
biolog
exam
normal
limit
chest
xray
right
infrahilar
intern
alveolar
opac
cardiomegali
sputum
cultur
reveal
bacteria
initi
consid
klebsiella
spp
identifi
r
planticola
sensit
amoxicillinclavulan
ceftriaxon
cefuroxim
trimethoprimsulfamethoxazol
tetracyclin
moxifloxacin
resist
ampicillin
patient
receiv
moxifloxacin
favor
evolut
day
treatment
conclus
r
planticola
infect
recent
report
human
patholog
publish
case
pneumonia
bacteria
confus
klebsiella
spp
could
explan
scarciti
case
record
literatur
case
health
care
associ
infect
patient
come
rural
area
gener
sensit
common
antibiot
rais
special
problem
present
case
clearli
aggress
multiresist
strain
could
problemat
treatment
futur
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
vitamin
secosteroid
differ
immunomodulatori
properti
sever
recent
studi
demonstr
relationship
vitamin
defici
sever
ill
mortal
purpos
studi
assess
vitamin
oh
statu
pediatr
patient
sepsi
associ
sever
score
biochem
characterist
method
studi
conduct
pediatr
depart
teach
hospit
infecti
diseas
clujnapoca
februari
march
perform
prospect
clinic
observ
studi
among
children
year
age
admit
depart
consecut
patient
infect
screen
sepsi
criteria
admiss
stratifi
two
group
without
sepsi
serum
vitamin
measur
perform
patient
within
day
admiss
defici
defin
concentr
oh
ngml
electron
databas
includ
age
gender
diagnosi
identifi
microorgan
pediatr
risk
mortal
iii
score
prismiii
hematolog
biochem
characterist
statist
analysi
perform
use
test
use
compar
nonparametr
variabl
relationship
vitamin
defici
clinic
biochem
variabl
determin
rel
risk
spearman
rank
correl
result
twentyeight
children
sepsi
without
sepsi
enrol
children
enrol
found
neg
correl
oh
level
prismiii
score
r
p
posit
correl
iron
total
ioniz
calcium
level
r
p
r
p
respect
r
p
patient
sepsi
significantli
lower
median
level
oh
compar
case
without
sepsi
ngml
versu
ngml
p
rel
risk
sepsi
p
specif
prismiii
p
specif
vitamin
concentr
ngml
compar
group
without
sepsi
sepsi
group
significantli
lower
level
hdlcholesterol
mgdl
vs
mgdl
p
albumin
gdl
vs
gdl
p
total
ioniz
calcium
mgdl
vs
mgdl
p
respect
mgdl
vs
mgdl
p
conclus
pediatr
popul
vitamin
defici
associ
sepsi
higher
prismiii
score
background
seen
patient
present
infecti
diseas
hospit
toma
complain
insect
bite
may
june
thirti
bitten
ixod
tick
method
studi
clinic
epidemiolog
aspect
prophylaxi
lyme
diseas
among
patient
present
tick
bite
clinic
infecti
diseas
hospit
toma
republ
moldova
result
among
patient
tick
bite
women
averag
age
year
men
age
person
urban
rural
area
seventeen
patient
group
show
symptom
lyme
borreliosi
group
diagnos
lyme
diseas
ld
mean
span
tick
attach
host
averag
day
among
person
first
group
second
one
day
incub
period
ld
patient
vari
day
last
averag
day
diagnosi
establish
base
clinic
present
erythema
migran
em
confirm
elisa
igm
igg
anti
borrelia
burgdorferi
bb
antibodi
frequent
reveal
complain
em
pain
local
burn
sensat
patient
first
group
given
prophylact
treatment
doxycyclin
mg
singl
dose
amoxicillin
case
contraind
none
develop
ld
day
follow
period
treatment
ld
patient
success
case
patient
given
doxycyclin
mg
twice
daili
bd
day
day
doxycyclin
mg
bd
day
amoxicillin
mg
oral
tid
day
prescrib
patient
day
dosag
patient
one
person
given
ceftriaxon
g
bd
day
patient
treatment
outpati
case
patient
need
hospit
treatment
day
follow
period
patient
still
complain
anxieti
headach
insomnia
anoth
one
complain
gener
weak
one
case
skin
lesion
persist
despit
long
last
cours
antibiot
conclus
day
period
ld
diagnos
patient
present
hospit
histori
tick
bite
fourteen
patient
given
doxycyclin
amoxicillin
prophylact
treatment
prove
effect
case
patient
ld
treat
success
doxycyclin
amoxicillin
cours
last
day
outpati
acut
ld
case
outcom
favor
background
drugresist
dr
tuberculosi
tb
grow
problem
hivinfect
patient
associ
high
rate
treatment
failur
mortal
accord
patient
diagnos
tb
hivinfect
rate
multidrug
resist
tb
mdrtb
newli
diagnos
tb
case
retreat
group
object
aim
describ
clinic
laboratori
characterist
drtb
hiv
infect
patient
method
retrospect
analyz
hivinfect
patient
diagnos
januari
decemb
tb
six
tertiari
care
facil
romania
includ
patient
diagnosi
drtb
base
genotyp
mtbrif
xpert
andor
cultur
plu
drug
suscept
test
result
identifi
hivinfect
patient
tb
microbiolog
confirm
nineteen
patient
drtb
six
patient
resist
isoniazid
rifampicin
mdrtb
hiv
diagnosi
establish
tb
diagnosi
patient
drtb
respect
patient
drug
suscept
ds
tb
p
ci
median
age
year
drtb
group
iqr
dstb
group
iqr
p
male
repres
drtb
group
vs
dstb
group
p
ci
drtb
group
patient
pulmonari
tb
extrapulmonari
tb
patient
concomit
pulmonari
extrapulmonari
tb
dstb
group
patient
pulmonari
tb
extrapulmonari
tb
patient
concomit
pulmonari
extrapulmonari
tb
tb
diagnosi
patient
drtb
antiretrovir
therapi
vs
patient
dstb
p
ci
seven
patient
drtb
group
vs
dstb
group
cotrimoxazol
prevent
therapi
p
ci
six
patient
drtb
previou
treatment
vs
patient
dstb
p
ci
rate
mdr
newli
diagnos
tb
case
retreat
group
inhospit
mortal
rate
higher
patient
drtb
vs
patient
dstb
p
ci
median
cell
count
patient
drtb
vs
dstb
cellscmm
vs
cellscmm
p
conclus
hivinfect
patient
drtb
caus
associ
previou
treatment
lower
median
cellcount
increas
inhospit
mortal
statist
signific
differ
two
group
regard
tb
site
rate
mdr
greater
hiv
noninfect
patient
background
urinari
infect
consid
trigger
interstiti
nephropathi
frequent
urinari
infect
determin
bacteria
rare
virus
yeast
author
aim
evalu
kidney
injuri
could
repres
specif
serolog
marker
patient
urinari
tract
infect
suscept
develop
kidney
dysfunct
method
author
develop
prospect
studi
patient
urinari
tract
infect
caus
escherichia
coli
control
case
subject
adult
normal
serum
lipid
normal
weight
balanc
diet
serum
profil
elisa
method
analyz
correl
marker
renal
dysfunct
renal
function
evalu
serum
urea
serum
creatinin
estim
glomerular
filtrat
rate
egfr
albumincreatinin
ratio
uric
acidcreatinin
ratio
result
compar
control
group
pgml
serum
level
higher
patient
urinari
infect
pgml
p
neg
correl
level
egfr
observ
patient
urinari
tract
infect
r
p
posit
associ
serum
creatinin
r
p
signific
correl
analyz
paramet
determin
conclus
result
sustain
idea
could
predict
factor
renal
dysfunct
patient
urinari
infect
background
benign
prostat
hyperplasia
bph
multifactori
patholog
affect
life
qualiti
elderli
men
recurr
urinari
tract
infect
frequent
present
patient
obstruct
benign
prostat
hyperplasia
bph
could
determin
molecular
disord
aim
studi
investig
effect
urinari
tract
infect
serum
gangliosid
method
studi
includ
subject
benign
prostat
hyperplasia
group
follow
group
case
benign
prostat
hyperplasia
urinari
tract
infect
group
b
case
benign
prostat
hyperplasia
without
urinari
tract
infect
gangliosid
statu
prostat
specif
antigen
psa
creactiveprotein
crp
prostat
volum
ipss
determin
serum
level
gangliosid
determin
spectrophotmoter
method
use
resorcinol
clorhidr
evalu
nm
psa
determin
elisa
crp
immunoturbidimetri
result
serum
level
gangliosid
significantli
higher
patient
bph
urinari
tract
infect
compar
without
infect
mgdl
group
versu
mgdl
group
b
p
statist
analysi
show
follow
correl
serum
level
gangliosid
psa
r
p
group
r
p
group
b
serum
gangliosid
crp
r
p
group
r
p
group
b
serum
gangliosid
ipss
r
p
group
r
p
group
b
relat
serum
gangliosid
prostat
volum
observ
conclus
increas
level
serum
gangliosid
patient
bph
could
consid
defens
mechan
infect
import
maintain
vital
biolog
balanc
serum
gangliosid
could
repres
use
monitor
paramet
patient
obstruct
prostat
benign
hyperplasia
urinari
infect
background
toxocariasi
caus
seri
relat
nematod
speci
routin
infect
dog
cat
throughout
world
studi
warn
geograph
region
underestim
region
moldova
toxocariasi
frequent
dog
cat
fox
method
studi
period
case
toxocariasi
admit
infecti
diseas
hospit
result
toxocariasi
preval
geograph
region
signific
gender
differ
say
major
case
age
group
year
year
minimum
number
case
found
age
group
year
case
gender
distribut
case
show
case
women
case
owner
pet
dog
gener
clinic
manifest
repres
latch
edema
headach
paresthesia
sweat
hoars
exanthema
abdomin
pain
locat
ocular
larva
cani
occur
often
older
children
year
adult
studi
case
met
decreas
visual
acuiti
case
case
uveiti
case
retin
granuloma
case
endophthalm
case
hospit
ophthalmolog
clinic
appropri
therapi
biochem
test
use
diagnosi
repres
major
hypereosiniphilia
hyperleukocytosi
increas
esr
gammaglobulin
studi
leukocytosi
found
case
hypereosiniphilia
certain
diagnosi
toxocariasi
use
serolog
method
consist
determin
specif
toxocara
antibodi
toxocara
antibodi
present
studi
patient
result
posit
case
neg
case
igg
antibodi
titer
found
case
describ
complic
sequela
met
case
respiratori
disord
ocular
larva
migran
splenomegali
uveiti
chorioretin
hepatomegali
conclus
toxocariasi
character
express
polymorph
clinic
manifest
asymptomat
variou
clinic
form
sever
express
need
term
futur
control
program
radic
develop
new
approach
effect
molecular
vaccin
base
dna
offer
possibl
lifelong
protect
background
pyogen
infect
oromaxillofaci
region
odontogen
origin
mix
infect
involv
aerob
anaerob
bacteria
microbiolog
investig
commonli
perform
infect
aim
present
studi
identifi
speci
level
collect
isol
anaerob
gramposit
cocci
store
ultrafreez
laboratori
microbiolog
depart
faculti
dentistri
univers
medicin
pharmaci
umf
carol
davila
bucharest
strain
previous
isol
pu
sampl
collect
needl
aspir
patient
among
treat
differ
type
odontogen
abscess
vestibular
abscess
submandibular
abscess
etc
depart
oromaxillofaci
surgeri
umf
carol
davila
bucharest
march
march
method
isol
anaerob
gramposit
cocci
identifi
speci
level
use
rapid
id
system
marcyl
etoil
franc
result
isol
except
one
belong
parvimona
micra
formerli
peptostreptococcu
micro
micromona
micro
remain
strain
identifi
finegoldia
magna
formerli
peptostreptococcu
magnu
conclus
parvimona
micra
far
predomin
speci
anaerob
gramposit
cocci
involv
odontogen
abscess
speci
identif
must
neglect
oromaxillofaci
infect
due
contribut
better
understand
etiopathogenesi
infect
acknowledg
present
studi
part
intern
research
plan
depart
microbiolog
faculti
dentistri
collabor
head
depart
epidemiolog
faculti
medicin
umf
carol
davila
bucharest
background
one
challeng
aspect
clostridium
difficil
infect
cdi
propens
recur
firstlin
therapi
associ
high
rate
recurr
object
assess
factor
associ
recurr
patient
hospit
cdi
method
retrospect
cohort
studi
adult
admit
septemb
august
cdi
includ
patient
diagnos
clinic
symptom
detect
cd
toxin
stool
use
polymeras
chain
reaction
treat
metronidazol
vancomycin
vancomycin
plu
least
day
tigecyclin
exclud
episod
data
calcul
atla
sever
score
avail
recurr
defin
anoth
episod
diarrhoea
posit
toxin
test
within
week
onset
previou
episod
result
total
episod
cdi
includ
episod
patient
treat
metronidazol
vancomycin
tigecyclin
associ
vancomycin
eightyeight
episod
cdi
recurr
includ
episod
fortyfour
episod
recurr
group
versu
episod
group
without
recurr
men
p
median
age
similar
group
year
patient
recurr
versu
year
patient
without
recurr
differ
regard
median
charlson
score
group
median
atla
sever
score
group
neoplast
diseas
diagnos
cdi
recurr
episod
versu
cdi
nonrecurr
episod
p
cdi
recurr
episod
includ
analysi
treat
metronidazol
case
vancomycin
case
vancomycin
plu
tigecyclin
case
p
thirtythre
episod
recurr
outcom
includ
episod
preced
recurr
versu
episod
without
recurr
current
episod
p
find
signific
associ
cdi
recurr
age
year
p
albumin
valu
less
gdl
p
leukocyt
number
greater
p
presenc
acut
renal
insuffici
p
concomit
system
antibiot
therapi
p
conclus
cdi
recurr
correl
older
age
presenc
neoplast
diseas
administr
concomit
system
antimicrobi
therapi
histori
anoth
cdi
recurr
sever
cdi
express
lower
albumin
high
number
leukocyt
presenc
acut
renal
insuffici
associ
tigecyclin
reduc
recurr
compar
convent
therapi
metronidazol
vancomycin
background
incid
tubercul
osteodisc
rise
mycobacterium
tuberculosi
current
consid
second
etiolog
agent
osteodisc
case
report
yearold
femal
present
clinic
lowgrad
fever
intens
back
pain
progress
medial
side
lower
limb
paresthesia
left
leg
pain
right
iliac
fossa
date
back
day
medic
histori
reveal
stage
hypertens
right
sylvian
hemorrhag
stroke
left
sequel
hemiparesi
bilater
pulmonari
thromboembol
clinic
exam
show
left
sequel
hemiparesi
slightli
diminish
deep
tendon
reflex
left
side
intens
impair
mobil
lab
report
show
acut
inflammatori
syndrom
coagul
disord
elev
serum
creatinin
lumbosacr
spine
mri
scan
conduct
one
day
prior
admiss
describ
spondylodisc
massiv
anterior
epidur
abscess
right
paravertebr
abscess
initi
label
probabl
staphylococc
osteodisc
therapi
initi
rifampin
levofloxacin
clinic
improv
persist
lowgrad
fever
day
rifampin
chang
linezolid
evolut
appar
favor
afebril
decreas
biolog
inflamm
marker
mri
conduct
one
month
treatment
reveal
lesion
progress
transfer
neurosurgeri
laminectomi
perform
surgeri
grayyellow
mass
suggest
mycobacterium
tuberculosi
tb
etiolog
found
wound
blood
cultur
neg
gram
stain
show
bacteria
ziehlneelsen
stain
fail
show
acidfast
bacilli
still
histopatholog
examin
highli
suggest
mycobacterium
tuberculosi
etiolog
antitb
therapi
initi
isoniazid
rifampin
pyrazinamid
ethambutol
clinic
biolog
improv
far
patient
undergon
antitb
therapi
month
neurolog
improv
repeat
mri
scan
schedul
patient
complet
month
therapi
conclus
present
case
clinic
radiolog
find
insuffici
allow
differenti
tubercul
staphylococc
etiolog
addit
activ
antistaphylococc
agent
rifampin
linezolid
mycobacterium
tuberculosi
mask
clinic
progress
diseas
prolong
time
etiolog
diagnosi
bacteriolog
test
fail
identifi
etiolog
agent
definit
diagnosi
eventu
base
histopatholog
examin
highlight
import
obtain
tissu
specimen
allow
accur
diagnosi
correct
interdisciplinari
manag
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
respiratori
syncyti
viru
rsv
import
pathogen
caus
respiratori
infect
often
sever
even
death
especi
children
younger
month
certain
popul
group
may
vulner
sever
rsv
infect
pregnant
women
immunocompromis
patient
person
chronic
diseas
usual
clinic
aspect
differ
determin
respiratori
virus
rsv
often
caus
coinfect
respiratori
virus
method
examin
nasopharyng
swab
taken
patient
diagnos
sari
sever
acut
respiratori
infect
admit
hospit
six
counti
bucharest
laboratori
techniqu
realtim
rtpcr
revers
transcriptionpolymeras
chain
reaction
detect
influenza
virus
type
type
b
multiplex
rtpcr
commerci
kit
rtpcr
onestep
ace
seeplex
seegen
detect
respiratori
virus
sequenc
fragment
base
pair
gene
sh
rsv
b
identif
confirm
rsv
result
sampl
posit
influenza
virusiv
respiratori
virus
rsv
hmpv
human
metapneumoviru
coronaviru
adenoviru
rhinoviru
bocaviru
three
patient
posit
rsv
die
one
death
occur
woman
year
one
woman
age
year
one
child
month
three
deceas
patient
associ
diseas
mention
februari
report
death
child
age
year
type
b
rsv
diseas
present
associ
diseas
lung
sampl
sequenc
patient
confirm
presumpt
diagnosi
rsv
infect
caus
type
b
sequenc
show
ident
two
piec
lung
ident
sequenc
genbank
conclus
although
type
b
rsv
give
sever
clinic
form
case
child
age
year
rsv
type
b
induc
sever
clinic
form
result
death
patient
associ
chronic
diseas
rsv
caus
either
death
seriou
infect
infect
like
flu
infect
due
rsv
spread
easili
commun
pathogen
mechan
understand
infect
need
along
studi
genotyp
gene
sequenc
rsv
background
postop
sepsi
occur
immunocompromis
elderli
patient
impos
complex
clinicaltherapeut
monitor
known
import
caus
mortal
popul
purpos
paper
present
clinic
case
acinetobact
baumannii
sepsi
associ
clostridium
difficil
enterocol
elderli
immun
suppress
patient
case
report
author
present
case
patient
year
urban
environ
acinetobact
baumanii
sepsi
associ
c
difficil
enterocol
patient
discharg
vascular
surgeri
clinic
undergon
right
femoralpoplit
bypass
transfer
clinic
nephrolog
massiv
edema
day
hospit
clinic
nephrolog
present
multipl
diarrheal
stool
posit
toxin
ab
c
difficil
sent
clinic
infecti
diseas
special
treatment
five
day
hospit
present
febril
episod
associ
chill
sweat
blood
cultur
harvest
hour
posit
acinetobact
baumannii
blood
test
result
includ
rbc
wbc
plt
neut
lymph
mono
eo
baso
hgb
gdl
hct
esr
h
fibrinogen
gl
serum
uric
acid
mgdl
af
ul
serum
creactiv
protein
mgl
chol
mgdl
trigli
mgdl
procalcitonin
ngml
hospit
receiv
therapi
metronidazol
mgday
oral
vancomycin
mgday
oral
c
difficil
enterocol
colistin
muiday
amikacin
mgday
sinerdol
mgday
accord
antibiogram
result
hydroelectrolyt
rebalanc
solut
intrainfecti
sever
anemia
hgb
gdl
impos
erythrocyt
mass
administr
evolut
favor
remiss
diarrheal
stool
fever
togeth
correct
anemia
hgb
gdl
discharg
conclus
earli
detect
postop
sepsi
associ
infect
c
difficil
alongsid
effect
therapeut
clinic
monitor
help
increas
life
expect
elderli
immunocompromis
patient
consent
written
inform
consent
obtain
patient
public
case
report
accompani
imag
copi
written
consent
avail
review
editor
journal
background
aim
studi
identifi
risk
factor
impact
psychopatholog
qualiti
life
among
peopl
live
hivaid
romania
order
obtain
risk
psycholog
profil
method
purpos
hivposit
patient
year
men
women
antiretrovir
therapi
evalu
use
psychometr
clinic
instrument
scale
questionnair
inventori
measur
depress
anxieti
psychosi
mania
posttraumat
stress
substanc
use
disord
person
dimens
big
five
model
qualiti
life
main
domain
physic
health
psycholog
health
level
independ
social
relationship
environ
spiritualityreligionperson
belief
analyz
follow
probabl
risk
factor
age
sex
urbanrur
locat
level
educ
attain
marit
statu
serostatu
asymptomaticsymptomaticaid
convert
mode
hiv
transmiss
percept
health
state
result
everi
studi
variabl
psychopatolog
qualiti
life
indic
gener
linear
model
glm
elabor
includ
probabl
risk
factor
level
educ
attain
sex
marit
statu
import
factor
risk
state
health
psysic
psycholog
qualiti
life
among
peopl
live
hivaid
level
educ
significantli
associ
depress
disord
anxieti
disord
post
traumat
stress
disord
obsessivecompuls
disord
substanc
use
abus
neurocognit
function
qualiti
life
indic
health
psycholog
social
relationship
environ
overal
qualiti
life
percept
sex
strongli
associ
global
cognit
function
depress
disord
substanc
use
abus
somat
symptom
disord
physic
spiritu
domain
marit
statu
associ
global
cognit
function
depress
disord
anxieti
disord
obsessivecompuls
disord
emot
stabil
psysic
domain
social
relationship
overal
qualiti
life
percept
age
risk
factor
regard
cognit
declin
serostatu
asymptomaticsymptomaticaid
convert
associ
depress
social
phobia
substanc
use
disord
perceiv
stress
gener
health
condit
subject
perceiv
sick
higher
risk
substanc
abus
isol
antisoci
behaviour
conclus
studi
identifi
psycholog
risk
profil
peopl
live
hivaid
romania
conclud
everi
singl
risk
factor
address
properli
specialist
multidisciplinari
team
background
expert
influenza
antivir
suscept
work
close
promot
understand
mean
prevent
treatment
control
influenza
viru
diseas
includ
emerg
antivir
resist
due
high
preval
resist
adamantan
class
drug
among
influenza
pandem
strain
neuraminidas
inhibitor
nai
current
antivir
use
treatment
respiratori
infect
caus
influenza
virus
less
prevent
romania
current
pharmaceut
option
treat
influenza
infect
opportun
use
prophylaxi
therapi
limit
remain
critic
need
surveil
nai
suscept
influenza
virus
circul
worldwid
also
romania
nation
influenza
center
cantacuzino
institut
perform
laboratori
diagnosi
virolog
surveil
influenza
virus
includ
antivir
suscept
test
method
cantacuzino
institut
antivir
suscept
test
perform
mainli
phenotyp
method
abl
detect
degre
reduct
neuraminidas
inhibit
respect
highli
reduc
inhibit
hri
indic
resist
influenza
viru
strain
concentr
antivir
substanc
requir
inhibit
neuraminidas
enzymat
activ
gener
assay
use
evalu
naisuscept
last
epidem
season
use
fluoresc
instead
chemiluminesc
substrat
introduc
phenotyp
assay
method
led
reliabl
analysi
function
increas
number
sampl
test
virus
strain
significantli
elev
analyz
convent
sequenc
identifi
known
marker
nai
resist
novel
chang
na
result
epidem
season
year
strain
influenza
viru
test
phenotyp
type
subtyp
type
b
except
two
strain
exhibit
valu
upper
limit
normal
inhibit
within
sensit
criteria
oseltamivir
zanamivir
conclus
due
implement
sensit
function
test
antivir
suscept
influenza
virus
circul
last
epidem
season
number
sampl
test
romania
increas
record
valu
baselin
characterist
strain
still
sensit
antivir
continu
monitor
antivir
suscept
need
allow
earli
detect
resist
strain
background
sepsi
remain
major
problem
modern
medicin
despit
consider
medic
advanc
recent
decad
undeni
relev
condit
explain
increas
incid
high
mortal
high
econom
cost
relat
treatment
case
sepsi
occur
annual
unit
state
number
increas
year
cost
treatment
estim
billion
usd
per
year
europ
number
sepsi
case
annual
record
approxim
case
accord
data
report
sever
author
number
fatal
would
vari
method
conduct
retrospect
studi
hospit
record
patient
admit
infecti
diseas
hospit
diagnosi
sepsi
data
element
assess
includ
demograph
inform
physiolog
variabl
comorbid
laboratori
measur
suspect
sourc
infect
administ
treatment
result
total
patient
admit
affect
age
rang
year
male
commonli
affect
women
diagnosi
referr
follow
patient
direct
sepsi
patient
came
acut
chronic
hepat
acut
respiratori
infect
salmonellosi
patient
diagnosi
refer
admiss
diagnosi
sepsi
establish
patient
fever
unknown
origin
patient
enterovir
infect
patient
case
diagnosi
acut
hepat
influenza
food
poison
yersiniosi
establish
identif
primari
sourc
infect
possibl
patient
infecti
endocard
case
urogenit
sepsi
case
hiv
tuberculosi
case
gener
form
salmonellosi
case
case
lung
infect
mediallob
pneumonia
case
skin
infect
identif
etiolog
agent
possibl
patient
bacteriolog
examin
caus
agent
frequent
found
speci
staphylococcu
staphylococcu
aureu
case
staphylococcu
epidermidi
case
staphylococcu
hemolyticu
case
case
salmonella
enteritidi
mycobacterium
tuberculosi
case
commonli
use
antibiot
gener
iii
iv
cephalosporin
alon
associ
antibiot
metronidazol
fluoroquinolon
aminoglycosid
case
vancomycin
aminoglycosid
administ
conclus
common
pathogen
identifi
etiolog
sepsi
speci
staphylococcu
correspond
literatur
data
